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ABSTRACT 
Aggrecan is a large- aggregating proteoglycan that is essential for the function of articular 
cartilage. A loss of aggrecan is one of the major event in osteoarthritis, a debilitating and 
degenerative joint disease. To understand how a gene is lost and what fails to prevent 
transcription in disease state, an understanding of the bases of transcription must first be 
sought. Transcription is the first step in gene regulation and the chromatin plays an 
important role in blocking or allowing transcription to occur. Enhancers are non-coding 
DNA sequences that allow the binding of proteins, such as transcription factors that drive 
transcription irrespective of distance or orientation. 
 
Enhancers are marked by histone modifications that distinguish them from promoters and 
divide them into poised or active and are generally highly evolutionary conserved. Using 
publically available data on histone modifications found on ENCODE and transgenic mice 
this study has added to the understanding of the transcriptional regulation of aggrecan 
along with the known enhancer at -10kb. 3 intergenic regions, -35kb, -65kb and -87kb and 
one intronic (+26kb) from the transcription start site of aggrecan expresses primarily in 
the chondrocytes at E15.5. The -87kb enhancer marks chondrocytes that commit to an 
articular cartilage fate, and is strongly active in adult mice. The -65kb appears 
developmentally active, marking hypertrophic chondrocytes. The -35kb and +26kb are 
expressed in all chondrocytes at E15.5 mice and the -35kb is active in adult tissue. These 
enhancers bind to Sox9 and a loss of Sox9 in the -35kb enhancer shifts the expression 
from chondrocytes to fibroblast or perichondrium cells. These enhancers may play a role 
in response to diseases such as OA, as when these enhancers are transfected into 
differentiated murine ADTC5 cells and treated with Il-1β or hOSM there is a reduced level 
of expression from the -87kb element and an increase expression of the -65kb in response 
to Il-1β. 
 
A highly conserved intronic sequences (+55kb) was identified that does not express in 
chondrocytes, rather in kidney and lungs and may play a role outside of aggrecan gene 
regulation. 
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Using the Acan promoter and the -35kb enhancer a cartilage-specific Cre recombinase line 
was generated providing a tool to explore the pathogenesis of cartilage genes in disease 
such as OA or in lineage tracing. 
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1. INTRODUCTION 
1.1. Skeletal development 
The formation and regulation of the axial and appendicular bones of the skeleton during 
adulthood can be considered as the end point of skeletal development. Evolutionary, it 
reflects the utilisation of different cellular sources and mechanisms to bring about the 
establishment of the structures that bring function. The formation is carried out in two 
processes: intramembranous and endochondral ossification. Mesenchymal progenitors 
have the potential to commit to the chondrocytic or osteoblastic linage depending on the 
restrictions applied to them and the developmental cues they receive (Tsang et al., 2015). 
All skeletal element form from one of three progenitors: the craniofacial derive from the 
cranial neural crest cells, limb and appendicular skeleton arise from lateral plate 
mesodermal cells and finally the paraxial mesoderm gives rise to the axial skeleton 
(Berendsen and Olsen, 2015). Bone formation follows defined steps: commitment to 
specialist cell linage, mesenchymal condensation, proliferation, extra-cellular matrix (ECM) 
disposition, mineralisation and maintenance.  
1.1.1. Endochondral ossification 
In embryonic development chondrogenesis occurs at the onset of skeletogenesis around 
embryonic day 9 (E9) in the mouse, and mesenchymal precursor cells commit to the 
chondrocyte phenotype by the signal cues from Paired box gene 1 (Pax1) and Pax9, which 
affects Nk3 homeobox 2 (Nkx3.2) and bagpipe homeobox homolog 1 (Bapx1) in the 
scleotome (Rodrigo et al., 2003). Sox9 a SRY-related high mobility group transcription 
factor is the most important factor during chondrogenesis, without its expression there is 
no commitment to the chondrocyte lineage (Bi et al., 1999). After initiation Sox9 
expression is required for cell morphology and chondrocyte differentiation (Barna and 
Niswander, 2007). As the extracellluar matrix is deposited this is regulated by the sox trio: 
Sox9, Sox5 and Sox6. Pax1 is later downregulated as Runt-related transcription factor 2 
(RUNX2) is expressed to induce hypertrophy of the chondrocytes at E13.5 in the mouse, 
Pax1 expressing progenitor mature to perichondrium cells and anlage of the intervertebral 
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disks (Takimoto et al., 2013, DiPaola et al., 2005, Wallin et al., 1994). Scleraxis (Sxc) marks 
chondroprogenitors cells and aids Pax1 in the initiation of chondrogenesis, later Scx 
expressing progenitors form the bridge between cartilage and ligaments/tendons (Figure 
2) (Sugimoto et al., 2013a, Sugimoto et al., 2013b, Cserjesi et al., 1995). Initially, the 
mesenchymal cells migrate to the site of future bone forming, the cartilage primordia, 
chondroprogenitors cells differentiate to chondrocytes to commence bone formation; 
they proliferate, mature and exit the cell cycle and lay down the outline of future bone. In 
the centre of the diaphysis of future long bones, the cells rapidly progress towards pre-
hypertrophy. These then become hypertrophic and form an avascular cartilaginous 
scaffold that is gradually surrounded by a dense connective tissue known as the 
perichondrium (Goldring et al., 2006). The hypertrophic chondrocytes secrete matrix 
vesicles that promote calcification of the cartilage, marking the start of bone formation. 
Adjacent to the chondrocytes, pluripotent stem cells differentiate into osteoblasts; these 
are able to secrete the bone matrix that forms a bone collar that begins to surround the 
hypertrophic chondrocytes. The osteoblasts align in and form the start of the diaphysis of 
the bone. The primary ossification centre (POC) develops as blood vessels penetrate the 
periosteum and progress towards calcified cartilage. Eventually, the osteoblasts lay down 
the bone matrix that forms trabecular bone (Figure 1) (Goldring et al., 2006, Mackie et al., 
2008).  
Epiphyses form where the chondro-osseous junctions form that split the cartilage 
template. This leads to the formation of the growth plate, around E14.5 in the mouse 
defined by the four morphologically identifiable zones: resting consisting of round 
chondrocytes, that serves as a reserve of progenitor-like cells; the proliferating regions 
that has the characteristic longitudinal columns formation where round cells divide, 
flatten and arrange in the direction of longitudinal growth under the influence of the non-
canonical Wingless (wnt) signalling pathway; the pre-hypertrophic is where the mature 
chondrocytes resides, the cells have left the cell cycle and undergo hypertrophic 
differentiation with the expression of indian hedgehog (Ihh) and collagen type X (Col10a1) 
(Yeung Tsang et al., 2014, Domowicz et al., 2009). The final zone, the hypertrophic, is 
divided into two sectors the upper and the lower, the chondrocytes expand in size in the 
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higher zone and in the lower zone cartilage calcifies to become bone (Goldring et al., 
2006, Yeung Tsang et al., 2014). At this stage the fate of the chondrocyte is controversial, 
it has been suggested they undergo apoptosis or autophagy whereas other believe that 
they undergo differentiation and lineage switch into osteoblasts. However, by the use of a 
Col10a1 cre recombinase lineage tracing experiment hypertrophic chondrocytes may 
switch lineages to osteocytes and osteoblasts and cre activated cells are detected in the 
POC and begin to express Col1a1, a marker for osteoblasts (Yang et al., 2014). From this 
point the growth plate expands and conventional bone growth, proliferation, matrix 
production and hypertrophy acts to increase the volume of the bone (Yeung Tsang et al., 
2014).  
Beneath the cartilage at the junction between the subchondral bone is separated by 
calcified cartilage, which persists after growth plate closure. Histologically is separated 
from the articular cartilage by the tidemark and is denser than the adjacent subchondral 
bone. It is uniquely adapted to transfer and distribute mechanical forces from 
physiological loading. Additionally, it helps to transform shear stresses into compressive 
and tensile stressing from the cortical plate during motion and joint loading (Milz and 
Putz, 1994, Burr and Gallant, 2012). 
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Figure 1: Endochondral bone formation 
 
Bone formation follows distinct phases that are recognised by the cell morphology. 
Chondrocytes follow from precursors and eventually become pre-hypertrophic and 
hypertrophic as the blood vessels infiltrate to allow cartilage matrix degradation and 
osteoblasts to rise. The chondrocytes arrange in the direction of bone growth to form the 
growth plates. As this occurs osteoblast lay down and mineralises the bone matrix that 
surround the chondrocytes. The growth plate is made by four populations of cells that for 
the hypertrophic, prehypertrophic, proliferating and resting zone (Yeung Tsang et al., 
2014). 
1.1.2. Intramembranous ossification  
Flat bones in the body such as those in the craniofacial skeleton (the calvaria, maxilla, and 
palate) are formed by intramembranous ossification. This occurs by the direct 
differentiation of mesenchymal cells into osteoblasts without the requirement of a 
cartilage template (Berendsen and Olsen, 2015). Neural crest-derived mesenchymal cells 
proliferate and aggregates into nodules, these cells commit to different linages, primarily 
osteoblasts but others will form vasculature such as capillaries. Osteogenic potential and 
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differentiation initiated in the mesenchymal cells via the signalling pathways fibroblast 
growth factor (FGF) and bone morphogenetic protein (BMP) and their target molecules 
Msh homeobox 1 (Msh1), FGF2 and Twist-related protein 1 (TWIST1) (Rice et al., 2000, 
Lenton et al., 2011). Vascular endothelial growth factor (VEGF) is essential in the 
development of the craniofacial skeleton and osteoblast-specific transcription factor 
osterix (Osx) are required for the commitment into intramembanous ossification (Duan et 
al., 2016, Duan et al., 2015). The osteoid forms between the forming blood vessels, the 
osteoid arise from the osteoblasts as they secrete collagen (mainly type 1) and 
proteoglycans that binds to calcium to allow mineralisation. As the osteoid becomes 
calcified, under the influence of TFs from the Wnt signalling  such as Wnt16 (Jiang et al., 
2014), osteoblasts move outwards leaving the matrix they secrete, dictating the direction 
of growth of the bone, some osteoblasts become trapped and become osteoclasts. 
Mesenchymal cells surround the osteoid and begin forming the periosteum creating layers 
of bone. Trabeculae in the periosteum thicken forming woven bone that is later replaced 
with lamellar bone and the vascular tissue become red bone marrow (Percival and 
Richtsmeier, 2013).  
The two developmental processes of bone development create one functioning 
skeleton.Understanding the critical steps of these processes are aiding in the development 
of treatment for cartilage and bone repair, remodelling and diseases. 
1.1.3. Postnatal skeletal development  
The epiphysis, metaphysis and diaphysis form the two ends and the shaft of the bone and 
the portion of these three sites increase with skeletal maturity. The longitudinal growth of 
the metaphysis and diaphysis continues after birth into childhood and adolescence. The 
epiphysis forms the spherical growth of the ends of the bone and shapes the articular 
surface that resides above it. It is also the site for the longitudinal growth by the 
expansion of the epiphyseal cartilage, resulting in defined regions. 
Formation of the secondary ossification centre (SOC) appears in humans around 3months 
to 3 years of age. The generation of the SOC follows the same pattern as the POC, a 
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cartilage scaffold is formed and is mineralised, angiogenesis occurs and de novo synthesis 
of the bone matrix by osteoblasts and appears to be regulated closely by the same 
signalling pathways dictating embryonic endochondral ossification. However, during the 
formation of the SOC vascularisation of the cartilage occurs much earlier, before the 
matrix mineralisation compared to the POC (Alvarez et al., 2005, Blumer et al., 2005).  
The growth plate chondrocytes reside on both ends of long bones and are essential for the 
continual linear growth of the bone  through cartilage deposition following the direction 
of mechanical stimulus, until in human they close at puberty and the metaphysis fuses 
with the epiphysis (Dirckx et al., 2013, Nowlan et al., 2010, Albro et al., 2011). In mice 
growth plates do not disappear rather the growth slows down to an almost resting state. 
The growth plate is divided into distinct zones that undergo cell proliferation, ECM 
synthesis, hypertrophy and mineralisation following the direction of bone growth. The 
formation of bone and the resorption of bone by osteoclasts in the cortical endosteal and 
lateral metaphyseal surfaces are tightly balanced to allow the shaping and growth of the 
bone. The hypertrophic chondrocyte is important in fracture repair, as cartilage promotes 
the vascularisation and integration of bone into the damaged site following the same 
procedure as endochondral ossification, but with the possibility of failure (Bahney et al., 
2014, Little et al., 2007). Additionally, the chondrocyte has the ability to transdifferentiate 
to osteoblasts during development, postnatally and during fracture healing (Zhou et al., 
2014, Ono et al., 2014).  
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Figure 2: Limb development and the key transcription factors of each stage 
 
Mouse limb development with key events in the chondrocytes and the transcription factors 
that act on each stage to delay or allow progression (Taher et al., 2011). 
1.1.4. Articular cartilage formation  
Cartilage is an abundant connective tissue found throughout the body, the chondrocyte is 
the only cell-type found in this tissue and it is progressively replaced by bone during 
development. However, some may remain in adulthood to provide support and natural 
function of joints. The gliding surfaces of synovial joints are covered by articular cartilage, 
a highly specialised tissue. The plentiful ECM comprising of proteoglycans and collagen 
fibrils that provide tensile strength defines cartilage and its ability to resist compressive 
loads and allow friction free movement. The articular cartilage forms when mesenchymal 
cells that are undergoing differentiation into chondrocytes cease to express col2a1 and an 
interzone starts and cells surrounding the forming joint express forming marked by 
growth and differentiation factor-5 (Gdf5) (Decker et al., 2015). In the mouse at E13.5 the 
dorsal and ventral cells of the developing joints express TGFβ type II receptor that remain 
in the localised zones to form the synovial lining, meniscal surface and groove of Ranvier 
(Figure 3) (Li et al., 2013). In the initial interzone cells that formed the intermediate 
compartment gives rise to the articular cartilage.  
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Postnatally, cells at the superficial region divide to allow for the articular cartilage to form 
and give raise to daughter cells that rapidly divide in the deeper zones that allows vertical 
growth along with the skeleton (Decker et al., 2014b, Decker et al., 2015).  
 
Figure 3: Synovial joint formation 
 
Mesenchymal condensations form (A) and as signals at the exact site of joint formation is 
initiated such as Hox cells gather and condense (B), the interzone forms (C) the interzone 
and epiphyseal cartilaginous tissue start moulding into the joint (D) and the components of 
the joint emerge with articular cartilage at each end (Pacifici et al., 2006). 
 
1.1.5. Fate determination of chondrocytes 
To regulate the lineage fate and bone development there are numerous signalling 
pathway ways that activate temporally. It is understood that the bone morphogenic 
proteins (BMPs) and transforming growth factor beta (TGF-β) signalling are required for 
the initiation of chondrogenesis. In mice at developmental day 10.5 (E10.5) the 
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mesenchymal cells in the limb buds aggregate to form condensed mesenchyme, the cell- 
cell association that occurs after cell aggregation and cluster formation are under the 
influence of BMPs and TGF (Barna and Niswander, 2007). Furthermore, BMP2 in a mouse 
embryonic fibroblasts culture induces chondrogenesis with a marked increase in the 
transcription factor (TF) High mobility group box member Sex-determining region Y- box 9 
(Sox9) expression. In mice, at E10.5, BMPs inhibit chondrogenesis whereas at E11.5 there 
is transient activation of the TGF-β signalling as chondrogenesis proceeds. Smad4 is 
common in both pathways and is essential in limb skeletogenesis (Benazet et al., 2012, 
Yan et al., 2014, Lorda-Diez et al., 2013, Retting et al., 2009). 
Sox9 along with L-Sox5 and Sox6 are a trio of TFs that are required and sufficient for 
chondrogenesis (Zhou et al., 1998, Ikeda et al., 2004, Bi et al., 1999). The Soxs have a Sry-
related HMG box domain which both binds and bends DNA. The protein contains 
additional sites including the dimerisation domain that allows binding of multiple sites on 
the DNA. The gene is switched on in mesenchymal cells expressed in prechondrocytes and 
switched off during the prehypertropyic stage of chondrogensis (Bi et al., 1999). The Sox 
trio orchestrates the organisation of the whole transcriptional machinery formation at the 
promoter. Sox9 is essential for chondrogenesis and cell determination of the chondrocyte 
lineage; indeed it is coined as the master regulator of chondrogensis (Bi et al., 1999, Bi et 
al., 2001, Dy et al., 2012). In the condensed mesenchyme Sox9 maintains cell morphology 
and promotes chondrocyte differentiation (Barna and Niswander, 2007). To show its 
importance, heterozygous human mutations in SOX9 results campomelic dysplasia a 
severe skeletal disorder characterised by poorly formed tracheal and rib cartilage 
(Akiyama et al., 2002, Akiyama et al., 2004, Bi et al., 2001). RUNX2 is essential for 
osteoblast lineage commitment. It is expressed co-ordinately with SOX9 and β-catenin 
(Akiyama et al., 2004, Clevers, 2006). WNTs/ β-catenin suppress Sox9 mediated 
differentiation and promote RUNX2 oestrogenic differentiation. The Hox proteins are 
essential in the developing embryo they are characterised by their ability to bind to the 
homeobox motif of DNA (Minguillon et al., 2012). The Hox-A and Hox-D are essential for 
limb patterning whereas HoxD 11-13 and HoxA13 regulate RUNX2 expression, therefore of 
importance in skeletal development (Kmita et al., 2005, Minguillon et al., 2012). BMPs, 
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WNTs and IHH are generated in the perichondrium cooperate or antagonise cell growth 
and the ability of cells to leave the cell cycle (Koyama et al., 2007). The non-canonical BMP 
signalling pathway plays a part in the maintenance of the growth plate (Retting et al., 
2009). Additionally, the transcription factors human short stature homeobox-containing 
gene (SHOX) has been identified to regulate limb bud development especially in the 
growth plate formation and the transition into mature chondrocytes (Beiser et al., 2014, 
Bobick and Cobb, 2012, Yu et al., 2007). IHH is needed for differentiation of round 
proliferative chondrocytes from the resting zone to the column forming chondrocytes. 
Additionally, the Gli transcription factors (1, 2 and 3) are important in mediating IHH 
signalling (Gualeni et al., 2010, Koziel et al., 2005, Hilton et al., 2005). They regulate 
proliferation and hypertrophy via a negative feedback loop with the parathyroid 
hormone-related protein (PTHrP) signalling (Mak et al., 2008, Hilton et al., 2007). This 
negative feedback determines the length of the proliferating zone and prevents 
premature hypertrophy, with PTHrP delaying the initiation of hypertrophic differentiation 
consequently regulating the size and length of the growth plate. Additionally, at this stage 
is it critical that the TF forkhead box C1 (FoxC1) direct and indirect activities, especially its 
interaction with Gli2  guide Ihh pathway to drive hypertrophy, as a specific loss of FoxC1 in 
chondrocytes results in abnormal skeletal development and death shortly after birth in 
knock-out mice (Yoshida et al., 2015).  In the proliferating zone chondrocytes divide in a 
column formation in the direction of bone growth, this spatial organisation is critical for 
the formation of normal bones. This is under the regulation of the non- canonical WNT 
signalling pathway allowing for planar cell polarity and organisation. Hypoxia inducible 
factor 1α (HIF-1α) has been shown to be active in chondrocytes (Lafont et al., 2007). It is 
required for ECM synthesis, chondrocyte survival and differentiation (Lafont et al., 2008, 
Lafont et al., 2007, Zhang et al., 2011). Notch signalling (Hilton et al., 2008). 
The final stage is the commitment of hypertrophic differentiation, on leaving the cell cycle 
they enter pre-hypertrophic state and initiate  the hypertrophic increase in size and cell 
shape. In the second stage of hypertrophy there is a swelling with no increase in mass. 
This stage may be partly dependant on IGF signalling (Cooper et al., 2013). 
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1.1.6. The chondrocyte environment: the ECM 
The chondrocyte in the articular cartilage secrete ECM that sustains the cartilage this plays 
an important structural and signalling medium for the cells, each chondrocyte is 
surrounded by a pericellular matrix (Akkiraju and Nohe, 2015). The ECM is highly ordered 
from the superficial layer to the deeper zones of the articular cartilage that can be divided 
into four zones: superficial, transitional, deep and calcified. The superficial contains 
collagen fibrils, collagen type II IX and XI and low levels of proteoglycans with the 
chondrocytes are elongated in shaped aligned parallel to the surface. This resists shearing, 
compressive force and tensile forces applied by locomotion (Yu and Urban, 2010, Gao et 
al., 2014).  
The transitional zone contains more proteoglycan therefore withstands compression 
better, it contains less collagen than the superficial that are organised in bundles or layers. 
The chondrocytes here are round and make up the majority of the height of the 
transitional zone. In the deep zones the chondrocytes share similar morphology to the 
transitional zone but aligned perpendicular to the articular surface with the largest 
composition of collagen that extend to the bone with proteoglycan content, especially 
aggrecan, is the highest here. The calcified zone is divided by the tidemark and acts as 
mechanical and physical interface between to the hyaline cartilage and the subchondral 
bone. Chondrocytes here are scarce and hypertrophic, the main function of this zone is to 
act as an anchoring point for the collagen fibrils (Cromar et al., 2014). 
The ECM is made up of collagens, proteoglycans, hyaluronan, link proteins and other 
smaller molecules. Collagens are the most abundant macromolecules that stabilises the 
matrix with the main type being type II. Proteoglycans make up the second largest group 
of macromolecules such as aggrecan, decorin and biglycan. (Akkiraju and Nohe, 2015, 
Belluoccio et al., 2006). The composition is the ECM is outlined in Table 1. 
 
 
Table 1: The composition of the extracelluar matrix 
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Protein Function 
Collagen 
Type II Tensile strength 
Type IX Tensile properties and interfibrillar connections 
Type XI Fibril formation 
Type VI Microfibrillar network by binding to hyaluronan, biglycan and 
decorin 
Type X Endochondral ossification  
Type XII Associated with collagen fibrils 
Type XIV Associated with collagen fibrils 
Proteoglycans 
Aggrecan Compressive stiffness 
Versican Calcium-binding and selectin-like properties 
Perlecan Cell-matrix adhesion 
Biglycan Binds collagen VI and TGF-β 
Fibromodulin Fibrillogenesis and interacts with type II collagen fibrils 
Decorin Binds collagen II and controls size and shape of collagen fibrils 
Lubricin Dose-dependent boundary lubricant of cartilage 
Chondromodulin-
1 
Glycosylated transmembrane protein. Inhibits angiogenesis 
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Proline arginine-
rich end leucine-
rich repeat 
protein (PRELP) 
Anchors basement membranes to connective tissue 
Osteoadherin 
(OSAD) 
Restricted to mineralised tissue, possible signalling molecule  
Chondroadherin 
(CHAD) 
Cell to matrix interaction by α2β1 integrin and cell surface 
proteoglycans 
Others 
COMP Stabilises collagen networks and fibril assembly 
Hyaluronic acid Interacts with aggrecan to allow retention 
Link protein Stabilises aggrecan G1 domain for hyaluronic acid 
Fibronectin Cell adhesion 
Laminins Glycoproteins, cell adhesion 
Matrilin-1 Ssh signalling, mechanical response, formation of filamentous 
network 
Matrilin-3  Binds to Collagen IX to form filamentous network 
Tenascin-C Extracellular matrix glycoprotein, modulates cell adhesion, integrin 
ligand 
The components of the ECM and cartilage (Belluoccio et al., 2006, Wilson et al., 2010, 
Sophia Fox et al., 2009). 
1.2. Aggrecan 
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1.2.1. The Lectican protein family  
Lecticans (also known as hyalectans) are family of proteoglycans that are found in the 
ECM and are only found in animals of a vertebrate lineage. There are four members of the 
family: Aggrecan (ACAN), Brevican (BCAN), Neurocan (NCAN), and Versican (VCAN), they 
are characterised by sharing similar C- and N- globular domains separated by a 
glycosaminoglycan attachment region (Kresse and Schonherr, 2001, Shibata et al., 2003).  
 
Each lectican has a characteristic distribution pattern in tissues. VCAN is ubiquitously 
expressed but mainly found in connective tissue, ACAN is the most abundant in cartilage, 
BCAN and NCAN are nervous system-specific.  
 
VCAN has hygroscopic properties that allow to help create a loose and hydrated matrix, it 
has a wide tissue distribution found in loose connective tissue fibrous, articular and elastic 
cartilage as well as in neuronal tissue. VCAN has roles in cell adhesion, proliferation, 
migration and ECM assembly. BCAN is one of the most important neural proteoglycan, 
unlike ACAN is does not contain a G2 domain and remains in a non-proteoglycan state. 
BCAN localised to the outer surface of neurons at perisynaptic sites and aids in the 
formation of the perineuronal net (Frischknecht and Seidenbecher, 2012). NCAN is 
expressed in the subplate and marginal zone of the brain and may play a role in neuronal 
migration and formation of axonal fibres (Maeda, 2015).  
 
The link proteins, also known as Hyaluronan and proteoglycan link proteins (HAPLN), are 
within close genomic proximity to the Lectican family genes. The link family stabilises the 
hyaluronic acid binding to the G1 domains of the Lectican family proteogylcans to allow 
aggregates to form. However, the close proximity of the link proteins to the proteoglycan 
in the genomic context does not mean they function together. For example HPALN3 is 
widely expressed in the heart, mammary gland, ovary, lymph node, spleen, thymus and 
lungs but ACAN is restricted to the aorta and trachea. Furthermore HAPLN1 is not co-
expressed in the same regions as VCAN (Spicer et al., 2003). HAPNL1 interacts with both 
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ACAN and VCAN but with the latter more strongly (Shi et al., 2004, Matsumoto et al., 
2003). 
1.2.2. The aggrecan protein 
The large aggregating chondroitin sulphate proteoglycan, aggrecan (ACAN), is the main 
structural proteoglycan found in the ECM, the main isoform of ACAN is around 240-270kD 
(Vilim and Fosang, 1993). It dictates the function of cartilage by the large number of 
glycosaminoglycans (GAGs) that surrounds it chondroitin sulphate (CS) and keratin 
sulphate domains (KS) (Valhmu et al., 1995, Kiani et al., 2002). HA is a large 
glycosaminoglycan that acts as a long-chain biopolymer in solution. HA facilitates in the 
retention of ACAN by forming aggregates stabilised by link proteins. The ACAN-HA 
complex is retained at the cell surface by connections with HA with HA synthase or HA 
bound to CD44.  The GAGs are highly negatively charged that attracts positively charged 
sodium ion from the tissue fluid which in turn retains water molecules into the local area 
due to a large osmotic swelling pressure that is created and extremely high fixed charge 
density (Kiani et al., 2002, Roughley, 2006, Johnson et al., 2014). ACAN is too large to 
redistribute and therefore forms a compression resistant gel. Additionally, ACAN swells in 
an aqueous environment limited by the collagenous framework which is in equilibrium 
and provides the tensile strength of the system. When a compressive force is applied 
water is displaced and ACAN concentration increases, once this load is removed the 
equilibrium is restored (Watanabe et al., 1998, Kiani et al., 2002). ACAN expression is well 
conserved in evolution and has been described in xenopus, mammals and other animals 
(Doege et al., 1991, Walcz et al., 1994, Li and Schwartz, 1995, Doege et al., 2002).  
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Figure 4: The chondrocyte environment 
 
The chondrocyte is the only cell type found in cartilage it produces all the nesscary 
elements of the matrix that gives cartilage its function. Aggrecan is found both in the 
territorial and interterritorial regions, it is the most abundant protein. It is reliant on the 
GAGs (green) that attaches to its CS and KS domains to keep the osmotic balance in 
cartilage. Collagen forms a network surrounding the chondrocyte that prevents the 
movement of aggrecan and the tension from the fibrils balances the osmotic pression 
created by the GAGs (Heinegard, 2009). 
1.2.3. The ACAN protein structure  
ACAN is synthesised as a 370kDa core protein precursor that undergoes post-translational 
modifications to make the mature 270kDa proteins and other isoforms. The protein 
structure of ACAN has three globular domains, one interglobular domain (IGD) and two 
GAGs attachment domains; CS and KS located between G2 and G3. The two N-terminal 
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globular domains, G1 and G2, show disulphide-bonded structural motifs (Figure 5). G1 
consist of three loop-like subdomains- loop A, B and B’ which are similar to link protein.  
The B and B’ loops form a tandem homologous repeat that is critical for hyaluronic acid 
binding activity and is therefore important in the formation of the ECM network. G2 lacks 
HA binding activity. Both G1 and G2 are highly conserved. The IGD is susceptible to 
cleavage by proteinases including matrix metalloproteinases (MMPs) and aggrecanases. 
The G2 domain is composed of disulphide-bonded B and B’ domains but with the inability 
to interact HA. KS domain allows GAG attachment composed of 6-residue amino acid 
repeats of proline and serine. The can be replaced by O-linked oligosaccharides or KS 
chains.  The CS domain follows the KS domain which is divided into two CS1 and CS2 
differentiated by their amino acid composition. CS1 has 19 amino acid repeats of two 
glycine-serine sequences, in humans this varies from 13-33 repeats; the reason for this is 
unclear. CS binds to the serine residues on GAGs. The CS2 has a variable amount of amino 
acids that allows the random distribution of CS chains. However, this leaves the region 
susceptible to cleavage from aggrecanases. The CS domain is the largest domain and is 
locate in the middle of the aggrecan core protein. It is divided into two subdomains CS1 
and CS2; it is coded for on a single exon, the CS chains consist of repeating disaccharides 
units of N-acetylgalactosamine and glucuronic acid, the N- acetylgalactosamine carbon 6 
and 4 are the sites for sulfation. Finally, the G3 domain is essential for the intra-cellular 
trafficking and secretion of the molecule. It is composite of three structural motifs: EGF-
like, Lectin-like and CRP-like. Its lectin domain is able to interact with other ECM proteins 
in vitro.  The lectin-like domain has been found to activate the complement pathway 
(Melin Furst et al., 2013). Due to proteolysis, the G3 domain is normally cleaved in the 
mature aggrecan molecule. Hyaluronan is a ubiquitous disaccharide chains and are non-
covalently bound to ACAN at the B and B’ domains to form aggregates (Watanabe et al., 
1997). After synthesis ACAN is secreted as monomers into the ECM and binds to 
hyaluronan by the intermediate link protein and 1 covalent link with matrilin-1 
(Heinegard, 2009, Cao et al., 1998), this allows the chondrocyte’s ECM to form distinct 
regions the territorial and interterritorial where the collagen fibrils form a mesh that 
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ACAN is too large to pass through localising the protein to the chondrocyte to confer its 
function (Figure 4) (Heinegard, 2009, Goldring, 2012). 
Figure 5: Human aggrecan protein and gene organisation 
 
The human aggrecan gene composes of 19 exons that code for the mature protein. The 
globular domains allows for the large size of the protein whereas the subdomains such as 
the KS and CS are sites where GAG attach. These sites are functionally important in 
preserving the ability of aggrecan to draw water into the cartilage (Morawski et al., 2012). 
1.2.4. Gene organisation of ACAN 
ACAN has now been fully sequenced and annotated in multiple genomes, for instance the 
human (Valhmu et al., 1995, Doege et al., 1991), mouse (Walcz et al., 1994, Watanabe et 
al., 1995, Krueger et al., 1999), rat (Doege et al., 1994), bovine (Hering et al., 1997) and 
more recently the equine (Caporali et al., 2015), throughout these species the gene 
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organisation remains conserved with the exception of the splice sites and variants derived 
from the G3 domain coding regions and the length of the introns (Table 2). The mouse 
aggrecan gene (Acan) spans more than 61kb and contains 18 exons, whereas the human 
aggrecan gene has been mapped to 15q26 containing 19 exons and 18 introns. The exon-
intron organisation of human and rat Acan are similar compared to the murine 
counterpart (Valhmu et al., 1995). In Acan for both mouse and human, exon 1 codes for 
the 5’ UTR and translation begins at exon 2, intron 1 is the largest intron being 21kb. 
Analysis of gene structure revealed that the B loops of G1 and G1 domains are encoded by 
two exons: B of G1 exons 4 and 5, B of G2 exon 8 and 9. B’ is encoded on 6 (G1) and exon 
10 (G2).  
Table 2: Gene organisation and comparison between human and mouse Acan 
 Human Mouse 
Domain Exons (bp) Introns (kb) Exons (bp) Introns (kb) 
5’ UTR 1 375 1 13.0 1 509 1 21.0 
Signal peptide 2 77 2 2.4 2 77 2 8.5 
G1-A 3 384 3 1.0 3 384 3 1.8 
G1-B 4 
5 
175 
128 
4 1.6 4 
5 
175 
128 
4 2.0 
5 1.5 5 1.6 
G1-B’ 6 294 6 1.9 6 294 6 1.4 
IGD 7 378 7 1.5 7 405 7 1.4 
G2-B 8 
9 
175 
128 
8 0.5 8 
9 
174 
129 
8 0.19 
9 1.4 9 1.5 
G2-B’ 10 294 10 2.1 10 294 10 3.0 
KS1 11 240 11 2.9 11 216 11 1.2 
KS2/CS 12 240 12 0.9 12 3482 12 4.7 
EGF1 13 114 13 8.4 13 114 13 2.8 
EGF2 14 114 14 3.2 - - 14 0.55 
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LEC 15 
16 
17 
159 
83 
145 
15 0.5 14 
15 
16 
158 
83 
145 
15 0.7 
16 0.8 16 0.9 
17 0.8 17 0.6 
CRP 18 183 18 0.5 17 183 -  
3’UTR 19 212 - - 18 74 -  
Comparison of gene organisation of aggrecan between human and mouse. The intron 
length between species varies although the coding sequences give similar coded proteins. 
The EGF2 within the G3 of the mouse aggrecan is not coded for. G1, G2 and G3 are the 
globular domains, keratan sulphate (KS) chondroitin sulphate (CS), and epidermal growth 
factor like domain (EGF), lectin- like (LEC) and complement regulatory protein- like (CRP) 
(Krueger et al., 1999, Watanabe et al., 1995, Valhmu et al., 1995, Walcz et al., 1994).  
IGD is located between the two globular domains and is coded for on solely exon 7 and is 
susceptible to proteinases. KS domain is located on the C-terminus of G2 and is coded for 
by exon 11 in mice and by exon 11 and the 5’ end of exon 12 in humans. Exon 12 encodes 
the CS domain. G3 region consist of two alternatively spliced EGF-like domains, a LEC-
domain and a CRP-like domain. Exon 13 and 14 encodes EGF-like, Exon 15, 16 and 17 for 
LEC-like region, only the exon 16 is capable of secretion of ACAN product (Luo et al., 
1996)and CRP-like by exon 18. In the mouse the EFG-like is coded for by exon 13 (Valhmu 
et al., 1995). The LEC-domain is coded for on exons 14, 15 and 16, and the CRP-like is 
encoded on exon 17 and 18 (Watanabe et al., 1995). Finally the extra exon in the human 
Acan, exon 19 codes for the 25 amino acid C-terminus of aggrecan core protein and the 3’ 
URT (Valhmu et al., 1995). 
1.2.5. Gene expression of Aggrecan 
ACAN has been found in various cartilage types such as in the growth plate and articular 
cartilage (Domowicz et al., 2009) as well as in developing limbs and bones, being 
expressed late in development. Additionally, ACAN is essential for the function of the 
intervertebral discs (IVD), located in the nucleus pulposus and it is contained by the 
collagen fibrils of the annulus fibrosis (Colombier et al., 2014, Melrose et al., 2008, 
Neidlinger-Wilke et al., 2006). 
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Additionally, it has been suggested that ACAN is involved in cardiogenesis. In chicks, at day 
7 of development the aortic wall is composed of the endothelium with little or no ACAN 
staining. By day 14 intimal thickening was clear a weak ACAN immunolabeling was 
observed. This was localised in the lamellar and interlamellar cell layers. At day 21 ACAN 
was still limited to the outer regions. Immunolabeling showed that ACAN had a restricted 
distribution across the aortic wall in chickens and ACAN content is low at all stages 
(Arciniegas et al., 2004, Zanin et al., 1999). It is further found in the endocardial cushion 
tissue cell, epicardial cells of the heart as well as the carotid artery and aorta (Lincoln et 
al., 2006b, Lincoln et al., 2006a, Fang et al., 2014). 
There are other  ACAN isoforms, such as those found lacking the GAG side chains, reside in 
the central nervous system found in the adult cerebral cortex, deep cerebellar, the 
colliculi, the spinal cord, dentate gyrus and in the hippocampus in rats (Domowicz et al., 
2008, Yamaguchi, 2000, Viapiano and Matthews, 2006). Other areas where ACAN has 
been identified include during liver fibrogenesis (Krull and Gressner, 1992) and in adipose 
(Voros et al., 2006). 
1.2.6. Aggrecan gene mutations 
Due to the importance of ACAN it is not surprising that Acan mutation associated diseases 
are uncommon due to lethality. However, when they do occur they result in severe 
skeletal defects, chondrodysplasias and early onset osteoarthritis (OA) (Gleghorn et al., 
2005, Aspberg, 2012).  To highlight the impact of genetic mutations in Acan, a missense 
mutation formed from a switch from G to A in exon 17 coding for the LEC-domain from 
the G3 domain results in a change in amino acid from valine to methionine (V2303M), this 
disrupts the interactions in the ECM and has been suggested to disorganise the ECM to 
cause the rare disease, autosomal dominant familial osteochondritis dissecans (Stattin et 
al., 2010). A disease characterised by the disassociation of the cartilage and subcondral 
bone from the surrounding tissue, disturbed chondroskeletal development, early OA and 
osteochondritic lesions in joints but doesn’t affect the translation of ACAN as normal 
levels of protein is detected compared to wildtype (Stattin et al., 2010). Another mutation 
in the LEC domain of the G3 domain results in an autosomal recessive form of 
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spondyloepimetaphyseal dysplasia, a disease characterised by severe short statue, 
brachydactyly. Radiographical examination reveals irregular epiphyses with widened 
metaphyses, spinal abnormalities such as platyspondyly and cervical-vetrabral clefts. The 
point mutation causes a substation of aspartic acid with asparagine (D2267N) obliterates 
one of the two calcium coordinates in the LEC-domain and creates an N- linked 
glycosylation site but is less disruptive then the V2303M mutant (Tompson et al., 2009). 
Whereas a failure in sulfation of ACAN can result in chondrodysplasia such as mutations in 
the enzyme Impad1, causes a loss of function leading to impaired sulfation of chondroitin 
on ACAN (Vissers et al., 2011). Histologically, in the mouse mutations in Impad1 shows 
delayed and disorganised maturation of the growth plate chondrocytes and no expression 
of ACAN in the joints (Sohaskey et al., 2008). Three loss of function heterozygous 
mutations in Acan results in advance bone age, early OA and short stature (Nilsson et al., 
2014). Mutations c.2026+1G>A, c706T>C missense mutation in exon 14 causes a protein 
switch of L2355P, and a frame shift c.272delA have different outcomes to ACAN. The first 
interrupts a highly conserved splice donor site leading to a disrupted protein sequence, 
the second in the LEC was predicted to perturb protein function and the third results in a 
truncated protein (Nilsson et al., 2014). This result in haploinsufficiency with the exception 
of the second with varying severity of disease.  Lastly, a failure of CS attachment or 
defective CS chain length results in short stature, delay cartilage formation and severe 
chondrodysplasia (Sato et al., 2011, Watanabe et al., 2010, Hiraoka et al., 2007, Schwartz 
and Domowicz, 2002). For example, a single nucleotide deletion or compound 
heterozygous nonsense mutation in the SLC35 gene family that codes for nucleotide-sugar 
transporter SLC35D1 in humans results in Schneckenbecken dysplasia (Hiraoka et al., 
2007). SLC35D1 is involved in CS biosynthesis and a loss reduces the chain length of CS and 
amount of chains on ACAN. Schneckenbecken dysplasia manifests itself with severe 
skeletal defects, a distinctive snail-like of the ilia from medial bone projection from the 
inner iliac margin, thoracic hypoplasia, flattening of the vertebral bodies and short, thick 
bones (Hiraoka et al., 2007). Acan mutations do not all affect the cartilage, Hodgkin 
lymphoma (HL) is a lymphoid neoplasm from B-cells, it is the most common cancer in 
adolescents with it aetiology poorly understood. A family with three of the five children 
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was diagnosed with classical HL and their blood was sequenced for a possibly genetic 
causes (Ristolainen et al., 2015). A homozygous deletion of Acan was found in all affected 
individuals and both parents and one unaffected child were heterozygous for the 
c2836_2892del which results in a 19 amino acid deletion (Ristolainen et al., 2015). It is 
thought that the microenvironment of the cancer cells promotes oncogenic potential, 
however due to heterogeneity of cancer, this deletion was part of a panel of 10 possible 
causative genes. Other interesting disorders arise from abnormalities in ACAN include 
schizophrenia (SZ) and biopolar disorder (BP), in the brain ACAN is localised to the 
perineuronal nets (PNN) and glial cells but in SZ and BP there was a decrease in ACAN in 
PNN and glial cells in (Pantazopoulos et al., 2015). Although not all variation in Acan are 
detrimental but beneficial in selective criteria and keeping genetic variation open in the 
population, for example a study conducted by Weedon et al in 2008 identified the SNP 
rs8041863 which appears to be one of the 20 important loci to determine the height of an 
individual (Weedon et al., 2008). 
In mice, mouse cartilage matrix deficiency (cmd) is naturally occurring disorder. It is 
caused by a 7bp deletion in exon 5 of Acan (Krueger et al., 1999). Autosomal recessive 
mutation characterised by cleft palate, short limbs, tail and snout. Heterozygous mice 
present normally whereas homozygous mice die of respiratory failure. This arise from 
poor formation of the tracheal cartilage resulting in the collapsed trachea (Watanabe et 
al., 1994).   
The Acan point mutations model the nanomelic chick is a lethal autosomal recessive 
genetic lesion, present with reduced trunk, head size and skeletal malformation due to 
reduced ACAN in the ECM (Domowicz et al., 2009, McKeown-Longo and Goetinck, 1982, 
Yamagata et al., 1993, Domowicz et al., 1996, Stattin et al., 2010, Li et al., 1993, Vertel et 
al., 1994). Nanomelic chondrocytes produce a truncated core ACAN protein precursor of 
300kDa, but fails to process the precursor at the endoplasmic reticulum and translocate 
the product (Vertel et al., 1993). 
In the Dexter and Scottish highland cattle Bulldog dwarfism is single locus disorder derived 
from a 4bp insertion in exon 11 (2266_2267insGCCA) known as ACANBD1 and a rarer -
I.M.H.Li  PhD Thesis 
 
Page | 46  
 
198C>T transition in exon 1 (ACANBD2) and follows classical Mendelian inheritance 
(Catalina Cabrera et al., 2016, Cavanagh et al., 2007). Homozygous present with severe 
chondrodysplasia of disproportionate dwarfism from abnormal cartilage formation, short 
vertebral column, micromelia, a large head with retruded muzzle, cleft palate, protruding 
tongue and die within the 7th month of gestation. Heterozygous cattle have a milder form 
of dwarfism. ACANBD1 and ACANBD2 results in nonsense mediated decay even heterozygous 
cattle have 8% mRNA levels of Acan when compared to their wildtype counterpart due to 
both variants of the disease producing premature stop codon in the mRNA (Cavanagh et 
al., 2007).  
1.2.7. Proteolysis of Aggrecan 
ACAN is sensitive to proteolysis at sites in the IGD between the N-terminal G1 and G2 
globular domains (Figure 6). MMPs, found in cartilage and bone have been shown to have 
the ability to degrading proteoglycans at neutral pH. MMP-3 was revealed in human 
articular cartilage to cleave at the Asn341- Phe342 bond in the IGD. Other MMPs -1, -2, -7 -8, 
-9 and -13 have been linked to the proteolysis of ACAN at the same site or sites closer to 
the C-terminus (Troeberg et al., 2014, Troeberg and Nagase, 2012). In OA patients the 
majority of ACAN fragments are not due to MMP activity but at the Glu373-Ala374 bond in 
the IGD (Sandy et al., 1992). This site is the work of aggrecanases, the first purified A 
Disintegrin And Metalloproteinase with Thrombospondin motif 4 (ADAMTS-4), then 
aggrecanase 2 or ADAMTS-5. The ADAMTS family of the metzincin superfamily of 
metalloendopeptidases have broad catalytic activities, they are proteinases that are both 
secreted and have extracellular potential. They have a common domain organisation of N-
terminus, signal peptide, pro-domain, catalytic, disintegrin-like domain, central 
therombospondin repeats, cysteine rich and spacers. ADAMTS-4 does not have further TS 
repeats. Proprotein convertase activity is required for the activation of ADAMTS 4 and 5; 
this enzyme allows for the removal the pro-domain to allow ACAN cleavage (Stanton et 
al., 2011). Cleavage sites for all the enzymes that degrade aggrecanare found in Figure 6. 
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Figure 6: Major proteolytic domains of ACAN 
 
Cleavage domains residing in the aggrecan core protein. MMPs (M), ADAMTS (A), Calpain 
(C) and HtrA1 (H) and the protein cleavage sites are named (Struglics and Hansson, 2012, 
Struglics and Hansson, 2010, Chamberland et al., 2009). 
In disease states where there is progressive loss of ACAN it is suggested that MMPs 
precede ADAMTS, temporal activation of the MMPs may due to the secretion and 
activation of the other enzymes. It is understood that MMP3 is required for the gradual 
truncation of the C-terminus of the G3 domain that is seen with age (Durigova et al., 
2011). Cleavage of ACAN occurs in the IGD, N-terminus of the G1 and G2 domains are 
pathologically important and found in OA patients. It should be noted that ADAMTS 
mediated ACAN loss is not blocked by Tissue inhibitor of metalloproteinase (TIMP) -1 or 
TIMP-2 or MMP inhibitors (Troeberg and Nagase, 2012). In the KS domain the releases of 
GAG chains leading to loss of function are thought to be instrumental in the progression of 
OA. Another proteases thought to have clinical importance in cleaving ACAN in the IGD 
are the mammalian high-temperature requirement A family of serine proteases (HtrA) as 
it is found in abundance in adult cartilage and is elevated in human OA cartilage 
(Chamberland et al., 2009). 
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Furthermore, certain regions of ACAN are targets of Cathepsins B, D and K cleavage. 
Cathepsin K has been shown specificity to G1, CS2 and KS domains. This cleavage site 
produces CS fragments which interact with Cathepsin K to allow for collagenolytic activity 
(Struglics and Hansson, 2012). It is predicted that the Cathepsins along with the MMPs 
allow the normal turnover of ACAN but their role in vivo requires further investigations. 
Although evidence from the Chloe mice, in which the aggrecan IGD is resistant to MMP 
cleavage, develop normally with normal growth plate (Little et al., 2005).  
In vitro experiments have identified M- calpain’s abilities to cleave ACAN at the IGD, KS 
and CS1 domains. There are multiple calpain cleavage sites with the fragments appear in 
arthritic cartilage as well as suggested for normal turn over (Struglics and Hansson, 2010)   
However, their clinical importance requires further experimentation (Maehara et al., 
2007).  
1.3. Transcription  
Transcription is the first step in eukaryotic gene expression, therefore its regulation 
underlines fundamental processes within the living organism such as differentiation and 
development. It is by no means static, but rather in development is episodic with a series 
of discontinuous bursts of gene activation and silencing occurring at the same time then 
an episode of relaxation while other genes are activated. Understanding how a gene is 
transcribed and the key regulators in this process provides avenues to understanding gene 
disorders and what happens in ageing. Additionally, provides targets for therapies and 
opportunities for development of tools to interrogate the signalling pathways and 
processes that define a cell. 
1.3.1. The chromatin landscape 
Each human cell contains around 2 metres of DNA, in the nucleus genes are encoded for 
by specific DNA sequences, which are organised around complex repeating unit of 
nucleoprotein (nucleosomes) structures collectively known as chromatins which need to 
be readily accessed during transcription and replication (Luger et al., 1997). The protein-
DNA complex of two tight superhelical turns of approximately 146bp of DNA around disk 
I.M.H.Li  University of Liverpool 
 
Page | 49  
 
shaped proteins. These proteins are composed of eight histone molecules two copies of 
H2A, H2B, H3 and H4 (Soboleva et al., 2014). These provide not only densely packaged 
DNA, but regulate transcription by not only providing a physical barrier or bend DNA to 
restricted access for DNA binding elements such as TFs. The histones occur approximately 
every 200bp and have a “beads on string” structure with DNA coating around (Olins and 
Olins, 1974). TFs are DNA-recognition proteins that interact with cellular enzymes or allow 
the conformational change of the chromatin. The nucleosome is formed by histone 
chaperones disposition of the histones and chromatin remodellers. This is organised 
differently depending on the cell-type and specificity these are dependent on 
modifications that the nucleosome presents such as histone modifications and DNA 
methylation (Siggens and Ekwall, 2014). Transcription can be permissive, repressed by 
methylation or repressed by polycomb (Figure 7). Post-transcriptional modifications of 
histones can dictate the transcriptional landscape, such as the polycomb transcriptional-
repression complexes. These are regulated by the PRC1 and PCR2 proteins known as PcG 
which are responsible for methylation of Histone 3 lysine 27 (H3K27) which results in a 
compact chromatin restricting access of TFs (Figure 7)(Di Croce and Helin, 2013). As cells 
differentiate the environment surrounding the DNA changes, the binding elements alters 
constantly which can dictate the activation of genes temporally. 
I.M.H.Li  PhD Thesis 
 
Page | 50  
 
Figure 7: The chromatin landscape  
 
The transcriptional landscape is a dynamic state and at promoters where transcription is 
initiated the DNA can be exposed to the transcriptionally permissive by the work of 
chromatin remodellers or histone marks such as acetylation. These histones in which the 
DNA is wrapped around undergo posttranscriptional modifications that mark the 
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transcriptional state from repressed or permissive. Methylation results in a blocking of TFs 
reducing transcription efficiency whereas the actions of polycomb proteins results in a 
compact landscape repressing transcription (Deaton and Bird, 2011). 
1.3.2. Mechanism of Transcription  
In eukaryotic cells RNA polymerase II (Pol II) carries out major gene transcription (Roeder 
and Rutter, 1969). For transcription to occur the DNA must be first unwound to expose 
the DNA sequence to allow the binding of the transcription machinery (Boeger et al., 
2003). The initial steps of transcription involve the recruitment of transcriptional 
activators that form the PIC (Figure 5) (Voss and Hager, 2014). The PIC at the promoter 
region bases before the TSS by the binding of activators and co-activators to specific 
sequences and completed by the recruitment of Pol II by protein- protein interactions 
(Murakami et al., 2013). The co-activator complexes act to strengthen the binding of 
activators and allow the DNA to be more accessible to the TFs. The histone is lost during 
transcription by the actions of ATP- dependent nucleosome-remodelling complexes. These 
promote the unravelling of the nucleosome by either moving or displacing the histones, 
this transient unwrapping of DNA, forming DNA loops or moving nucleosomes to allow 
better accessibility for TFs (Lorch et al., 2005, Lorch et al., 2010). Conversely, not all 
nucleosomes are removed; acetylated histones appear to accumulate during gene 
activation. Histones are not static, especially in actively transcribed genes in which histone 
dimers can be easily exchanged into and out of the nucleosome with the aid of 
chaperones. Additionally, the TFs binding sites of more active genes apparently positions 
in nucleosome free regions of DNA which are more exposed to the proteins in the nuclear 
environment.  
Pol II is independently capable of unwinding DNA during synthesis of RNA yet alone it is 
unable to recognise a promoter and initiating transcription. To facilitate its actions a 
system comprising of evolutionary conserved proteins termed the general (or basal) TFs: 
TFIIA, TFIIB, TFIID, TFIIE, TFIIF and TFIIH, are vital for basal transcription. The mediator, 
along with Pol II, is essential for transcription to start in almost all Pol II directed 
transcription and during mRNA elongation (Figure 8) (Kornberg, 2005, Takagi and 
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Kornberg, 2006). It facilitates PIC formation and bridges between protein activators at 
distant cis-regulatory elements such as enhancers and Pol II at the promoter (Kelleher et 
al., 1990, Robinson et al., 2016). Transcription starts at the assembly of nearly 60 proteins 
to form the transcription machinery (Conaway and Conaway, 1993). Pol II is positioned at 
the core promoter by a combination of TFIID, TFIIA and TFIIB. TFIIH allows the positioning 
of DNA into the PIC and RNA synthesis to occur. At this point the entire machinery may 
abort (abortive initiation) or escape (promoter escape) the promoter site, by the 
disassociation of TFIIB and the promoter sequence of the DNA, allowing transcription to 
be permitted (Liu et al., 2010). The “open” chromatin is a common feature of active 
transcription. 
Figure 8: The transcriptional pathway 
 
I.M.H.Li  University of Liverpool 
 
Page | 53  
 
Transcription is initiated at the promoter by the recruitment of activators and chromatin 
remodelling enzymes. This action removes or modifies the histones that the DNA surround 
to allow the exposure of transcription factor binding sites and other interaction sites on the 
DNA. The preinitiation complex forms with the arrival of the general transcription factors 
and DNA polymerase II. The mediator then interacts with upstream or downstream 
elements to permit transcription (Li et al., 2007). 
DNA enters the transcription machinery as a duplex, unwinds 3 bases before the active 
site of the machinery and sharply bends to allow the next nucleotide base to be flipped to 
face the active site. All 4 NTPs are found in the entry site of the machinery, they rotate to 
sample the DNA strand at the binding site. The addition of the NTP occurs by the motion 
of the trigger loop that is in contact with all moieties of the NTP. It swings like a trap door 
(Huang et al., 2010). The 2’-OH group that has been added to the RNA, the histidine 
promotes the flow of electrons during the nucleophilic attack of the 3’-OH acting as a 
proton donor triggering phosphodiester bond formation resulting in the positive selection 
of the complementary NTP. The wrong NTP creates a misalignment of the trigger loop 
therefore the network cannot form (Gnatt et al., 2001).   
Elongation Pol II CTD undergoes two major phosphorylation events. Ser5 is 
phosphorylated by TFIIH in the 5’ end of the open reading frame and Ser2 is 
phosphorylated by Ctk kinase as Pol II moves towards the 3’ end. A bridge helix in Pol II 
bends to allow the translocation of the template strand while allowing the RNA strand and 
DNA to remain in close proximity (Gnatt et al., 2001).  
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Figure 9: The chromatin 
 
The chromatin is composed of DNA wrapped around the histone octamers; these can 
permit or repress transcription. The promoter is situated around the transcription start site 
and is aided in the recruitment of activators and transcription factors by the proximal 
regions. Enhancers regulate transcription by interacting with the mediator at the promoter 
to facilitate transcription. Other elements such as insulators allow specific transcription 
and silencer to “turn off” transcription (Ong and Corces, 2011). 
RNA is released from the transcription machinery by the effects of 3 protein loops- fork 
loop 1, rudder and lid. The Rudder and lid lie between the DNA and RNA with the lid in 
contact with the RNA and rudder with the DNA. The lid acts like a wedge keeping the two 
strands as separate entities. The fork loops stabilises the complex (Kornberg, 2007). 
However, the promoter requires further signals from cis-regulatory elements to allow 
transcription to occur. Such elements include enhancers, silencers, repressors and 
insulators (Figure 9).  
1.3.3. Histone modifications  
The mammalian genome is partitioned into two states, the euchromatin (meaning 
permissive of transcription) and heterochromatin (inhibitory of transcription), the 
heterochromatin is generally considered as silencing of the gene, particularly in 
development and is enforced by the Polycomb group and is able to switch which is noted 
in diseases such as cancer (Dejardin, 2015, Trojer and Reinberg, 2007). Both the 
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euchromatin and heterochromatin are littered with histone modifications. The 4 histones 
are composed of the site of active transcription is free of nucleosomes whereas the 
histones that surround these sites show evidence of post transcriptional modification. 
These modifications can be said to be markers of the activity states of transcription. 
Histone tails and globular domains are subjected to post-translational changes including 
methylation, acetylation (by histone acetyltransferase complexes), ubiquitination, ADP-
ribosylation and phosphorylation of serines and threonines (Table 3, Table 4) (Lawrence et 
al., 2016).  
Methylations can affect the ability of certain protein binding affinity to the chromatin. In 
particular methylation at lysine 4 (H3K4me) is associated with active transcription, a tri-
methylation of histone 3 lysine 4 known as H3K4me3 is characteristic of transcriptional 
promoters due to the ability to recruit elements that can result in the formation of the 
PIC. Additionally, tri-methylation occurs around the TSS and appear to show the frequency 
of PolII that has travelled along this point. Conversely, it has little or no effect on 
elongation or Pol II processing but more like act like signalling centres. The nucleosome 
can be modified asymmetrically and symmetrically that appear to be of importance in 
development allowing certain genes to be poised for transcription especially in the case of 
methylation of lysine.  
Acetylation of lysine increases the accessibility of the DNA wrapped around nucleosomes 
(Voss and Hager, 2014, Kouzarides, 2007). It is generally a transient event that is linked to 
active transcription and a permissive chromatin such as acetylation of lysine 27 of histone 
4 (H4K27ac). The results of acetylation can reduce the positive charge of the histone 
resulting in a looser relationship between the DNA backbone and the histone tails 
allowing easy access for transcription factors (Soutoglou et al., 2000). As transcription is 
carried out there is dynamic acetylation and deacetylation and then resets the chromatin 
to reduce transcription getting out of hand. Additionally, heavily deacetylation of histones, 
along with cysteine methylation facilitates gene silencing.  
These histone modifications have the potential to change the net charge of the DNA 
resulting in a weakness in the protein-DNA interactions that allow DNA to unravel or 
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histone to be displaced (Zhao et al., 2005). They may allow different proteins to interact 
by protein-protein interactions and therefore influence the higher order chromatin 
structure. What is clear is that they have no single function but many in a dynamic 
environment. 
 
 
Table 3: Histone tail modification and their actions 
Histone Modification Type Effect 
H2A S1P Phosphorylation Chromatin assembly 
K4/5ac Acetylation Transcriptional activation 
K7ac Acetylation Transcriptional activation 
K119uq Ubiquitination Transcriptional repression 
H2B S33P Phosphorylation Transcriptional activation 
K11/12ac Acetylation Transcriptional activation 
K15/16ac Acetylation Transcriptional activation 
K123uq Ubiquitination Transcriptional activation 
H3 K4me2 Methylation  Permissive euchromatin 
K4me3 Methylation Transcriptional elongation 
R17me Methylation  Transcriptional activation 
K27me3 Methylation Transcriptional silencing; bivalent 
gene/ poising 
K36me3 Methylation Transcriptional elongation 
K9ac Acetylation Histone deposition/ 
Transcriptional activation 
K14ac Acetylation DNA repair/ Transcriptional 
activation 
K18ac Acetylation DNA repair/ Transcriptional 
activation 
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K27ac Acetylation Transcriptional activation 
T3P Phosphorylation Mitosis 
S10P Phosphorylation Mitosis/ Transcriptional activation 
H4 R3me Methylation Transcriptional activation 
K20me1 Methylation Transcriptional silencing 
K20me3 Methylation Heterochromain 
K5ac Acetylation Histone deposition 
K8ac Acetylation Transcriptional activation/ DNA 
repair 
K12ac Acetylation Histone deposition 
S1P Phosphorylation Mitosis 
Common histone tail modification on the N terminus and their effect on the nucleosome. K: Lysine, 
S: Serine, R: Arginine and T: Threonine. Table edited from (Lawrence et al., 2016) and (Karlic et al., 
2010). 
 
More recently novel histone modifications and cross-talk have been identified through the 
use of mass spectrometry (MS) and single molecule imaging (Shema et al., 2016). These 
include lysine crotonylation (the addition of the univalent radical crotonyl CH3-CH=CH-CO-
), lysine butyrylation, lysine propionylation, lysine succinylation and lysine hydroxylation, 
incorporation of small ubiquitin-like modifiers (SUMOlyation) (Tan et al., 2011). Histone 
modifications can form though a combination of different modifications, histone 
modification interactions (Hall et al., 2009), this leads to a histone landscape that can vary 
depending genes and the reason for this diversity remains unclear (Rothbart and Strahl, 
2014, Heintzman et al., 2009b, Henikoff and Shilatifard, 2011). 
Table 4: Histone globular domain modifications 
Histone Modification Type Effect 
H2A K36ac Acetylation Unknown 
K99me Methylation Unknown 
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K95me Methylation Unknown 
Q105me Methylation  Reduce 
nucleosome 
occupancy 
K119ac Acetylation Unknown 
K199uq Uniquitylation Unknown 
K75me Methylation DNA binding 
H2B K40me Methylation DNA binding 
K82ac Acetylation Charge 
neutralisation 
R96me Methylation Unknown 
K105ac Acetylation Unknown 
K117ac Acetylation Unkown 
H3 K122ac Acetylation  Active 
transcription 
K115ac Acetylation Destabilisation of 
nucleosome  
K64ac Acetylation  Transcriptional 
start/ mRNA 
generation 
K56ac Acetylation Transcriptional 
activation 
K56me3 Methylation Repressive 
T118P Phosphorylation Nucleosome 
assembly 
K79me3 Methylation Transcriptional 
start 
Y41P Phosphorylation Transcriptional 
activation 
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R42me1 Methylation Transcription 
activation 
K64me3 Methylation Pericentromeric 
heterochromatin/ 
Nucleosome 
stability 
H4 K91ac Acetylation Destabilisation of 
nucleosome  
K31ac Acetylation DNA binding 
S47P Phosphorylation  DNA binding 
K79ac Acetylation Silencing 
R92me Methylation Unknown 
Common histone globular domain modification on the N terminus and their effect on the 
nucleosome. K: Lysine, Q: Glutamine, S: Serine, R: Arginine, T: Threonine and Y: Tyrosine. Table 
edited from (Lawrence et al., 2016), (Tessarz and Kouzarides, 2014) and (Cosgrove et al., 2004). 
Therefore, the histones give an indication of the transcriptional state and the structure of 
the chromatin which can be used to mark out regulatory elements in the genome and a 
small number of corresponding histone modification taken together can predict levels of 
gene expression (Karlic et al., 2010).  
1.3.4. Variation of histones 
Nucleosome-free region at active TSS are followed by a strongly positioned +1 
nucleosome immediately downstream of the TSS that is independent from the class of 
promoter and is not constant throughout the cell cycle. The +1 nucleosome at active 
promoters is followed by uniform or phased arrangement of nucleosomes into the gene 
body; this is directional and apparently dependant on transcription since it is never found 
upstream of the promoter. Whereas a repressed gene lacks the phasing of nucleosomes 
and at the TSS is covered by histones (Lantermann et al., 2010, Valouev et al., 2011).  
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The H2A.Z histone variant is evolutionally conserved and critical for early development 
and gene expression regulation in embryonic stem cell differentiation is a variant of the 
H2A histone (Pandey and Dou, 2013, Subramanian et al., 2013, Hu et al., 2013). The 
function of the H2A.Z histone is associated with active transcription, since it is generally 
recognised at promoters or enhancers (Barski et al., 2007). When this histone is acetylated 
and ubiquitylated has shown to confer gene activation and repression (Sarcinella et al., 
2007, Valdes-Mora et al., 2012). The incorporation of SUMOylated H2A.Z appears to 
destabilise the chromatin and initiate the DNA damage response (Kalocsay et al., 2009, 
Schwertman et al., 2016). 
Other histone variants mark different events in transcription, such as the H3 variant H3.1 
is found almost exclusively during DNA replication (Tagami et al., 2004) whereas H3.2 and 
non-allelic H3.3 mark interphase and nucleosome disassembly and reassembly that 
maintains chromatin structure during transcription (Ahmad and Henikoff, 2002).  
These histone variants offer differences in the stability of the entire structure or exposes 
new sites for posttranslational modifications. For example during DNA double strand 
break repair the histone variant phosphorylated H2.AX (γH2.AX) cross talks with H3 
acetylation the instant DNA damage occurs to open up the chromatin exposing binding 
sites for DNA repair proteins (Lee et al., 2010, Shema et al., 2016). 
1.3.5. Promoters 
The core promoter is considered as a structural and functional transcription regulator. It 
contains the minimal sequence required for the interaction of the transcription machinery 
to initiate transcription. The DNA binding motifs are recognised by the general 
transcription factors TFIID recognises the promoter sequence (it is composed of TATA-box 
binding protein (TBP) and TATA-box binding protein -associated factors). Core promoters 
are a collection of DNA binding motifs that can be found together or independently to 
bring about transcription at the transcription start site (TSS). These motifs include the 
classical TATA box (Thomas and Chiang, 2006), TFIIB recognition element (BREu and BREd) 
(Burke and Kadonaga, 1996), Initiator (Inr) (Smale and Baltimore, 1989), motif ten element 
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(MTE) (Lim et al., 2004), downstream core promoter element (DPE) (Burke and Kadonaga, 
1997), Bridge, TCT, X core promoter element 1 (XCPE1) and downstream core element 
(DCE) (Kadonaga, 2012, Lewis et al., 2000). The TATA box is a classical site that is found at 
some eukaryotic promoters, it is located between 30-100 nucleotides before the TSS 
which the TATA box binding protein interacts with to partially unwind DNA and bend it 75-
80 degrees towards the major groove (Thomas and Chiang, 2006). This allows distant parts 
of the DNA to be closer facilitating transcription factors to make contact. However, it is 
now know that fewer than 22% of promoter regions in eukaryotic cells contain TATA 
boxes (Gershenzon and Ioshikhes, 2005). Promoter can be distinguished into focus and 
dispersed. Focus is deemed by a single or a close cluster of promoter sequences where 
transcription is initiated from. Where dispersed is a collection of “weak” promoter 
sequences spanning 100 nucleotides and the most common in the genome (Juven-
Gershon et al., 2008).  
In vertebrates cytosine bases in the configuration of CG are highly underrepresented in 
the genome with the exception of CpG islands. Cytosine in genomic DNA can be 
methylated at the 5th carbon to become 5-methylcytosine, these DNA methylation can act 
as a barrier for transcription attracting methylated DNA binding proteins that block 
binding sites (Siggens and Ekwall, 2014). The CpG regions are characterised by the CG 
repeats stretching on average 1kb with the dinucleotide, and unusually they are 
unmethylated. These are highly associated with promoter function and transcription start 
sites found in the 5’ region of genes (Spruijt and Vermeulen, 2014). Methylation of the 5’ 
of cytosine (5mC) can be read by 5mC readers that act, paradoxically, to regulate 
transcription on methylated cytosine, whereas normally methylation is normally a mark of 
gene silencing. Additional features of active promoters are the presence of histone 
modifications that prevent methylation events. The region immediately upstream of the 
core promoter is defined as the proximal promoter and is characterised by the multiple 
activator binding sites. The proximal region and the promoter tend to act synergistically as 
mutations in these regions dampen the ability of the core promoter (Hernandez-Garcia 
and Finer, 2014).  
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1.3.6. Insulators 
Insulators play an important role in segmenting the chromosome and creating 
independent domains and restricting the effects of other cis-regulatory elements such as 
silencers and enhancer to their target gene only. There are two types of insulators: 
enhance-blocking and barrier (Sun and Elgin, 1999, Ali et al., 2016). 
Enhancer blocking insulators are defined by their ability to interfere with the enhancer- 
promoter interactions when placed between the two. The mechanism of enhancer- 
blocking appears to be the ability to loop the DNA thus separating the two elements 
(Gaszner and Felsenfeld, 2006). In humans, this is done by the binding of the CCCTC-
binding factor (CTCF) at the insulator sequence. CTCF is a zinc-finger protein works in two 
suggested models. CTCF binds to the chromatin fibre via the protein nucleophosmin 
creating a loop and keeping enhancers and promoters in different domains so they cannot 
interact (Yusufzai et al., 2004, Ali et al., 2016). This model would explain the short 
distances for enhancers but does not account for the long distance interaction of 
enhancers, this is where it has been shown that CTCF can reduce the acetylation of 
histones and the recruitment of pioneer and activating TFs such as CBP and p300 resulting 
in a blocking of PolII (Zhao and Dean, 2004). The way CTCF affects transcription may be 
dependent on the context and the strength/ activity of the enhancer in which it insulates 
(Varma et al., 2015).  
Barrier insulators protect against position effects variegation, where  a gene in a lightly 
packed chromatin area is juxtaposed with a heterochromatin by rearrangement or 
transposition therefore silencing the region (Elgin and Reuter, 2013). Barrier insulators 
operate independently from the CTCF protein but rely on a heterodimer of Upstream 
transcription factor 1 and 2 (USF1/2) that recruit histone modifying enzymes to the region 
such as histone methyltransferases and histone acetyltransferases to deposit high level of 
transcription repressing the heterochromatin protein 1 (HP1) and protects the histones 
from H3K9 methylation thus preventing the spread of the heterochromatin (Ghirlando et 
al., 2012, Gaszner and Felsenfeld, 2006). 
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1.3.7. Silencers/repressors 
Silencers prevent gene expression and they are sequence specific elements that allow the 
binding of transcriptional repressors. There are three models that suggests how a silencer 
operates, in the first they silence transcription by interfering with PolII or pioneer factors 
(mainly TFIIB) from binding by promoting local chromatin condensation. The second is by 
the formation of transcriptional block by competition of a binding site, disrupting 
quenching or inhibiting activating TFs, forming a heterochromatin (Johnson et al., 2013, 
Thurman et al., 2012). For example the recruitment of polycomb complexes PRC1 and 
PRC2 to target sites condenses the chromatin forming a physical barrier for transcription 
(Chopra et al., 2012, Johnson et al., 2013).  The final by anti-looping between enhancers 
and promoter (Li and Arnosti, 2011, Chopra et al., 2012, Chen and Widom, 2005). In 
Drosophila it has been observed that Snail acts a repressor by binding at silencers and 
blocking enhancer- promoter looping and by inhibiting release of PolII from the 
transcription machinery (Chopra et al., 2012, Bothma et al., 2011). Silencers can be found 
in the proximal promoter, within enhancers or as standalone elements. For instance the 
Pax8 proximal promoter contains as a silencer, the Pax8 silencer drives tissue specific 
repression to allow expression in a tissue specific manner, such as the tail bud in Xenopus 
(Ochi et al., 2012). This silencer contains repressor motifs for RE1- silencing transcription 
factor (REST) and the homobox family Nkx which recruits histone methlytranferases (Muhr 
et al., 2001).  
1.3.8. Enhancers  
Enhancers are clusters of transcription factor binding motifs, those close to the promoter 
site are recognised as proximal promoters, first identified in viral genomes they were 
defined simply as DNA fragments that are located outside of the core promoter that 
increases the transcription of another gene (Banerji et al., 1981). These can regulate 
transcription by allowing distant transcription factors to interact with activators and co-
activators at the promoter or by direct contact with the promoter of the target gene (Yao 
et al., 2015). They play an active role in transcriptional bursting, periods of time where 
many transcripts are formed by release of PolII from active promoters then a refractory 
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period therefore instrumental in developmental gene activation. Areas of active 
enhancers are void of nucleosomes making the DNA regions accessible to the 
transcription machinary. Furthermore, they are marked by certain histone modifications 
to show a permissive chromatin such as acetylation of the 3rd histone at the 27th lysine 
(H3K27ac) and H3K4me1 (Heintzman et al., 2009a, Heintzman et al., 2007). They are able 
act independently of distance and orientation in relation to their target gene and are 
generally highly conserved in evolution.  Enhancers’ activation coincides with DNase1 
hypersensitivity (Lelli et al., 2012). Their suggested mode of action is by bending the DNA 
in loops to interact with their promoters even from a distance or by direct interactions 
(Tolhuis et al., 2002, Deng et al., 2012). 
1.3.9. Classification of enhancers 
1.3.9.1. Locus control regions 
The locus control region (LCRs) was first described in the β- haemoglobin gene, they are 
group of DNA elements that can regulate an entire locus or gene cluster (Schubeler et al., 
2001, Talbot et al., 1989). Defined by the ability to drive tissue specific and physiological 
expression of a linked transgene in a position-dependant and copy number dependant 
manner from a distance (Li et al., 2002). LCRs do not just encompass enhancers but 
include silencers, insulators, scaffold attachment regions and nuclear matrix binding sites 
that are regulated by TFs, coactivator and chromatin modifiers. They act as chromatin 
hubs that allow an open chromatin to loop to exclude or bring regions closer or further 
away to activate or repress transcription (Maston et al., 2006, Krivega and Dean, 2016). 
LCRs are uncommon in the genome and many genes do not contain LCRs, but studies have 
identified the human CD2 LCR is able to control cell lineage, suggesting the regulation of 
gene transcription may have evolved to encompass different mechanism that may be due 
to importance of the gene (Menzel et al., 2011). Furthermore, LCRs have been identified 
in the Th2 cytokine family IL-4, IL-5 and IL-3 (Lee et al., 2003) as well as in the human 
growth hormone multigene cluster LCR is able to form long range looping to form a hub to 
regulate the cluster in different tissues such as the placenta or pituitary (Tsai et al., 2016). 
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1.3.9.2. Stretch enhancers 
Stretch/ stitched enhancers (SEs) are clusters of enhancers, sharing the same selection 
criteria as normal enhancers, spanning greater than 3kb with no gap and are tissue 
specific with an overlap with the LCRs. Cell- specific gene activation appears to reside in 
SEs with genetic traits in genome wide association studies and are housed within these 
regions (Parker et al., 2013, Quang et al., 2015). They are thought to provide flexibility, 
precision and diversity in expression of important genes and resemble super-enhancers 
but without a high affinity to a master TF (Quang et al., 2015). 
1.3.9.3. Shadow enhancers 
Nature tends to have a backup for stochastic, genetic and environmental perturbations, 
this is known as canalisation (Siegal and Bergman, 2002). On a transcriptional level it has 
emerged that developmentally important genes have functional redundancy by using two 
enhancers that drive transcription with overlapping functions, normally found with the 
normal enhancer within the first intron and the second, coined the “shadow” enhancer, 
and is found upstream of the promoter. They also confer a more precise expression of the 
gene (Hong et al., 2008, Hobert, 2010, Perry et al., 2010, Frankel et al., 2010, Metzger et 
al., 2015). Shadow enhancers have been mainly described in the Drosophila studies into 
patterning where if one enhancer is removed, in optimum conditions there is no effects 
on the gene being transcribed, however, in extreme conditions such as high temperatures 
the loss of the enhancer is recovered by the second enhancer (Perry et al., 2010, Frankel 
et al., 2010, Staller et al., 2015). It must be noted that functionally redundant enhancers 
appear widespread in the genome suggesting that there is a level of transcriptional 
regulation we do not yet comprehend (Cannavò et al., 2016). 
1.3.9.4. Super-enhancers 
Recently the emergence of a new class of enhancers entered the field, termed Super-
enhancers. They are described as a group of putative enhancers in close genomic 
proximity with unusually high mediator (Med1) binding (Whyte et al., 2013, Loven et al., 
2013, Hnisz et al., 2013, Hnisz et al., 2015). The original selection criteria for super-
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enhancers were regions of the genome that were enriched in the master TFs Oct4, Sox2 
and Nanog based on ChIP-seq within 12.5kb of each other were known as stitched 
enhancers. These stitched enhancers were then ranked by Med1 binding with no 
functional assessment, the enhancers not enriched for Med1 were termed “normal” 
enhancers (Whyte et al., 2013, Pott and Lieb, 2014). However, the biological rational for 
the term super-enhancer is only based on the enrichment of histone marks and 
transcription factor. What remains to be determined is their functionality. Other groups 
have looked to define super-enhancers as binding to the master TFs for each cell type 
such as Sox9 for chondrocytes (Loven et al., 2013, Liu and Lefebvre, 2015). However, it is 
becoming clear without more functional studies and better characterisation there appears 
to be no evolutionary benefit or any difference between a super-enhancer as opposed to 
a cluster of normal enhancers, for example, within super-enhancers there are some single 
enhancer elements that are able to drive expression in the absence of the other 
enhancers in the cluster and it is also known that enhancers themselves can act co- 
operatively (Whyte et al., 2013, Pott and Lieb, 2014, Carey et al., 1990).  
Although the differentiation between enhancers and super-enhancers is weak it is certain, 
that the genome is highly enriched for enhancers that drive high level expression of a 
gene. Their importance is undisputed, as a single enhancer in these clusters can delay the 
time specific activation of a gene, the lineage fate of an entire cell, cell identity and in 
cancer allows heightened expression of oncogenes (Hnisz et al., 2013, Hnisz et al., 2015, 
Huang et al., 2016, Proudhon et al., 2016). 
1.3.9.5. Temporarily phenotypic enhancers 
Clustered regulatory interspaced short palindromic repeats (CRISPR) and its CRISPR 
associated protein (Cas9) has revolutionised genome editing, using bacterial defence to 
remove foreign DNA, it has been modified to target regions of the genome to delete, 
insert, activate and repress regions with high precision (Carroll et al., 2016, Chu et al., 
2015b, Dow et al., 2015, Ran et al., 2015, Sander and Joung, 2014, Shalem et al., 2015, Wu 
et al., 2013, Wu et al., 2015, Yin et al., 2014, Hwang et al., 2013, Thakore et al., 2015). 
CRISPR/cas9 has been utilised to identify on a large scale enhancers and to delineate the 
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higher chromatin order (Dominguez et al., 2016, Gilbert et al., 2013, Huang et al., 2016, 
Korkmaz et al., 2016, Li et al., 2014, Meyer et al., 2015, Miura et al., 2015, Nissim et al., 
2014, Pefanis et al., 2015). A recent development in enhancer biology is the identification 
of a class of enhancers termed “Temporarily phenotypic enhancers. This work is in its 
infancy and in dire need for further investigation it demonstrates the importance of 
technology guiding better understanding of the eukaryotic gene regulation. The 
identification of this class of enhancers arise from a screen for cis-acting elements of the 
POU5F1 gene in embryonic stem cells using 1964 RNA guides for CRISPR of the topological 
associated domain (TAD) identified 174 candidates. Introduction of mutations into 2 of the 
elements (DHS_65 and DHS_108) and using the technique of local condition phasing of an 
enhancer green fluorescence protein (eGFP) to detect the changes in the expression of the 
promoter due to these mutations, identified that the cells were able to recover from a dip 
in eGFP expression after loss of the enhancer elements (Diao et al., 2016, Selvaraj et al., 
2013). The group termed these Temp enhancers, and describes them as a non-canonical 
regulatory element that resides in an open chromatin, with low/weak level of activity in 
vitro activity, distal from their cognate promoter but their loss leads to a transient loss of 
activity at the promoter (Diao et al., 2016).  
1.4. The 3D genome: looping in and looping out 
Enhancers allow communication in the chromosome by interacting with promoters or 
direct contact with a corresponding loci, however, direct physical association does not 
account for all chromosome cross-talk as stochastic contact between proteins only occur 
when they are in close proximity. There are other proposed modes of communication 
such as diffusion of TFs, chromosome organisation and long range interactions. This is true 
for the epigenetic X-chromosome inactivation that communicates in more than one form. 
Inactivation is controlled by the long noncoding RNA Xist and its regulatory complex X-
inactivation centre (Xic). Xist forms at the cis-acting elements in the Xic and spreads the 
signal to inactivating proteins to gradually silence the X-chromosome, this also requires 
initial inter-chromosome communication by transient contact to initiate signals by TFs to 
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allow long range chromatin interactions and eventual chromatin spreading and silencing 
and (Galupa and Heard, 2015, Chu et al., 2015a).  
Genome compartmentalisation into megabases that reduces the distance between 
regions of the chromosome so during the cell cycle these regions can interact within one 
cycle. Active regions interact with active regions and inactive with inactive, this allows 
genes to be highly expressed during the cell cycle. How these boundaries regulate gene 
activation is still poorly understood, but it is thought that looping of the chromatin 
facilitates interactions, or excludes regions to silence the region and it is believed that 
enhancers allows the looping of these regions (Figure 10) (Dekker and Mirny, 2016, 
Chopra et al., 2012, Deng et al., 2012, Fukaya et al., 2016, Goloborodko et al., 2016a, 
Goloborodko et al., 2016b). In a study that challenges the looping mechanism, the 
Drosophila enhancers’ hunchback proximal enhancer and even-skipped (eve) stripe 2 
enhancer activity was visualised by labelling their target promoters MS2-YFP that contains 
the sna shadow enhancer and promoter and the MCP-GFP (Fukaya et al., 2016). The study 
showed that weak enhancers do not promote strong transcriptional bursts compared to 
strong enhancers and that bursts of transcription were coordinated at each promoter that 
share the two enhancers rather than enhancers alternating promoters, and forming loops 
to activate them, this suggests that promoters and enhancers not only forms loops but are 
directly linked or that promoters are linked to each other and that transcriptional 
activation is coordinated (Fukaya et al., 2016). With advancing technology in chromosome 
capture and imaging of chromosomes, it may reveal the role of enhancers and their role of 
interacting with promoters.  
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Figure 10: Looping interactions during the cell cycle that regulate gene activation 
 
Loop extrusion (A) creates distances between regions of the chromatin to prevent 
interaction while bringing regions of the DNA to closer proximity which can be blocked by 
insulator regions or boundary elements such as CTCF (B). Looping allows the formation of 
domains in which transcription can be regulated more tightly and can allow long range 
interactions (Dekker and Mirny, 2016). 
1.5. Transcriptional regulation of ACAN  
1.5.1. The promoter 
Unfortunately there is little known of the regulation of the ACAN gene despite its essential 
role in cartilage. In regards to the transcriptional regulation of the Acan a screen of rat, 
mouse and human aggrecan gene showed that it lacks classical TATA box binding sites, 
which is the location the TBP  binds to initiate transcription or a CCAAT box (Doege et al., 
1991, Doege et al., 1994, Watanabe et al., 1995, Pirok et al., 1997). However, at the 
predicted position there is a TATG site and multiple AP-2, AP-4 and SP-1 binding sites that 
can mediate the transcription start of TATA-less promoters (Valhmu, 1998, Pirok et al., 
1997). Further studies have linked other factors that can influence the transcription of 
aggrecan such as TGF-β signalling (Radons et al., 2006), HIF-2α (hypoxic conditions) 
(Lafont et al., 2007) and hydrostatic pressure (Neidlinger-Wilke et al., 2006). Recently, 
Acan has been shown to be a target of SHOX proteins along with Sox9, which are able to 
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upregulate Acan mRNA and protein levels (Aza-Carmona et al., 2014, Aza-Carmona et al., 
2011, Tiecke et al., 2006). 
1.5.2. Silencer 
When determining the regulatory sequences in Acan a 1.8kb sequence was gradually 
reduced in pGl2 luciferase reporter assays that were transfected into 14 day chick sternal 
chondrocytes (Pirok et al., 1997). Two silencer sequences were identified in the 5’ UTR of 
the chick sequence. The first sequence located between -873 and -721, contained the 
CACCTCC (CIIS2) sequence which was shown to repress Col2a1 promoter (Savagner et al., 
1990). The second sequence ACCCTCTCT (CIIS1) was found at position 127 is identical to 
the Col2a1 sequence and location. The removal of these two sequences removes the 
tissue specificity of the Acan promoter expression, suggesting that the silencer acts in 
different tissue types to down regulate Acan expression (Pirok et al., 1997). The Col2a1 
silencers are regulated by mouse Snail family Snail and Slug which acts as transcriptional 
repressors interacting with FGF receptors to down regulate ACAN and Col2a1 in pre-
hypertrophic chondrocytes (Seki et al., 2003, Hong et al., 2009). 
1.5.3. The untranslated region 
The 5’ and 3’ UTR of genes tend to play critical roles in regulating transcription, the Acan 
UTRs are no different. To determine the role of the UTR the 5’ and 3’ regions were cloned 
to the pGEM-luc reporter and upstream of the CMV promoter and then transfected in to 
bovine articular chondrocytes. The 5’ region alone significantly down regulated the 
luciferase activity by 92% (Valhmu, 1998). However, when the Acan promoter replaced 
the CMV promoter and the 5’ UTR was placed directly upstream the expression increased 
by 7.7 fold when compared to promoter alone. Whereas  the 3’UTR downregulated the 
Acan promoter expression by 68%whereas and together the UTRs reduced expression by 
45% (Valhmu, 1998). It is noted that sequential removal of the promoter had little effect if 
the 5’UTR is present but removal of the 5’ UTR reduced expression from between 85% to 
100% suggesting this region can act as a promoter for Acan (Valhmu, 1998). 
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1.5.4. Enhancer elements in the aggrecan gene 
In terms of enhancer elements of Acan recent work has attempted to delineate the 
regulatory elements of the gene. Doege and colleagues showed that a 4.6kb segment 
12kb upstream of the transcription start site in the rat Acan was able to activate ACAN 
expression in chondrocyte cells. Additionally, this region weakly promoted ACAN 
expression in transgenic mice embryos E14.5, in a cartilage specific manner, but only in 
hypertrophic chondrocytes (Doege et al., 2002). This segment does not however drive 
ACAN expression in intervertebral discs and distal digits in development, suggesting other 
regions in the gene may cooperate in ACAN expression in vivo. One verified highly 
conserved enhancer of Acan, approximately -10kb in the mouse gene found in the 4.6kb 
segment previously analysed, was first described by Han and Lefebvre (2008), and with 
which the Sox trio interacts to allow the normal function of the enhancer. They noted 
Sox9 required the interactions of the L-Sox5 and Sox6 to bind to the enhancer. This 
enhancer element could drive ACAN expression in both transfected cells and in vivo in 
both adult and embryonic tissue in a specific manner typical of ACAN expression (Han and 
Lefebvre, 2008). SHOX and SHOX2 interact with Sox9, L-Sox5 and Sox6 to activate the -
10kb Acan enhancer shown by yeast two-hybrid assay and luciferase expression in human 
bone osteosarcoma epithelial cells. These TFs collectively could allow activation of ACAN 
in limb development. Hu and colleagues utilised ENCODE data and conservation in the 
human aggrecan gene to locate possible enhancer motifs. They identified 11 regions 
capable of regulating ACAN expression in zebrafish. In these 11 regions, one was 
homologous to the known enhancer region. However, in zebrafish the expression was 
apparent in skeletal muscle which diverges from expression described by Han and 
Lefebvre. 8 of the 11 regions regulated cartilage specific expression at varying time points 
in development with the remaining regions only expressing in certain cartilage cells. 6 of 
the 11 regions were conserved at the chicken locus. Upon transfection of the chicken 
homologous sequence into zebrafish the results showed that 5 of the sequences 
presented with  conserved expression. Of these regions, two had predicted sites of Sox 
binding, two with multiple transcription factor binding sites and one with none predicted 
(Hu et al., 2012). Their data suggests that Acan has multiple enhancer regions which may 
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regulate ACAN expression at different stages of development or they may form part of a 
redundant regulatory system. Ikeda and colleagues reanalysed the Han and Lefebvre 
(2008) regions. They showed that in the region -10kb from the Acan TSS (which was 
named A1) there is another element capable of expressing ACAN strongly in transiently 
transfected chondrocytes (Ikeda et al., 2014). However, they failed to show its expression 
in vivo. This data points to a greater transcriptional control of Acan compared to other 
ECM based genes.  
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2. AIMS AND OBJECTIVES  
The aim of this body of work is to identify and verify whether Acan expression is driven by 
other enhancer elements. The revelation of TFs that bind to the core sequences and 
regulate the chondrocyte phenotypic expression of these regions or to establish if there is 
temporal expression of different TFs which allow differential activation of Acan would 
allow an appreciation of the mechanism of transcription. This is because it appears to be 
more complex for this gene based on current knowledge. 
The transcriptional regulation of aggrecan in adult articular cartilage remain vague. It is 
uncertain if developmental expression of ACAN and adulthood expression of ACAN is 
maintained by different cis- acting elements or if there is a balance of other contributing 
factors. Therefore, the establishment of any enhancers identified is specific to adulthood 
would be essential for the understanding of maintenance of adulthood expression of 
ACAN; if particular enhancers interact with different transcription factors during this age 
or if there is redundancy in the system, would also be a critical understanding to the 
transcriptional environment of ACAN.  
It is known that ACAN and the mRNA of Acan are found in other non- cartilaginous tissues, 
but the drivers of this expression are poorly understood. Different enhancers can allow 
tissue, or even cell type, specific manifestation of certain genes or the possibility that the 
enhancers of one tissue type represses that expression in other tissues. Therefore, the 
identification of other enhancers that define tissue expression can set the ground work for 
future studies into non-cartilage degenerative disease involving ACAN.  
An appreciation of the transcriptional regulation of aggrecan can give us the basic 
understanding of normal systems within joints and the possible pathways that deteriorate 
in disease states such as osteoarthritis, where the loss of ACAN is one of the major events. 
Once identified the key regulatory regions of Acan it is in hope that these sites can be 
targets for cell-specific treatments of such diseases as enhanceropathies are being 
established as modes for disease progression. 
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3. MATERIALS AND METHODS 
3.1. Competent Bacterial Strains 
For general cloning the competent bacteria used for were the One Shot® TOP10 
Chemically Competent Escherchia coli (E.coli) (ThermoFisher Scientific, C404010) or in-
house propagated TOP10s. For cloning the pGl3 luciferase vectors Subcloning Efficiency™ 
DH5α™ (ThermoFisher Scientific, 18265-017), Single-Use JM109 (Promega, L2005) and 
JM109 propagated in-house were used.  
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3.1 Cloning vectors 
3.1.1. Invitrogen™ Gateway™ Cloning 
Figure 11: Schematic pCR8 GW vector 
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3.1.2. pCR™8/GW/TOPO® TA  
The pCR™8/GW/TOPO® vector was used in TA based cloning to place PCR products into an 
intermediate ready for further cloning, it creates an entry vector for Gateway® cloning. 
The TOPO® utilises a single 3’ thymidine to take Taq polymerase amplified products. It 
benefits from Topoisomerase I from Vaccinia virus covalently bound to the ends of the 
linear vector at the TA site that binds to “CCCTT” sites on DNA to break the 
phosphodiester bonds on one strand of DNA and releases energy that is used to for 
another bond between 3’ phosphate of the cleaved strand and the Tyr-274 residue on the 
Topoisomerase I. The attL sites that flank the inserted PCR product allows the flipping of 
the insert into a destination vector. 
Figure 12: TOPO insert site  
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3.1.3. HSP68/LacZ/GW  
Figure 13: HSP68/LacZ/GW vector schematic 
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The HSP68/LacZ/GW was a gift from Nadav Ahituv (Pennacchio et al., 2006), it is used to 
generate the transgenic mice used in this study. It contains a Gateway® cassette fused the 
heatshock protein 68 minimum promoter (HSP68) (-664 to +113bp/ heatshock protein 
family A member 1A)  and LacZ gene (Kothary et al., 1989) which has no constitutive 
expression in transgenic mice. The Gateway® cassette allows the vector to be the 
destination vector when the entry vector is introduced in the presence of the 
bacteriophage lambda recombination protein Integrase and Excisionase found in the LR 
Clonase mix (Invitrogen).  
3.2. Luciferase based vectors  
3.2.1. pGl3- Promoter 
The pGl3-Promoter has MSC to allow insertion of genes/ sequences of interest. It contains 
a modified Photinus pyralis firefly luciferase and synthetic poly(A). It houses a Simian virus 
40 (SV40) promoter with MCS upstream and downstream to assess the function of DNA 
elements. This was used to characterise the expression of the Acan enhancers in cells in 
the absence of the endogenous promoter 
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Figure 14: pGl3-promoter vector 
 
3.2.2. pRL-TK 
The pRL-TK contains a Renilla luciferase and is used as an internal control reporter to 
normalise for transfection efficiency. The herpes simplex virus thymidine kinase (TK) 
promoter luciferase was chosen due to its low level of expression when transfected into 
mammalian cells. 
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Figure 15: pRL-TK vector 
 
3.3. Plasmid preparation  
3.3.1. Making TOP10 competent cells for general cloning 
3.3.1.1. Recipes  
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3.3.1.1.1. TFBI 
Reagent  For 500mL 
30mM Potassium acetate (KOAc) 1.45g 
50mM Manganese (II) chloride 
(MnCl2)* 
4.9g 
0.1M Rubidium chloride (RbCl) 6g 
10mM Calcium chloride (CaCl2) 0.735g 
15% Glycerol 75mL of 100% 
glycerol 
0.2M Acetic acid Use to pH to 5.2 
dH2O To 500mL 
*MnCl2 was added last as it precipitates otherwise 
TFBI was filter sterilised using a 0.2µm filter and store in 45mL aliquots at -20°C. 
3.3.1.1.2. TFBII 
Reagent  For 200mL  
10mM MOPS sodium salt 
pH7 
20mL 
75mM Calcium chloride 
(CaCl2) 
2.2g 
10mM Rubidium chloride 
(RbCl) 
0.24g 
15% Glycerol 30mL 
TFBII was filter sterilised using a 0.2µm filter and stored in 12mL aliquots in the dark at -
20°C. 
Chemically competent E.coli used for propagation of vector constructs were grown in-
house from a small amount of One Shot® TOP10 Chemically Competent E.coli. A portion of 
the original bacterial stock was collected using a sterile inoculation loop and streaked onto 
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an antibiotic free Luria-Bertani with Lennox L agar (LB-agar) plate. The plate was 
subsequently incubated overnight at 37°C. The following day 4mL of Luria-Bertani broth 
(LB-broth) was inoculated by a single colony from the LB agar plate and incubated for 16 
hours at 37°C shaking at 150rpm to create a starter culture. The starter culture was 
transferred to 2x 150mL of LB broth and grown in at 37°C shaking incubator (225rpm) for 
2-4hours until the optical density reached 0.3-0.4 at wavelength 600nm. The culture was 
then centrifuged at 8,000g for 10 minutes to create a bacterial pellet and the supernatant 
aspirated and disposed of. The pellet was resuspended in 10mL of ice cold TFBI on ice by 
trituration and incubated on ice for 15 minutes and then centrifuged at 8,000g for 5 
minutes. The supernatant was aspirated and disposed of and the remaining pellet was 
resuspended slowly in 500 µL ice cold TFBII on ice by pipetting. The resultant chemically 
competent bacteria was pooled and diluted in 8mL of ice cold TFBII, inverted to mix, 
aliquoted, snap frozen in liquid nitrogen and stored at -80°C until use.  To check for errors 
a sample was plated on LB agar plate which contained 100μg/mL of ampicillin to ensure 
no growth occurred after overnight incubation. To check the transformation competency, 
pUC19 were transformed in parallel with the new stock compared to the old stock in a 
dilution series to ensure similar colony-forming units (CFUs). 
3.3.2. Preparation of JM109 or DH5α E.coli competent cells 
3.3.2.1. Solutions  
3.3.2.1.1. 60mM CaCl2 
Reagent For 500mL 
CaCl2 (Sigma) 4.4g 
1,4-Piperazinediethanesulfonic acid 
(PIPES) 
1.73g 
Glycerol 70mL 
ddH2O  To 500mL 
I.M.H.Li  University of Liverpool 
 
Page | 83  
 
Adjusted to pH7 with NaOH, filter sterilised using 0.2μM syringe filter and stored at 4°C.  
A stock of JM109 or DH5α E.coli was streaked onto LB agar plate with no antibiotics 
and incubated overnight at 37°. A single colony was selected from the plate and 
incubated in 5mL of LB broth with no antibiotics at 37°C shaking at 225rpm to create 
a starter culture. 2 x 250mL LB broth with no antibiotics were inoculated with 2.5mL 
of starter culture and then incubated at 37°C until OD at 600 was between 0.3 -0.4. 
The 250mL cultures were divided into 50mL Ultra High performance (up to 20,000g) 
centrifuge polypropylene tubes and centrifuged at 1600g to produce a pellet. The 
supernatant was discarded and the bacterial pellet was pooled by suspending gently 
on ice in 40mL of ice cold 60mM CaCl2. The suspension was centrifuged at 4°C at 
1100g for 5 minutes and the supernatant was discarded. Following this the bacteria 
was suspended in 40mL of ice cold 60mM CaCl2 and incubated on ice for 30 minutes. 
Bacteria was then centrifuged at 1100g for 5 minutes at 4°C and the pellet was then 
resuspended in 8mL of ice cold 60mM CaCl2 and aliquoted into 100μL stocked in pre-
chilled 1.5mL centrifuge tubes and frozen on dry ice before storage at -80°C. To verify 
and test efficiency new stock, a sample of new and old stock of bacteria were 
streaked onto ampicillin LB plates and incubated at 37°C overnight. In parallel 10ng of 
pUC19 control vector was transformed into 25μL of old and new stock of bacteria and 
incubated at 37°C overnight. No colony should be observed on ampicillin plates and 
the number of CFU in the transformation was compared. 
3.3.3. Mini-prep of plasmids DNA 
After successful transformation a single colony of bacteria was used to inoculate 4mL 
of LB broth containing appropriate antibiotic for selection, and incubated overnight 
at 37°C with shaking to create a starter colony.  The following day 3mL of culture was 
pelleted in a 1.5mL centrifuge tube and resuspended in 100μL buffer P1 (Qiagen) 
followed by alkali lysis by the addition of 100μL of buffer P2 (Qiagen), inverted 6 
times and incubated at room temperature for no longer than 5 minutes. 100μL Buffer 
P3 (Qiagen) was added to neutralise the solution and the tube inverted 6 times and 
incubated on ice for 5 minutes. The chilled solution was centrifuged at 16,000g for 10 
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minutes. The supernatant was transferred to a clean 1.5mL centrifuge containing 
500μL 200 proof EtOH and place at -20°C for up to an hour. The DNA was pelleted by 
centrifugation at 16,000g for 10 minutes at room temperature. The EtOH removed 
and the pelleted washed with 750μL 70% EtOH and allowed for air-dry. The pellet 
was resuspended in 50μL of nuclease free dH2O. The purified plasmid was subjected 
to restriction enzyme digestion and electrophoresis to ensure the correct plasmid 
was present and then stored at -20°C. The remaining starter culture was used to 
create a glycerol stock to store vectors long term.  
3.4. Identification of limb specific aggrecan enhancers  
The Encyclopedia of DNA Elements project (ENCODE) provides publically available data 
sets on functional elements of the genome that can be viewed on  their hub or at The 
University of California at Santa Cruz (UCSC) genome browser (https://genome.ucsc.edu/ 
). These data set has advanced throughout this project into difference accessions and 
experiments which can be annotated and utilised for our gene of interest, additionally, 
custom tracks taken from datasets available from the Gene Expression Omnibus (GEO) can 
be edited and visualised on the browser, this has enabled us to focus our efforts of 
characterising Acan enhancers on areas of particular interests. Initially, the mouse 
assembly July 2007 mm9 (NCBI37/mm9) was used to identify sequences up to 100kb 
upstream of Acan of interest. Epigenetic signatures H3K4me1, H3K27ac, H3K4me3 in 
E14.5 mouse limbs detected by ChIP-Seq was selected from the ENCODE Ludwig Institute 
for Cancer Research (ENCODE/LICR) project track data, DNase I hypersensitivity in E11.5 
mouse limb buds, from the ENCODE project University of Washington (UW DNaseI HS) and 
high conservation throughout vertebrate genomes were used as selection criteria’s for the 
possibility of chondrocyte specific enhancers. At later stages of the work, to compare 
between developmental ages the mouse assembly December 2011 (GRCm38/mm10) was 
used as the reference assembly, to compare histone marks from ChIP-seq data at E12.5, 
E13.5 and E15.5 from Bing Ren’s lab (UCSD) found on the ENCODE project experiment 
matrix database (https://www.encodeproject.org/matrix/?type=Experiment). To 
determine if other prediction software could identify enhancers which may have been 
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overlooked in our initial screen the mm10 mouse assembly and limb specific DNase1 HS 
and H3K27ac, using ENCODE annotations (http://zlab-annotations.umassmed.edu/). 
These prediction was compared to Sox9 data and the mm9 assembly. Furthermore, GEO 
data sets for Sox9 ChIP-seq and histone ChIP-seqs were downloaded as .Bed, .wig or 
.bedGraph files and added as custom tracks using UCSC genome browser custom track 
tab, dataset consisted of Sox9-ChIP from primary mouse rib chondrocytes and embryonic 
E17.7 nasal chondrocytes series: GSE69111 (Ohba et al., 2015), rat chondrosarcoma sox9-
ChIP series: GSE70144 (Liu and Lefebvre, 2015), sox-9 ChIP from E12.5 limbs and heart 
valves accession GSE73225 (Garside et al., 2015), H3K122ac and H3K64ac for mouse 
embryonic stem cells and H3K122ac, H3K27ac and H3K4me1 for human bone marrow cell 
line K562 from dataset: GSE66023 (Pradeepa et al., 2016), K56ac from primary mouse 
embryonic stem cells series: GSE47387 (Tan et al., 2013). Additionally, to compare the 
zebrafish data which screened the Acan locus for enhancers from Hu et al 2012, were 
mapped to the GRCh37/hg19 human assembly and converted to the NCBI37/mm9 
assembly and a custom track for the genome browser expressing and screened was 
created (Hu et al., 2012). Due to the strong conservation of the Acan enhancers we 
mapped each one to the human (GRCh37/hg19) accession to determine the chromatin 
state in different cell types (Ernst et al., 2011). 
The genome browser tool LiftOver (https://genome-euro.ucsc.edu/cgi-
bin/hgLiftOver?hgsid=213826534_FQkMJ6mDgKnn5Xme0ooE1AlOaNWi ) was used to 
annotate datasets from different species or accessions. Data points were created, 
converted and then manually formatted into the Browser Extensible Data (.BED) format 
and each point colour coordinated using the RGB colour model.  
Figure 16: General editing window for custom tracks 
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3.5. Standard manipulation of nucleic acids 
3.5.1. Oligonucleotides 
To design and verify the primers used in PCR based studies web based program primer 
blast was used (http://www.ncbi.nlm.nih.gov/tools/primer-blast/ ). Additionally, primer 
temperatures prediction and primer dimer estimation were assessed using the Multiple 
Primer Analyzer (https://www.thermofisher.com/uk/en/home/brands/thermo-
scientific/molecular-biology/molecular-biology-learning-center/molecular-biology-
resource-library/thermo-scientific-web-tools/multiple-primer-
analyzer.html#/legacy=www.thermoscientificbio.com ). Primers were obtained from 
Eurofins genomic and resuspended in nuclease-free water to a concentration of 100pmol/ 
μL.  
3.5.2. Polymerase Chain Reaction (PCR) 
All DNA fragments used for cloning were amplified by PCR from 100ng of mouse genomic 
DNA (Bioline, BIO-35027 and Promega, G3091). For Gateway™ based cloning a non- high-
fidelity DNA taq polymerase, REDExtract™-N-Amp ReadyMix™ (Sigma, E3004) was used to 
utilise the ability of the taq polymerase to perform A’ tailing to allow for TA cloning. 
Reaction parameters of 94°C for 3 minutes to denature the DNA, 30 seconds at the 
specific primer annealing temperature (58°C - 62°C), extension of 2 minutes at 72°C for 30 
cycles a prolonged final extension time of 10 minutes and a soak step at 4°C. Q5® High-
Fidelity DNA polymerase (NEB, M0491S) was used for cloning the Acan regions for 
luciferase based reporters. The reaction consisted of in a final volume of 25μL, 1X Q5 
Reaction buffer, 1X Q5 High GC Enhancer, 200μM of dNTPs, 0.5μM of each primer 
(forward and reverse) and 0.02U of polymerase. The DNA was denatured at 98°C, primer 
annealed depending on specific annealing temperature (60°C- 68°C) and a final extension 
at 72°C. All PCR reactions was verified by agarose gel electrophoresis. 
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3.5.3. PCR clean up 
Taq polymerase, MgCl2, buffer and dNTPs were removed from PCR products by Monarch® 
PCR & DNA clean up kit (5μg) (NEB). For 20μL of PCR reaction 100μL of DNA Clean up 
binding buffer was added and mixed. Samples were placed into the spin column and 
centrifuged at 16,000g at room temperature for 1 minute and the flow-through was 
discarded. 200μL of DNA wash buffer was added and the column spun again at 16,000g for 
1 minute and repeated. The column was placed into a clean 1.5mL centrifuge tube and 
10μL of warmed (50°C) DNA elution buffer was added to each column and incubated at 
room temperature for 5 minutes then centrifuged at 16,000g for 1 minute to elute. 
3.5.4. Restriction enzymes digestion 
All restriction enzymes used were purchased for New England Biolabs (NEB). Restriction 
digestion was carried out in 20μL volume with 10 units of enzymes per 1μg of vector used 
following the manufacturers recommendations. For verification of inserts 1-hour digests 
were carried out, for cloning overnight digestions was used.  Following digestion enzymes 
were heat inactivated when possible at either 65°C or 80°C for 20 minutes or gel purified.  
3.5.5. DNA Dephosphorylation 
After restriction digestion, vectors were desphosphorylated to prevent self-ligation. 
Shrimp alkaline phosphatase (rSAP) (NEB) was used, alternatively Antarctic phosphatase 
(NEB) replaced rSAP. rSAP was added directly to the restriction mix whereas Antarctic 
phosphatase buffer was used to supplement the restriction mix and the volume brought 
up to 30μL. The phosphatase was added to each reaction at 1-5 units per 1pmol of DNA 
ends based on the calculation:  
𝜇𝜇𝜇𝜇 𝐷𝐷𝐷𝐷𝐷𝐷 ×  𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝600𝑝𝑝𝜇𝜇  ×  106𝑝𝑝𝜇𝜇1𝜇𝜇𝜇𝜇  × 1𝐷𝐷  × 2 × 𝑘𝑘𝑘𝑘1000𝑘𝑘𝑝𝑝  = 𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝 𝐷𝐷𝐷𝐷𝐷𝐷 𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒  
 
N is the nucleotides in kilobases, 660pg/mol is the average molecular weight of a 
nucleotide pair, 2 is the number of ends, Kb/1000bp is the conversion factor.  
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Reactions were then incubated at 37°C for 1hour for rSAP and 30minutes Antarctic 
phosphatase then heat inactivated at 65°C for 5 minutes for rSAP or 80°C for 2 minutes for 
Antarctic phosphatase.   
3.5.6. Agarose gel electrophoresis  
Gels were made as 0/8% (w/v), 1% (w/v), 1.5% (w/v) or 2% (w/v) using low 
electroendosmosis (EEO) agarose (Sigma) added to 1X Tris- acetate- EDTA (TAE) buffer and 
microwaved for 1 minute and 20 seconds for every 100mL. Ethidum bromide (EtBr) 
(0.2μg/μL) or SafeView nucleic acid stain (5μL) (NBS Biologicals) were used to allow for 
visualisation under ultraviolet (UV) exposure. Electrophoresis was carried out at a 
constant electrostatic field of 10V/ cm and gels were visualised on a UV transilluminator 
(BioRad ChemiDoc XRS) at 254nm for analysis or on a UV transilluminator platform at 
312nm for cloning. 
3.5.7. Purification of DNA from agarose gel   
DNA were isolated from agarose gels using the QIAquick gel extraction kit (Qiagen, 28706) 
following manufacturers instruction and eluted with pre- warmed (50°C) nuclease-free 
water. 
3.5.8. Cloning of Acan enhancers in vivo constructs 
Enhancer sequences were generated by PCR using primers designed with flanking 100bp 
5’ and 3’ identified from the ENCODE analysis. PCR products were gel purified on a 1% 
agarose gel. Fragments were then cloned into the pCR™8/GW/TOPO® vector using the 
pCR™8/GW/TOPO® TA Cloning Kit (Invitrogen, K2500-20) following manufacturer’s 
instructions. In short, 2μL of DNA freshly extracted DNA product, 1μL salt solution, 0.5μL 
TOPO® vector was gently mixed with 2.5μL dH2O, touch down centrifuged and incubated 
at 22-25°C for 30 minutes for short fragments of up to 1.5kb and 1 hour for >1.5kb. 4μL of 
the TOPO® reaction was transformed into TOP10 bacteria and incubated overnight at 37°C 
on streptomycin (50μg/mL) LB- agar plates. The following day starter cultures were 
created and then minipreped.  
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Name Sequence 5’ – 3’  
Acan +60kb F AAT CAC CTG CAC AGA CCG TGA 
Acan +60kb R TGT AGC CTG TGC TTG TAG GTG T 
Acan +55kb F ATA AAC CAG GCG TGA TGC TAC ATA CCT GTA 
Acan +55kb R AAG GCA GGA GGC TGC AGG AAA GAT 
Acan +26kb F CTG AGT CTT GAC AGA GCT GCT A 
Acan +26kb R GAT TGG TCA GTA GTG GAG CAC A 
Acan +26kb Small F TCC ATC TCA GGC CTT CCT CT 
Acan +26kb Small R AGG GCA TAG AGG CAC ATG AC 
Acan -10kb F GGT GAC ACC CAA ACT AAC AGC 
Acan -10kb R  ATC TCA CAC GTG GGC ATT TGC 
Acan -35kb F GGC TAG ACC AGT AGA ACC CA 
Acan -35kb R TGC ATC ATT ACA GTC TTT CTT CAG 
Acan -35kb Small F CGC ATG CAC ACC GCC CTC CT 
Acan -35kb Small R CTT CAG CAG TCA GGC AGG GGA  
Acan -65kb F ATG TTC AGA CAG CTC CAA CCC 
Acan -65kb R GGG TTG TGT TAA TAG GCA CGG 
Acan -87kb F CAG ACT GTA TTT CCC GAG TAC CT 
Acan -87kb R TGG AAG AGG GGC AAA ATG AGA 
Acan -87kb Small F GTG AGG ACT GAA GGG AAC GA 
Acan -87kb Small R CCT GGG ACA AGG TTT TGT GG 
Acan -68kb F CGT GAG TAT CCA GAG TCT CCT 
Acan -68kb R GAA GAT GCT GGC ATT GTG CTT 
Acan -108kb F GGG TGT GCC TTA TTG AAT GGC 
Acan -108kb R AGA AGC ATC TTG AGT GAA GGG T 
Acan -115kb F AGC CCC CTA GAA CCT TGC T 
Acan -115kb R ACC TTT TCA AAT GGA AAT TCAA CGC 
Acan -128kb F CCC TGA CCA ACG TCC CAT C 
Acan -128kb R GCT GGG ACT GAT TCT GCA CTT 
In bold are the constructs that were created but never injected 
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Cloning success and correct orientation of insertion was checked and verified by 
restriction enzyme digestion and Sanger sequencing, sequencing was performed by 
SourceBioscience. The enhancer sequences were transferred from the 
pCR8/GW/enhancer entry vector to the HSP68/LacZ/Gateway® destination vector 
(Pennacchio et al., 2006) using Gateway LR Clonase II Enzyme mix (Life Technologies, 
11791-020). The following reaction was set up in a 1.5mL centrifuge tube: 
Reagent Volume 
HSP68/LacZ/Gateway® 
vector 
37ng/μL 
Entry vector 37ng/μL 
  
LR Clonase II enzyme was thawed for 2 minutes on ice then vortexed for 2 seconds twice, 
0.5μL of the enzyme was added to the reaction mix, mixed and then incubated at 25°C for 
1 hour or up to 16 hours for larger fragments. The reaction was stopped by the addition of 
0.25μL of Proteinase K solution (2μg/μL) and incubated at 37°C in a water bath for 15 
minutes. The entire reaction was transformed in the TOP10 bacteria and plated onto 
ampicillin selection plates. The following day starter cultures and then miniprep was 
performed.  
3.6. Generation transgenic mice 
All animal procedures were approved by local ethical review and licensed by the UK Home 
Office and licensed under the Animal (Scientific Procedures) Act 1986, project licence 
number (PPL) 70/7288. Mice used for transgenic studies are mixed background C57BL/6 X 
CBA B6CBAF1. Animals were housed in the University of Liverpool Biomedical service unit 
(BSU) a specific pathogen free (SPF) mouse facility, in 12/12 hour light/dark cycle, 45 ± 
10% humidity and a constant temperature of 22 ± 2°C. 
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3.6.1. Preparation of DNA for microinjection 
In preparation of oocyte microinjection constructs 5μg of expression vector was digested 
overnight at 37°C with restriction enzymes XhoI and NotI or EagI. Fragment of interest 
were gel purified using 0.8% agarose with 0.5μg/mL EtBr and the Qiaquick Extraction kit. 
The concentration was determined and diluted to 2ng/μL in embryo water (Sigma) and 
filter purified using Durapore®-PVDF 0.22μM centrifuge filters (Merck Millipore LtD), and 
stored at -20°C. DNA was warmed to room temperature prior to injection. Primary 
responsibly of the mice resided with myself with the help of the staff at the BSU for daily 
care. 
Transgenic mice were generated by oocyte microinjection detailed previously (Sacilotto et 
al., 2013) and carried out by Dr Ke Liu.  
3.6.2. Superovulation of egg donors  
Superovulation was performed on F1 females aged between 4-6 weeks old. 5 IU of follicle 
stimulating hormone was injected intraperitoneally, after 46hours 5 IU of luteinising 
hormone was administered via intraperitoneal injection. Females were then mated with 
F1 males overnight. The following day copulation plugs were checked to identify mated 
females. Females were anesthetised and oviducts were removed and dissected in M2 
media (Millipore, Specialty Media, EmbryoMax®). Eggs were transferred to clean media 
via mouth pipetting. Cumulus cells were removed by hyaluronidase (300μg/mL) treatment 
in M2 media with gentle shaking until visibly detached from the egg surface. Eggs were 
then rinsed and transferred to M16 media (Millipore, Specialty Media, EmbryoMax®) 
ready for injection.  
3.6.3. Injection of fertilised eggs and transfer to pseudopregnant recipients  
Injections of fertilised eggs were carried out by Dr Ke Liu (University of Liverpool) and has 
been previously described (Hogan et al., 1994), with video aid found in the Journal of 
Visualized Experiments (JoVE) (Stein and Schindler, 2011). Injection pipettes piece the 
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oocyte avoiding the nucleus and DNA was injected. Undamaged eggs were transferred to 
clean M16 media and incubated until transfer into pseudopregnant F1 females.  
Pseudopregnant females were generated by mating vasectomised F1 males overnight the 
day before injection of fertilised eggs. Copulation plugs were checked and females were 
used 1 day post-coitum. Females were anaesthetised with 50μL hypnorm and 50μL 
hypnoval by intraperitoneal injection. Eggs were microinjected at the 1 cell stage and 
transferred through the infundibulum to the oviducts. On average 20-30 eggs were 
transferred per female.  
3.7. Transgenic mouse analysis 
3.7.1. X-gal staining of mouse embryos E15.5 and adult tissue 
3.7.1.1. Solutions 
1M Sodium Phosphate (NaPi) Buffer pH7.4 
138g of sodium dihydrogen phosphate (NaH2PO4 –H2O) (Sigma, 71507) was dissolved in 1 
litre of ddH2O and pH 7.4. 142g sodium phosphate dibasic (Na2HPO4) (Sigma, S7907) was 
dissolved in 1 litre of ddH2O, pH 7.4. To make 1M NaPi buffer 423mL of NaH2PO4 –H2O and 
577mL of Na2HPO4 was mixed together.  
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3.7.1.2. X-gal Fixative     
Reagent  For 300mL 
0.2% Glutaraldehyde 2.4mL of 25% solution (Sigma, G6257) 
0.1M Na Pi buffer pH7.3  30mL of 1M stock 
5mM ethylene glycol tetraacetic 
acid (EGTA), pH 8.0  
15mL of 0.1M stock (Sigma, E0296) 
2mM MgCl2  600μL of 1M stock (Sigma, M1028) 
2% formalin 60mL of 10% stock or 15ml of 40%  
stock 
ddH2O Up to 300mL 
 
3.7.1.3. Rinse solution     
Reagent For 1 Litre 
0.1M NA Pi buffer pH 
7.3 
100mL 1M stock 
2mM MgCl2 2mL of 1M stock 
0.1% Na deoxycholate 1g (Sigma, 30970) 
0.2% NP40 substitute 2mL (Sigma, 
74385) 
ddH2O Up to 1 litre 
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3.7.1.4. Stain Solution     
Reagent For 100mL 
Rinse solution 100mL 
Potassium ferricyanide (K3Fe(CN)6) 
(Sigma, 702587) 
165mg 
Potassium ferrocyanide (K4Fe(CN)6) 
(Sigma, 60279) 
184mg 
Stored in the dark at 4°C  
3.7.1.5. X-gal stock (25mg/mL) 
0.5g of 5-bromo-4-chloro-3-indolyl-β-d-galactopyranoside (VWR, 437132J) (X-gal) was 
suspended in 20mL of N, N- dimethylformamide (Sigma, D4551) and store at -20°C. 
3.7.1.6. X-gal staining 
Transgenic mouse embryos were collected at E13.5 and E15.5. After dissection and 
removal of yolk sac and placenta, samples were rinsed in ice-cold 1X PBS and fixed in 6X 
the volume of ice cold X-gal fix for 45 minutes whilst rotating. After fixation embryos were 
washed three times in rinse solution, embryos were then stained overnight in the dark at 
room temperature in 1 mg/ml X-gal solution containing 5 mM K4Fe(CN)6, 5 mM K3Fe(CN)6, 
0.1% sodium deoxycholate, 0.2% Nonidet P-40, 2 mM MgCl2 and 0.1 NaPi buffer. After 
staining, embryos were rinsed through a series of three 30 minutes washes, and then fixed 
for 24 hours in 6X the volume of the embryos in 10% neutral buffered formalin (NBF) at 4 
°C.  
Eight week old transgenic mice were culled by cervical spinal dislocation and dissected. All 
bones and cartilaginous tissue were taken, muscle cleaned off and then fixed in 6X the 
volume of x-gal fix for 2 hours at room temperature whilst rotating. Following 3X 30 
minutes washes in rinse solution tissue was stained in x-gal stain solution overnight in the 
dark. The following day, samples were washed, imaged and fixed in 10% NBF for 24 hours 
before decalcification with 10% EDTA for 2 weeks.    
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Imaging of whole embryos and adult tissue was performed using the Olympus SZX12 
equipped with the Qimaging QIClick™ CCD camera and QCapture Pro software. For each 
enhancer, embryos and adult tissue were also sectioned for histological analysis to 
investigate localisation of X-gal staining. Samples were process by dehydration with 
ethanol washes, cleared by xylene and paraffin wax-embedded following table  
3.7.1.7. Clearing and imaging of whole mount embryos 
To visualise whole mount x-gal stained embryos with better contrast and visualise the 
skeletal elements better, embryos up to E15.5 were fixed in 6X the volume of 10% NBF 
overnight at 4°C and then 70% EtOH at 4°C overnight. Embryos were then cleared in 15 mL 
of 20%, 50%, 80% and 100% glycerol in 1% potassium hydroxide (KOH) solution for 3 days 
at room temperature with agitation. 
Images were taken as previous on the Olympus SZ12 in bright field with embryos 
suspended in 100% glycerol.  
3.7.2. Tissue processing 
Processing of LacZ stained Embryo up to E14.5: 
Reagent Immersion Period 
(Minutes) under vacuum 
70% Ethanol 30 
90% Ethanol 30 
100% Ethanol 10 
100% Ethanol 10 
100% Ethanol 10 
100% Ethanol 10 
Xylene 10 
Xylene 10 
Wax 100 
Wax 100 
I.M.H.Li  PhD Thesis 
 
Page | 96  
 
 
For larger LacZ stained embryos E14.5 to E18.5: 
Reagent Immersion Period (Minutes) 
under vacuum 
70% Ethanol 30 
90% Ethanol 30 
100% Ethanol 10 
100% Ethanol 10 
100% Ethanol 10 
100% Ethanol 10 
Xylene 30 
Xylene 30 
Wax 120 (2hours) 
Wax Overnight 
 
For decalcified bone: 
Reagent Immersion Period (Minutes) 
under vacuum 
70% Ethanol 15 
95% Ethanol 60 
100% Ethanol 60 
100% Ethanol 60 
100% Ethanol 60 
100% Ethanol 60 
Xylene 60 
Xylene 60 
Wax 120 
Wax Overnight 
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6-μm sections were prepared using the Micron HM355S microtome with cool-cut and 
tissue transfer system (Thermo Scientific), de-waxed, and counterstained with Eosin 
(Leica). Histo-Clear (National diagnostics) was used in place of xylene to prevent the 
leeching of the X-gal staining. Eosin counter-stained sections were imaged on the Olympus 
BX60 using the CellD software. Images were collated and processed using Corel Paintshop 
Pro X6. 
3.7.3. BR1 and HAPLN3 antibody staining for aggrecan and link protein 3  
The antibody, BR1, was generated by Professor Tim Hardingham and donated by Alan 
Murdoch, is a polyclonal rabbit anti-pig antibody raised against the G1 domain of 
aggrecan. It was used to determine the endogenous expression pattern of ACAN in 
embryonic and 8 week old mouse tissues. The HAPLN3 antibody HPA039237 from Sigma, 
is a polyclonal anti-human raised in rabbit and was used to determine expression of link 
protein 3 in 8 week old mouse tissue. The Dako EnVision+ System-HRP (DAB) for use with 
rabbit primary antibody was used to visualise the BR1and HAPLN3 antibody.  
 
Tissue sections were dehydrated overnight at 37°C, then dewaxed in 2X xylene for 5 
minutes each. The samples were rehydrated in 2X 100% EtOH, 90% EtOH and 75% EtOH 
for 5 minutes each, rinsed in distilled water for 30 seconds and washed in 3x PBS for 5 
minutes each with agitation. Slides were then incubated with bovine testicular 
hyalouronidase (1000U/mL made up in PBS) (Sigma) for 1 hour at 37°C. Slides were then 
rinsed in 3x PBS for 5 minutes each with agitation then incubated with peroxidase block 
for 10 minutes and washed again in 3x PBS for 5 minutes each. 1% non-fat milk made up 
in PBS was then added to the tissue for 1 hour at room temperature. Slides were then 
incubated with BR1 or HAPLN3 antibody (1:1000 or 1:500 made up in Dako antibody 
diluent) at 4°C for 16 hours. Slides were then rinsed in 3x PBS for 5 minutes then 
incubated with the secondary antibody (peroxidase labelled polymer conjugated to goat 
anti-rabbit immunoglobulins) and then washed again in 3x PBS for 5 minutes each. 
Peroxidase substrate (DAB+ chromogen made up in DAB+ substrate buffer) was added for 
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30 seconds up to 5 minutes. Slides were then placed in running tap water for 10 minutes. 
Counterstained with Harris haematoxylin for 3 minutes and rinsed in running tap water for 
10 minutes then dehydrated in a series of 70% EtOH, 90% EtOH, 2X 100% EtOH for 2 
minutes each then 2x xylene for 5 minutes each and coverslipped using PERTEX® 
mounting media (Histolab). 
3.7.4. Genotyping of transgenic mice 
3.7.4.1. Solutions 
3.8.2.1.1 Lysis buffer 
 
Reagents Volume  
50mM Tris-HCL (pH8) 4.5mL of 2M stock 
0.1M NacL 7mL of 3M Stock  
1% SDS 8mL of 10% 
20mM EDTA 7.2mL of 500mM Stock 
dH2O 144.3mL 
Autoclaved and store at room temperature 
3.8.2.1.2 Proteinase K Stock  
10mg/mL in 50% Glycerol stored at -20°C 
3.7.4.2. Proteinase K based extraction of DNA 
Transgenic lines were created for each of the expressing cis-acting elements. Ear notches 
of adult mice and tail samples from embryos were used for genotyping. Samples were 
digested in 100μL lysis buffer with proteinase K (10mg/μl) at 55°C overnight. To 
precipitate the proteins out of solution 100μL 3M ammonium acetate (C2H3O2NH4) was 
added to the lysed tissue and vortexed briefly. The solution was incubated on ice for 5 
minutes prior to centrifugation at 16000g for 10 minutes at room temperature. 100% 
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chloroform was added to allow for phase separation and centrifuged at 16,000g for 10 
minutes at room temperature. The upper phase was taken and placed into a fresh 
centrifuge tube containing 500μL of ice cold 200 proof 100% EtOH, the tubes were 
inverted twice and incubated at -20°C for 30 minutes to an hour to precipitate the DNA. 
The tubes were then inverted twice and centrifuged for 10 minutes at room temperature, 
the 100% EtOH was removed and replaced with 750μL 70% EtOH to wash the DNA pellet, 
the tubes were briefly centrifuged at 16,000g. The EtOH was then removed and the DNA 
pellet allowed to air-dry for up to 2 hours. The pellet was resuspended in TE buffer 
overnight at 4°C before long term storage at -20°C.  
 
3.7.4.3. Genotyping of Transgenic mice using PCR 
50ng/μL of purified DNA was used for multiplex PCR using the GoTaq®G2 Flexi DNA 
polymerase (Promega, M7805) supplemented with 2.5mM MgCl2 using LacZ specific 
primers with internal control and verified using a second LacZ primer set. 
Primer 
Name 
Sequence 5’ – 3’ Specie
s 
Annealin
g Tm 
Target Product 
Size 
HELp00
8 
TGG ACA GGA CTG GAC CTC TGC 
TTT CCT AGA 
Mouse 68 Fabp2 
(Internal
)  
 
HELp00
9 
TAG AGC TTT GCC ACA TCA CAG 
GTC ATT CAG 
Mouse 68 Fabp2 
(Internal
)  
194bp 
HELp01
2 
GTT GCA GTG CAC GGC AGA TAC 
ACT TGC TGA 
Mouse 68 LacZ  
 
HELp01
3 
GCC ACT GGT GTG GGC CAT AAT 
TCA ATT CGC 
Mouse 68 LacZ  389bp 
prIL010 GAA CTA CCG CAG CCG GAG A Mouse 61 LacZ  
prIL011 GGT AAT GGT AGC GAC CGG C Mouse 61 LacZ 1000bp 
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3.8. Characterisation of Acan enhancers 
3.8.1. Identification of Transcription factor binding sites 
Each sequence was aligned to other species conserved sequences using ClustalW and 
subjected to analysis using the Transfac software (BioBase) (Matys et al., 2006) and 
Transcription Factor Affinity Prediction (TRAP) webtools (http://trap.molgen.mpg.de/cgi-
bin/home.cgi ) (Thomas-Chollier et al., 2011) and conservation for the most represented 
sites to take forward for analysis. Sequences of around 18-30 nucleotides long were used 
for EMSA experiments to determine TFs binding affinity.  
3.8.2. Electrophoretic mobility shift assay 
3.8.2.1. Solutions 
Black’s buffer (10X): 400mM KCl, 150mM, HEPES (pH7.9), 10mM EDTA, 5mM DTT, 50% 
glycerol  
2X anneal buffer: 100mM Tris pH7.6, 10mM DTT, 20mM MgCl2, 2mM spermidine  
Elution buffer: 40mM KCl 
10X Tris-Boric-EDTA (TBE) buffer: 890mM Tris-borate, 890mM boric acid, 20mM EDTA  
3.8.2.2. Oligonucleotides for EMSA  
Probes and double stranded oligos used in EMSA were designed to have a “CTAG” 
overhang on the 5’ end of the forward and 3’ of the reverse to allow for radiolabelling, the 
exceptions are the Rbpj-k control oligos that have “GG” instead of the “CTAG”. Oligos 
were synthesised by Integrated DNA Technologies (USA) and resuspended in nuclease-
free water to a concentration of 1mg/mL.  
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Name Sequence 5’- 3’ 
Sox9 control F CTAGGATCCAAAGCCCCATTCATGAGATCTG 
Sox9 control R CTAGCAGATCTCATGAATGGGGCTTTGGATC 
Rbpj-k control F GGGGTGAGGTCTATTTCCCACGACATACTTCC 
Rbpj-k control R GGGGGAAGTATGTCGTGGGAAATAGACCTCAC 
Nfat control F CTAGTGCTCTGAAACATTTTCCTCCTTCACAGT 
Nfat control R CTAGACTGTGAAGGAGGAAAATGTTTCAGAGCA 
Acan -35kb Sox 1F CTAGCTTGAACACTGCCTGCTGTCCCAACC 
Acan -35kb Sox 1R CTAGGGTTGGGACAGCAGGCAGTGTTCAAG 
Acan -35kb Sox 
1mut F 
CTAGCTTCCTGACTGCCTGCACCCCCAACC 
Acan -35kb Sox 
1mutR 
CTAGGGTTGGGGGTGCAGGCAGTCAGGAAG 
Acan -35kb Sox 2F CTAGAAAGGAACACAACCCTCCCTTGTGCCCTCCT 
Acan -35kb Sox 2R CTAGAGGAGGGCACAAGGGAGGGTTGTGTTCCTTT 
Acan -35kb Sox 
2mutF  
CTAGAAAAGGGGCTCCGCCCTCCAGGGAGCCCTCCT 
Acan -35kb Sox 
2mutR 
CTAGAGGAGGGCTCCCTGGAGGGCGGAGCCCCTTTT 
Acan -35kb Sox 3F CTAGGTGCCCTCCTGATATTTCCAGTAAAAAGTACCTT 
Acan -35kb Sox 3R CTAGAAGGTACTTTTTACTGGAAATATCAGGAGGGCAC 
Acan -35kb Sox 
3mutF 
CTAGGTGCCCTCCTTGGGCCTCCCGTCCACGTACCTT 
Acan -35kb Sox 
3mutR 
CTAGAAGGTACGTGGACGGGAGGCCCAAGGAGGGCAC 
Acan -35kb Sox 4F CTAGCCTTGAACACAATCTTGCTGCCACAGCCCTAA 
Acan -35kb Sox 4R CTAGTTAGGGCTGTGGCAGCAAGATTGTGTTCAAGG 
Acan -35kb Sox 
4mutF 
CTAGCCTTGAGCGCGATCTTGCCGCCACAGCCCTAA 
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Acan -35kb Sox 
4mutR 
CTAGTTAGGGCTGTGGCGGCAAGATCGCGCTCAAGG 
Acan -35kb Sox 5F CTAGCCCTAATTATGTGTGAAATCATTTTTTTTAAAGC 
Acan -35kb Sox 5R CTAGGCTTTAAAAAAAATGATTTCACACATAATTAGGG 
Acan -35kb Sox 
5mutF 
CTAGCCCTAATTATGTGGGCCCTCATTTTTTTTAAAGC 
Acan -35kb Sox 
5mutR 
CTAGGCTTTAAAAAAAATGAGGGCCCACATAATTAGGG 
Acan -35kb Sox 6F CTAGAAAGCTTTAAACCAAAGCAACAAGCCCTA 
Acan -35kb Sox 6R CTAGTAGGGCTTGTTGCTTTGGTTTAAAGCTTT 
Acan -35kb Sox 
6mutF 
CTAGAAAGCTCTGGCCCAACGCACACAGGCCCAT 
Acan -35kb Sox 
6mutR 
CTAGATGGGCCTGTGTGCGTTGGGCCAGAGCTTT 
Acan -35kb Sox 7F CTAGCCCATACAGAGAGGCCCATTCTCCCAGCCC 
Acan -35kb Sox 7R CTAGGGGCTGGGAGAATGGGCCTCTCTGTATGGG 
Acan -35kb Sox 
7mutF 
CTAGGGCTGGGAGCCTGGGCCCCTCCGTATGGG 
Acan -35kb Sox 
7mutR 
CTAGGGCTGGAGCCTGGGCCCCTCCGTATGGG 
Acan -35kb Sox 8F CTAGGGTTACCTCAGGCTACACAGAGGCC 
Acan -35kb Sox 8R CTAGGGCCTCTGTGTAGCCTGAGGTAACC 
Acan -35kb Sox 
8mutF 
CTAGGGTTACCTCCTCCTACTTGGAGCGCC 
Acan -35kb Sox 
8mutR 
CTAGGGCGCTCCAAGTAGGAGGAGGTAACC 
Acan -35kb Rbpj-A F CTAGACACACCCTCCCTTGTGCCCTCCT 
Acan -35kb Rbpj-A R CTAGTCAGGAGGGCACAAGGGAGGGTGTGT 
Acan -35kb Rbpj-A 
mutF 
CTAGACACAACCCTCGGTTCGGCCTCCTGA 
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Acan -35kb Rbpj-A 
mutR 
CTAGTCAGGAGGCCGAACCGAGGGTTGTGT 
Acan -35kb Rbpj-B F CTAGACCTTGAACACAATCTTGCTGCC 
Acan -35kb Rbpj-B R CTAGGGCAGCAAGATTGTGTTCAAGGT 
Acan -35kb Rbpj-B 
mutF 
CTAGACCTTGAACGTGGCTTGCTGCC 
Acan -35kb Rbpj-B 
mutR 
CTAGGGCAGCAAGCCAACGTTCAAGGT 
Acan -35kb Rbpj-C F CTAGCCTAATTATGTGTGAAATCATTTTTT 
Acan -35kb Rbpj-C R CTAGAAAAAATGATTTCACACATAATTAGG 
Acan -35kb Rbpj-C 
mutF 
CTAGCCTAATTATTTGTTAAATCATTTTTT 
Acan -35kb Nfat1 F CTAGCTAGCTGGAAAAGGAACACAA 
Acan -35kb Nfat1 R CTAGTTGTGTTCCTTTTCCAGCTAG 
Acan -35kb Nfat1 
mF 
CTAGCTAGCTCAGTGGCCTTCAA 
Acan -35kb Nfat1 
mR 
CTAGTTGAAGGCCACTGAGCTAG 
Acan -35kb Rbpj-C 
mutR 
CTAGAAAAAATGATTTAACAAATAATTAGG 
Acan -87kb Sox 1F CTAGGGAACGACAAAATGTCCT 
Acan -87kb Sox 1R CTAGAGGACATTTTGTCGTTCC 
Acan -87kb Sox 1mF CTAGGGAACGTCGGAATGTCCT 
Acan -87kb Sox 1mR CTAGAGGACATTCCGACGTTCC 
Acan -87kb Sox 1_2F CTAGGGAACGACAAAATGTCCTTACTGTCCCCAC 
Acan -87kb Sox 
1_2R 
CTAGGTGGGGACAGTAAGGACATTTTGTCGTTCC 
Acan -87kb Sox 
1_2mF 
CTAGGGAACGACATTATGTCCTTACTGGACCCAC 
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Acan -87kb Sox 
1_2mR 
CTAGGTGGGTCCAGTAAGGACATAATGTCGTTCC 
Acan -87kb Sox 2_3F CTAGGTCCTTACTGTCCCCACTTGTGGTCCA 
Acan -87kb Sox 
2_3R 
CTAGTGGACCACAAGTGGGGACAGTAAGGAC 
Acan -87kb Sox 
2_3mF 
CTAGGTCCTTCCGGTCCCCACTGGTGGTCCA 
Acan -87kb Sox 
2_3mR 
CTAGTGGACCACCAGTGGGGACCGGAAGGAC 
Acan -87kb Sox3F CTAGCCCCACTTGTGGTCCAATCTGCCAAC 
Acan -87kb Sox3R CTAGGTTGGCAGATTGGACCACAAGTGGGG 
Acan -87kb Sox3mF CTAGCCCCACTGGGGGTCCATTCTGCCAAC 
Acan -87kb Sox3mR CTAGGTTGGCAGAATGGACCCCCAGTGGGG 
Acan -87kb Sox4F CTAGGAGAGTACATTTCCACGAGGC 
Acan -87kb Sox4R CTAGGCCTCGTGGAAATGTACTCTC 
Acan -87kb Sox4mF CTAGGAGAGTTCCTTTCCACGAGGC 
Acan -87kb Sox4mR CTAGGCCTCGTGGAAAGGAACTCTC 
Acan -87kb Sox5F CTAGTCCCAAACAACAGTACGGGC 
Acan -87kb Sox5R CTAGGCCCGTACTGTTGTTTGGGA 
Acan -87kb Sox5mF CTAGTCCCAAATTAGGGAACGGGC 
Acan -87kb Sox5mR CTAGGCCCGTTCCCTAATTTGGGA 
Acan -87kb Sox6F CTAGCATATTTGTCTTGGCC 
Acan -87kb Sox6R CTAGGGCCAAGACAAATATG 
Acan -87kb Sox6mF CTAGCATCGGGTCTTGGCC 
Acan -87kb Sox6mR CTAGGGCCAAGACCCGATG 
Acan -87kb Sox7 
Nfat3 F 
CTAGAAAGACAGATTTTCCTTTCCC 
Acan -87kb Sox7 
Nfat3 R 
CTAGGGGAAAGGAAAATCTGTCTTT 
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Acan -87kb Sox7 
Nfat3 mF 
CTAGAAAGACAGACGATCCACCCCC 
Acan -87kb Sox7 
Nfat3 mR 
CTAGGGGGGTGGATCGTCTGTCTTT 
Acan -87kb Sox8F CTAGCCAGCCATTGGCCTCCGC 
Acan -87kb Sox8R CTAGGCGGAGGCCAATGGCTGG 
Acan -87kb Sox8mF CTAGCCAGCCCGGTTCCTCCGC 
Acan -87kb Sox8mR CTAGGCGGAGGAACCGGGCTGG 
Acan -87kb Sox9F CTAGGTGAGGCTTGTTTGGGATGG 
Acan -87kb Sox9R CTAGCCATCCCAAACAAGCCTCAC 
Acan -87kb Sox9mF CTAGGTGAGGACGGAACGGGATGG 
Acan -87kb Sox9mR CTAGCCATCCCGTTCCGTCCTCAC 
Acan -87kb Sox10F CTAGGATGGGCCACAAAACCTTGTCCC 
Acan -87kb Sox10R CTAGGGGACAAGGTTTTGTGGCCCATC 
Acan -87kb 
Sox10mF 
CTAGGATGGGCAACTTAACATCGTCCC 
Acan -87kb 
Sox10mR 
CTAGGGGACGATGTTAAGTTGCCCATC 
Acan -87kb Nfat1 F CTAGTGAGAGTACATTTCCACGAGGCCCAGG 
Acan -87kb Nfat1 R CTAGCCTGGGCCTCGTGGAAATGTACTCTCA 
Acan -87kb Nfat1 
mF 
CTAGTGAGAGTACATCCACGAGGCCCAGTTT 
Acan -87kb Nfat1 
mR 
CTAGAAACTGGGCCTCGTGGATGTACTCTCA 
Acan -87kb Nfat2 F CTAGATCTGGAATCTTCCAGCCCT 
Acan -87kn Nfat2 R CTAGAGGGCTGGAAGATTCCAGAT 
Acan -87kb Nfat2 
mF 
CTAGATCTGGAATCCCCCAGCCCT 
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Acan -87kb Nfat2 
mR 
CTAGAGGGCTGGGGGATTCCAGAT 
Acan -65kb Sox1F CTAGAGAATGCGTCTTTGCTCGACCA 
Acan -65kb Sox1R CTAGTGGTCGAGCAAAGACGCATTCT 
Acan -65kb Sox1mF CTAGAGAATGCGTTGGTGCTCGACCA 
Acan -65kb Sox1mR CTAGTGGTCGAGCACCAACGCATTCT 
Acan -65kb Sox2F CTAGCAGGGCAGCATCAGAGGAGCGAGGA 
Acan -65kb Sox2R CTAGTCCTCGCTCCTCTGATGCTGCCCTG 
Acan -65kb Sox2mF CTAGCAGGGCAGTATCAGATTAGCGAGGA 
Acan -65kb Sox2mR CTAGTCCTCGCTAATCTGATACTGCCCTG 
Acan -65kb Sox3F CTAGGAGCTGGACAAGGGCAGGCTTTGTGCGCAGCG 
Acan -65kb Sox3R CTAGCGCTGCGCACAAAGCCTGCCCTTGTCCAGCTC 
Acan -65kb Sox3mF CTAGGAGCTGTACCAGGGCAGGCGGTGTGCGCAGCG 
Acan -65kb Sox3mR CTAGCGCTGCGCACACCGCCTGCCCTGGTACAGCTC 
Acan -65kb Sox4F CTAGTGTCTACTCTGAAGGAAAAT 
Acan -65kb Sox4R CTAGTGTCTACTCTGAAGGAAAAT 
Acan -65kb Sox4mF CTAGTGTAGACTCTGCCGGAGGAT 
Acan -65kb Sox4mR CTAGATCCTCCGGCAGAGTCTACA 
Acan -65kb Sox5F CTAGAGTCATTTCAAGGAATTGAATTTCAAGGAATCCT 
Acan -65kb Sox5R CTAGAGGATTCCTTGAAATTCAATTCCTTGAAATGACT 
Acan -65kb Sox5mF CTAGAGTCATTTCTTAAAACTGAAGCTCGGGGAATCCT 
Acan -65kb Sox5mR CTAGAGGATTCCCCGAGCTTCAGTTTTAAGAAATGACT 
Acan +26kb 
Sox1Rbpj1 F 
CTAGGCTTTCCTTCCCATTGAGAAAGGTCTCT 
Acan +26kb 
Sox1Rbpj1 R 
CTAGAGAGACCTTTCTCAATGGGAAGGAAAGC 
Acan +26kb Sox1 
Rbpj1 mF 
CTAGGCTTTCCTTCCCAGGGAGCTAATTCTCT 
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Acan +26kb Sox1 
Rbpj1 mR 
CTAGAGAGAATTAGCTCCCTGGGAAGGAAAGC 
Acan +26kb Sox2F CTAGGAAAGGTCTCTCTGTCCACGAG 
Acan +26kb Sox2R CTAGCTCGTGGACAGAGAGACCTTTC 
Acan +26kb Sox2mF CTAGGAAAGGTTTATCTGGCTACGAG 
Acan +26kb Sox2mR CTAGCTCGTAGCCAGATAAACCTTTC 
Acan +26kb Sox3F CTAGTCCCTATTTTTCTTTACAAC 
Acan +26kb Sox3R CTAGGTTGTAAAGAAAAATAGGGA 
Acan +26kb Sox3mF CTAGTCCCTATTTCGACATACAAC 
Acan +26kb Sox3mR CTAGGTTGTATGTCGAAATAGGGA 
Acan +26kb Sox4F CTAGCTGAGAAAACACACACAAACACAAGAGC 
Acan +26kb Sox4R CTAGGCTCTTGTGTTTGTGTGTGTTTTCTCAG 
Acan +26kb Sox4mF CTAGCTGAGAATCCTCACACGCACACAAGAGC 
Acan +26kb Sox4F CTAGGCTCTTGTGTGCGTGTGAGGATTCTCAG 
Acan +26kb Sox5F CTAGCAGGGAGAAAAACAGAGCCAGCCCAAA 
Acan +26kb Sox5R CTAGTTTGGGCTGGCTCTGTTTTTCTCCCTG 
Acan +26kb Sox5mF CTAGCAGGGAGAATATCAGAGCCAGCGCAAA 
Acan +26kb Sox5mR CTAGTTTGCGCTGGCTCTGATATTCTCCCTG 
Acan +26kb Sox6F CTAGCAAACCCCACAGAGCACCATTGCATC 
Acan +26kb Sox6R CTAGGATGCAATGGTGCTCTGTGGGGTTTG 
Acan +26kb Sox6mF CTAGCAAACCTGACAGGCTACCATTGCATC 
Acan +26kb Sox6mR CTAGGATGCAATGGTAGCCTGTCAGGTTTG 
Acan +26kb Sox7 
Rbpj3 F 
CTAGCAGCTTGTTCAGAGAGCGAGGGAAGAAACA 
Acan +26kb Sox7 
Rbpj3 R 
CTAGTGTTTCTTCCCTCGCTCTCTGAACAAGCTG 
Acan +26kb Sox7 
Rbpj3 mF 
CTAGCAGCTTGACCAGAGAGCGACGGTAGAAACA 
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Acan +26kb Sox7 
Rbpj3 mR 
CTAGTGTTTCTACCGTCGCTCTCTGGTCAAGCTG 
Acan +26kb Rbpj2 F CTAGTTTCATTCCTTCCCATTTCCTGGTT 
Acan +26kb Rbpj2 R CTAGAACCAGGAAATGGGAAGGAATGAAA 
Acan +26kb Rbpj2 
mF 
CTAGTTTCATTCCTTCAAATCGTCCTGGTT 
Acan +26kb Rbpj2 
mR 
CTAGAACCAGGACGATTTGAAGGAATGAAA 
 
3.8.2.3. Making protein for EMSA  
Proteins for indirect competition EMSAs were made using the TNT® T7/SP6 coupled 
reticulocyte lysate system (Promega, L5020) for Sox9 using 4XFLAG-tagged SOX9 
expression plasmid (Lefebvre et al., 1998), Nuclear factor of activated T-cells (NFAT) core 
binding domain from pCITE 2B vector, recombination signal binding protein for Ig kappa J 
(Rbpj-κ) from pcDNA3.1 plasmid using T7 following manufacturer’s instructions. In short, 
50μL reaction volume was assembled (shown in table below) and incubated at 30°C for 1 
hour and 30 minutes. Unprogrammed protein was used as controls to non- specific 
binding was generated by replacing expression vector with an empty. 
Reagent Volume 
TNT® Rabbit Reticulocyte lysate  25μL 
TNT® reaction buffer 2μL 
TNT® T7 RNA polymerase 1μL 
Amino acid mix minus Leucine, 1mM 0.5μL 
Amino acid mix minus methionine, 1mM 0.5μL 
Plasmid DNA  1μg 
ddH2O Up to 
50μL 
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3.8.2.4. Generating radioactively labelled probes for EMSA  
Double stranded oligonucleotides were labelled with [α-32P]-dCTP (3000Ci/mmol 
10mCiml, 250μCi, EasyTide, Perkinelmer) using DNA polymerase I Large (Klenow) 
(Promega) to fill in overhanging ends and purified on non-denaturing acrylamide gel (40% 
acrylamide/bis 19:1, Biorad).  
3.8.2.5. Preforming the shift assay 
A competitive shift assay consisted of 20μL binding reactions with 2μg protein, 0.48μg of 
poly (dG-dC) for Sox9 and poly (dI-dC) for RBPJ- κ and 2μL 10X binding buffer. 100-fold 
excess or increasing concentration of competitor oligonucleotides was added to the 
binding reaction in a volume of 1μLand incubated at 30°C for 20 minutes. Radiolabelled 
probes were added at an activity of 40,000cpm/μL and incubated for a further 40 minutes. 
Gels were electrophoresed on a 6% non-denaturing polyacrylamide gel at 4°C for 2 hours. 
Gels were dried and exposed to X-ray films for 12 to 72 hours and then processed.  
3.8.3. Generation of mutated binding sites 
Mutant forms of the binding sites that were identified were generated by identifying the 
core binding sequence using MotifMap (http://motifmap.ics.uci.edu/ ) and single 
nucleotides were replaced to diminish the binding. The mutant forms were examined in 
EMSAs and then taken for in vivo studies.  
Mutant versions of the -35kb and -87kb enhancer were generated as custom-made, 
double-stranded linear DNA fragments synthesised by GeneArt® Strings™ (Life 
Technologies) and were treated as PCR products used for cloning and generation of 
transgenic mice. The -87kb mutant TF binding constructs were never analysed in this study 
in vivo although they were generated. 
3.8.4. In vitro analysis of Acan enhancers  
To unravel the role multiple enhancers play in regulating the response of Acan 
transcription we created luciferase based reporters to evaluate in cell lines.  
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3.8.5. Generation luciferase reporter constructs 
The +26kb, -10kb, -35kb, -65kb and the -87kb regions enhancer elements were examined 
in vitro by expression vectors containing luciferase. Enhancer regions were amplified from 
genomic DNA using Q5 High Fidelity polymerase (NEB) to generate blunted PCR products. 
PCR products were cleaned up using the Monarch® PCR & DNA clean up kit (NEB) prior 
phosphatase treatment These were then treated using T4 polynucleotide kinase (T4 PNK) 
(NEB) in the following reaction in 0.2mL PCR reaction tubes: 
Reagent  Volume 
PCR product Up to 1μg 
10X T4 ligase  2μL 
T4 PNK 1μL 
dH2O Up to 20μL 
 
The reaction was incubated at 37°C for 1 hour then heat inactivated at 65°C for 20 
minutes in a thermal cycler.  Phosphatased inserts were blunt end cloned into the pGl3-
promoter vector that has been digested with SmaI and dephosphorylated with rSAP or 
Antarctic phosphatase. Acan B small pGl3 – promoter was generated by extraction of the 
regions by restriction digestion of the Acan_B_wt pMa that was created by Life 
technologies GeneArt plasmid generation using KpnI and SacI overnight and gel purified. 
The region was then inserted into the pGl3- promoter that had been digested with KpnI 
and SacI overnight and dephosphorylated with rSAP.  
Ligations were carried out at a 4:1 molar ratio of insert to vector. To estimate the 
concentration of construct, 2μL of sample was ran on a 1% agarose gel alongside 0.5μg 
and 1μg of lambda DNA-HindIII digest ladder and visualised, samples were also 
nanodropped for comparison. Amount of insert in a 10μL ligation mix was determined 
based on the calculation: 
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𝑝𝑝𝑚𝑚𝑒𝑒𝑒𝑒 𝑝𝑝𝑜𝑜 𝑖𝑖𝑒𝑒𝑒𝑒𝑒𝑒𝑖𝑖𝑖𝑖 (𝜇𝜇)= 𝑒𝑒𝑒𝑒𝑒𝑒𝑖𝑖𝑖𝑖𝑒𝑒𝑒𝑒 𝑖𝑖𝑒𝑒𝑒𝑒𝑒𝑒𝑖𝑖𝑖𝑖
𝑣𝑣𝑒𝑒𝑣𝑣𝑖𝑖𝑝𝑝𝑖𝑖
𝑝𝑝𝑝𝑝𝑝𝑝𝑚𝑚𝑖𝑖 𝑖𝑖𝑚𝑚𝑖𝑖𝑖𝑖𝑝𝑝 × 𝑝𝑝𝑚𝑚𝑒𝑒𝑒𝑒 𝑝𝑝𝑜𝑜 𝑣𝑣𝑒𝑒𝑣𝑣𝑖𝑖𝑝𝑝𝑖𝑖 (𝜇𝜇)  × 𝑖𝑖𝑚𝑚𝑖𝑖𝑖𝑖𝑝𝑝 𝑝𝑝𝑜𝑜 𝑖𝑖𝑒𝑒𝑒𝑒𝑒𝑒𝑖𝑖𝑖𝑖 𝑖𝑖𝑝𝑝 𝑣𝑣𝑒𝑒𝑣𝑣𝑖𝑖𝑝𝑝𝑖𝑖 𝑝𝑝𝑒𝑒𝑒𝑒𝜇𝜇𝑖𝑖ℎ𝑒𝑒  
Ligations were carried out in the following reaction: 
 
Reagent  Volume  
10X T4 Ligase 
Buffer 
1μL 
Vector 1μL 
Insert X 
T4 DNA Ligase 
(NEB) 
1μL 
For blunt end SmaI 1μL 
ddH2O Up to 10μL 
 
Blunt end ligations was carried out in the presence of the blunt end enzyme to prevent 
vector re-ligation. Ligations were incubated at 16°C overnight then heat inactivated at 
65°C for 10 minutes. 5μL of ligation mix was used to transform into competent bacteria 
and plated onto ampicillin selective plates. After miniprep vectors were checked for 
correct insertion using restriction enzyme digestion.  
3.9. Cell Culture 
Two chondrocytic cell lines were used to study the effects each Acan enhancer has in 
vitro. All cells were cultured in 5% CO2, atmospheric O2 and at 37°C. ATDC5 mouse 
chondrocytes from 129 teratocarinoma AT805 are a model of cartilage differentiation was 
cultured in DMEM: Ham’s F12 (1:1), GlutaMAX™ with L-glutamine (Gibco), 5% fetal Bovine 
Serum (FBS) (Gibco), 100 I.U/ penicillin and 100μg/mL streptomycin. To push ATDC5s into 
differentiation they were cultured in the presence of 1% insulin, transferrin, and selenium 
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(Insulin-Transferrin-Selenium-Sodium Pyruvate, ITS-A) (Gibco) for 28 days (Atsumi et al., 
1990). The ATDC5 cells retain a fibroblast like morphology until differentiation in which 
they form cartilage like nodules and depose a matrix. The T/C-28-I2 are immortalised 
human costal cartilage from primary culture (Goldring et al., 1994). Cultured in DMEM: 
Ham’s F12 (1:1) with L-glutamine, 10% FBS (Gibco), 100 I.U/ penicillin and 100μg/mL 
streptomycin. A fibroblast cell line was used to determine the activation of enhancers in a 
different cell type. These were the murine embryonic fibroblast, NIH3T3, maintained in 
DMEM high glucose (4500mg/L) plus L-Glutamine (Gibco), 10% FBS (Gibco), 100 I.U/ 
penicillin and 100μg/mL streptomycin. For transfections FBS was replaced with 2% TCM® 
(MP biomedicals) define serum replacement as it contains no growth factors, steroid 
hormones or extraneous proteins that could interfere with cytokine treatment.  
3.9.1. qPCR to determine chondrocyte phenotype of ATDC5 cells 
ATDC5 were seeded to a density of 2.5x104 in 48 well cell bottom tissue culture plates in 
differentiation media for 48hours prior to RNA extraction  
3.9.1.1. TRIzol® based RNA extraction 
RNA was extracted using TRIzol® RNA isolation reagent (Invitrogen). Media was removed 
from each of the wells and washed once with room temperature PBS. All PBS was 
removed and 200μL of TRIzol® was added to each well and mixed by pipetting and 
incubated at room temperature for no more than 5 minutes. The solution was then placed 
into RNase and DNase free 1.5mL centrifuge tubes, 200μL of chloroform was added to the 
tube and vigorously shaken by hand for 15 seconds and incubated at room temperature 
for 3 minutes. Subsequently, centrifuged at 12,000g at 4°C for 15 minutes. The clear 
aqueous phase was removed by pipetting and placed into a fresh RNase and DNase free 
1.5mL centrifuge tube, 10μg of GlycoBlue™ (Invitrogen) and 500μL of isopropanol was 
added to the solution and inverted twice and left at room temperature for 10 minutes. 
Centrifuged at 12,000g for 10 minutes at 4°C and the supernatant was discarded. 1mL of 
ice cold 75% ethanol was then added and vortexed for 2 seconds before centrifugation at 
7500g for 5 minutes at 4°C to wash, the supernatant was discarded and the RNA pellet 
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was left to air dry for 10 minutes. 50μL of RNase-free water was added to the RNA pellet, 
mixed by pipetting and placed at 55°C for 15 minutes. RNA concentration and purity was 
determined by UV spectroscopy. 
3.9.1.2. cDNA synthesis  
RNA was diluted to 100ng/μL and used for cDNA synthesis using the High-Capacity cDNA 
reverse transcription kit (Applied Biosystems). Reactions were set up in 20μL reactions 
with 2μL 10x RT buffer, 0.8μL 25x dNTP mix, 2μL RT random primers, 1μL MultiScribe™ 
reverse transcriptase, 4.2μL RNase-free water and 10μL RNA (100ng/μL). The reaction was 
then carried out in a thermocycler with the parameters: 25°C for 10 minutes, 37°C for 120 
minutes, 85°C for 5minutes and held at 4°C. 
3.9.1.3. Real time PCR 
qPCR was carried out using the SensiMix™ SYBR® Hi-ROX kit (Bioline) for MMP13, Sox9, 
Runx2, Col1a1 and Col2a1. cDNA was diluted 1:5 and qPCR reactions were carried out in 
20μL reaction consisting of 10μL 2x SensiMix™, 0.6μL of each of the forward and reverse 
primer (listed in table below), 6.8μL nuclease free water and 2μL of diluted cDNA for each 
sample. Each reaction was performed in triplicates per sample. A three-step with melt 
reaction was performed on the Corbett (now Qiagen) Rotor Gene RG-6000, initial step of 
95°C for 10 minutes, then 40 cycles of 95°C for 15 seconds, 60°C for 10 seconds, 72°C for 
30 seconds and acquire on green and orange (for ROX loading control) channel. A melt 
curve was generated at the end of the run to ensure a single product had been amplified. 
Housekeeping gene and target genes were performed in the same runs to avoid 
discrepancies. Gene expression analysis using TaqMan® assays was used for Acan 
(mm00545794_m1) with the house keepers hypoxanthine guanine phosphoribosyl 
transferase (Hprt) (mm00446968_m1) and Rplp0 (Mm01974474_gH) in a mix containing 
1X TaqMan® Universal PRC mix (ABI), 1XTaqMan® gene Expression Assay , 100ng of cDNA 
in a final volume of 20μL. The cycling conditions 50° for 2 minutes, 95°C for 10 minutes, 
95° for 15 seconds and 60° for 1 minute for 40 cycles detection on Green and Orange. 
Samples were analysed in three technical replicates with NTCs to allow normalisation. 
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Results were annotated on the Rotor-Gene 6000 series software version 1.7. The 
housekeeping gene used for Col1a1 was 18S, for Col2a1 and MMP13 GAPDH, for Sox9 and 
Runx2 RPLP0. ∆CT was calculated for each gene after normalisation to the housekeeping 
gene using:  
 = 2−(𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 𝐶𝐶𝐶𝐶 𝑜𝑜𝑜𝑜 𝑎𝑎𝑎𝑎𝑔𝑔𝑎𝑎 𝑜𝑜𝑜𝑜 𝑖𝑖𝑔𝑔𝑖𝑖𝑎𝑎𝑎𝑎𝑎𝑎𝑖𝑖𝑖𝑖−𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 𝐶𝐶𝐶𝐶 𝑜𝑜𝑜𝑜 ℎ𝑜𝑜𝑜𝑜𝑖𝑖𝑎𝑎𝑜𝑜𝑎𝑎𝑎𝑎𝑜𝑜𝑖𝑖𝑔𝑔𝑎𝑎 𝑎𝑎𝑎𝑎𝑔𝑔𝑎𝑎) 
 
 
Primer name Sequence 5’ – 3’ 
mSox9 F GAC AAG CGG AGG CCG AA 
mSox9 R CCA GCT TGC ACG TCG GTT 
mRunx2 F CCC AGC CAC CTT TAC CTA CA 
mRunx2 R TAT GGA GTG CTG CTG GTC TG 
mCol1a1 F CAT GTT CAG CTT TGT GGA CCT 
mCol1a1 R GCA GCT GAC TTC AGG GAT GT 
mCol2a1 F  TGG GTG TTC TAT TTA TTT ATT GTC 
TTC CT 
mCol2a1 R GCG TTG GAC TCA CAC CAG TTA GT 
m18S F GGA AAG CAG ACA TCG ACC TCA 
m18S R AGT TCT CCA GCC CTC TTG GT 
mGAPDH F  GGG CTC ATG ACC ACA GTC CAT GC 
mGAPDH R CCT TGC CCA CAG CCT TGG CA 
mRPLP0 F ATG GGT ACA AGC GCG TCC TG 
mRPLP0 R GCC TTG ACC TTT TCA GTA AG 
To determine the efficiency of primer pairs the following calculation was used and the 
primers were initially examined using standard curves: 
 
𝐸𝐸𝑜𝑜𝑜𝑜𝑖𝑖𝑣𝑣𝑖𝑖𝑒𝑒𝑒𝑒𝑣𝑣𝐸𝐸 = �10− 1𝑖𝑖𝑠𝑠𝑜𝑜𝑜𝑜𝑎𝑎 − 1� × 100 
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3.9.2. Lipofectamine mediated transfection 
ATDC5 were seeded to a density of 2.5x104 cells/well, T/C 28 I2 at 3.0x104 cells/well and 
NIH3T3 at 1.75x104 cells/ well in 48 well clear bottom tissue culture treated plates 
overnight (around 12 hours). Transfection were only conducted when cells were around 
80% confluent and completed using Lipofectamine® 2000 (Invitrogen). Cells were co-
transfected in duplicates with the enhancer constructs and Renilla luciferase control 
vector, pRL-TK (Promega) to allow normalisation of transfection efficacy. Blanks, pGl3 
vector with no inserts and pRL-TK alone were included in each experiment as controls  
For each experiment the following reaction was set up: 
Tube 1 Tube 2 
80 μL Opti-MEM® Medium  80 μL Opti-MEM® Medium 
2μg DNA  3μL Lipofectamine® 2000 
120ng pRL-TK vector  
 
After 5 minutes of incubation at room temperature 80μL from tube 2 was added to tube 
1, mixed by flicking and incubated at room temperature for 25 minutes. 40μL of the mix 
was added to each well so the final concentration of DNA was 500ng with 0.75μL of 
lipofectamine and 30ng of TK- vector. Cells were assayed after 48 hours or treated with 
catabolic agents before assays.  
3.9.3. Induction of catabolic events in cells 
Oncostatin M (OSM) produces mild catabolic events in chondrocytes through JAK3 and 
suppresses Acan expression and elevates the effects of IL-1 in human, rat and mouse 
chondrocytes (Goldring and Otero, 2011) and IL-1β has been implicated in OA, by 
increasing the enzymes which break down the matrix. To examine if these two cytokines 
effects the expression of the Acan enhancer we treated transfected cells with these 
agents. Human oncostatin M (hOSM) (Cell Signalling) was diluted in PBS to a concentration 
of 1μg/mL and human IL-1β (Cell Signalling) with carrier was diluted in PBS to the same 
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concentration. 24hours after cells were transfected with luciferase based vectors the 
media was replaced with media containing either 10ng/mL of hOSM or 10ng/mL of hIL-1β 
for 24hours before luciferase assay. 
3.9.4. Luciferase cell assay 
Luciferase assays were conducted using the Dual-Luciferase® Reporter Assay system 
(Promega). Reagents were prepared fresh for each experiment, with the exception of the 
Luciferase Assay Reagent II (LARII). Passive lysis buffer was prepared by adding 1 volume 
of 5X concentrate into 4 volumes of distilled water and inverted to mix. (LARII) was 
prepared by adding 10mL of Luciferase Assay Buffer II to the lyophilised luciferase assay 
substrate and stored in aliquots of 1mL at -80°C 1 volume of Stop & Glo® substrate was 
added to 50 volumes of Stop & Glo® buffer and inverted to mix. Cells were allowed to 
equilibrate to room temperature for 10 minutes and then 65μL of Passive lysis buffer was 
added to each well and incubated at room temperature for 15 minutes while rocking. 
50μL of LARII was added to each well of a white 96-well plate and a background reading 
was read, 10μL of cell lysis was transferred into the plate and mixed by pipetting, within 
10 minutes the plate was read in the GloMax®-multi detection dual injector system 
equipped with a 96-plate holder and luminescence module read at 0.3 seconds per well. 
50μL of Stop & Glo® Reagent was added to each well, mixed before the Renilla 
luminescence was read. The luminescence was normalised to the control vector and the 
relative response ratio (RRR) was calculated using the following formula: 
𝑅𝑅𝑅𝑅𝑅𝑅 =  (𝑒𝑒𝑒𝑒𝑝𝑝𝑒𝑒𝑖𝑖𝑖𝑖𝑝𝑝𝑒𝑒𝑒𝑒𝑖𝑖𝑚𝑚𝑝𝑝 𝑒𝑒𝑚𝑚𝑝𝑝𝑝𝑝𝑝𝑝𝑒𝑒 𝑖𝑖𝑚𝑚𝑖𝑖𝑖𝑖𝑝𝑝) − (𝑒𝑒𝑒𝑒𝜇𝜇𝑚𝑚𝑖𝑖𝑖𝑖𝑣𝑣𝑒𝑒 𝑣𝑣𝑝𝑝𝑒𝑒𝑖𝑖𝑖𝑖𝑝𝑝𝑝𝑝 𝑖𝑖𝑚𝑚𝑖𝑖𝑖𝑖𝑝𝑝)(𝑝𝑝𝑝𝑝𝑒𝑒𝑖𝑖𝑖𝑖𝑖𝑖𝑣𝑣𝑒𝑒 𝑣𝑣𝑝𝑝𝑒𝑒𝑖𝑖𝑖𝑖𝑝𝑝𝑝𝑝 𝑖𝑖𝑚𝑚𝑖𝑖𝑖𝑖𝑝𝑝) − (𝑒𝑒𝑒𝑒𝜇𝜇𝑚𝑚𝑖𝑖𝑖𝑖𝑣𝑣𝑒𝑒 𝑣𝑣𝑝𝑝𝑒𝑒𝑖𝑖𝑖𝑖𝑝𝑝𝑝𝑝 𝑖𝑖𝑚𝑚𝑖𝑖𝑖𝑖𝑝𝑝)  
 
3.9.5. Statistical analysis 
Paired T-test was conducted to determine if there was a fold change between samples 
and treatments. A P value of <0.05 was considered significant.  
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3.10. Analysis of Acan -35kb Cre recombinase mouse 
3.10.1. Preparation of tamoxifen for IP injection 
Tamoxifen (Sigma) was prepared by dissolving in 200 proof absolute ethanol to a 
concentration of 100mg/mL by vortexing to create stock solution. Stock was emulsified in 
corn oil (Sigma) to 10mg/mL. Prior to injection the emulsified solution was sonicated and 
kept at room temperature, fresh batches were made before each injection.  
3.10.2. Generation of Acan -35kb Cre mouse 
The Acan -35kb cre was created by Grace Chu, formally of the University of Liverpool/ 
Kennedy Institute of Rheumatology, Oxford, the construct was named pChu9 after the 
creator. The Acan -35kb enhancer was blunt end ligated to the human Acan promoter. 
The pCreERT2 vector (Feil et al., 1997) was digested with PvuII and BglII and blunted using 
T4 DNA polymerase (NEB) following manufacturers instruction and dephosphorylated 
using FastAP thermosensitive alkaline phosphatase (Thermo Scientific). Blunt end ligation 
was conducted at a 4:1 ratio overnight at 16°C to create the pChu9 vector. To prepare for 
oocyte microinjection the pChu9 was digested with SalI and AatII to linearised. Four lines 
of pChu9 were created: pChu91, pChu92, pChu93 and pChu94 for analysis. 
 
3.10.3. Genotyping of Acan -35kb cre 
Genotyping was carried out as previously described using primers specific to cre 
recombinase and LacZ with internal. 
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Primer 
Name 
Sequence 5’ – 3’ Species Annealing 
Tm (°C) 
Target Product 
Size 
HELp010 GCA TTA CCG GTC GAT GCA 
ACG AGT GAT GAG 
Mouse 68 Cre 
 
HELp011 GAG TGA ACG AAC CTG 
GTC GAA ATC AGT GCG 
Mouse 68 Cre 389bp 
 
3.10.4. Analysis of Acan Cre x R26R reporter mouse  
To determine the best transgenic line to take forward we utilised the Gtrosa26tm1Sor 
(R26R) reporter mice. The R26R allows to detection of a cre expression pattern, as the 
activation of the cre removes the “STOP” codon that are flanked by LoxP sites. The 
recombination allows the expression of the LacZ gene (Soriano, 1999). Male pChu94 mice 
were time mated with a female R26R mouse and 1mg of tamoxifen was administered by 
intraperitoneal injection (IP) on day 13 of pregnancy with half dose of progesterone 
(Sigma) (up to 2ng)  to reduce abortion rates, injections were carried out by Dr Ke Liu. 
Females were sacrificed and embryos collected at E15.5 and stained for LacZ. Adult pChu9 
x R26R mice were injected with 3 doses of 1mg tamoxifen at 8 weeks from each line were 
sacrificed 8 weeks post injection to determine adult expression of each line by LacZ 
staining.  
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4. RESULTS 
 
4.1. Characterisation of chondrocyte specific Acan enhancers 
4.1.1. In silico identification of possible Acan enhancers using ENCODE 
To establish regions to examine for cis-acting elements of Acan we first screened the TAD 
of the gene with a search range of -150kb to +65kb of the TSS (chr7:86,069,981-
86,262,128 in mouse), as Acan appears to contain a dessert of non-coding region 
upstream of the promoter it was the best region to start. Using the mm9 mouse 
accession, as it was the most complete and readily provided the data tracks for histone 
modifications and DNaseI hypersensitivity in limb only. This in contrast with the earlier 
and the latest accession of the human and mouse genomes on the genome, where user 
input were more heavily relied on, these accession would be used in later analysis to 
strengthen our predictions. Identification by eye was then carried out or a parametric 
linkage analysis, LOD was used. After comparison we deemed by eye was the quickest and 
generated the same data.  
LOD scoring ranked regions where the vertebrate Phastcons are high, with intersections of 
overlap with H3K4me1, H3K27ac and absence of H3K3me3 in the limb and limited to no 
overlap and a score greater than or equal to 300. With LOD analysis 5 regions upstream of 
Acan showed promise for enhancer activity, the -115kb, -100kb, -87kb, -35kb and the 
already known enhancer at -10kb (Figure 17). Based on the histone modification peaks we 
predicted 16 possible enhancers that lie intronic and intergenic of Acan (Figure 18). We 
took a selection of possible regions to examine further, the -35kb and -87kb contained a 
strong level of H3K27ac and H3K4me1 localisation and low H3K4me3 indicating the 
presence of an actively open chromatin at E14.5, high LOD score but had low limb specific 
DNaseI hypersensitivity. The next to be considered was the -65kb region as it contained 
defined peaks of H3K4me1, H3K427ac and both hind and fore limb E13.5 DNaseI 
hypersensitivity indicative of a active enhancer. Although there is a strong mark of 
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H3K4me3 commonly associated with promoters it has been noted that H3K4me3 is 
deposited at enhancers where PolII is highly associated and for this reason the LOD 
analysis excluded this region (Chen et al., 2015, Pekowska et al., 2011). Additionally, we 
looked at 3 intronic sequences that did not get flagged by the LOD analysis, the +26kb 
because of the histone marks and limb specific DNaseI, and in the final two introns 
contained high conservation which indicated a highly important region in the gene and 
worth pursuing although that had little or no histone modifications in the limb. We utilised 
the function of liftover on the genome browser to examine the regions in humans to see if 
there was an agreement between the two species and to allow further work to be done in 
understanding the enhancer’s role in humans. The hg19 accession provides information 
on the chromatin that are not available in mice, however lacks limb specific data tracks 
which may mean these predicted enhancers may not have chondrocyte specificity. On the 
other hand these data sets offers histone modifications, chromatin interactions analysis 
by paired- end tags (ChIA-PET), chromatin state using ChIP-seq a Hidden Markov Model 
(HMM) in human cell types. 
Table 5: Cells used in the ENCODE project 
Cell name Cell type 
GM12878 Lymphoblast  
H1-hESC Human embryonic stem cells 
K562 Mesoderm linage: bone marrow 
HepG2 Hepatocytes  
HUVEC Endothelial 
HMEC Dermal microvascular endothelium 
HSMM Myoblasts 
NHEK Epidermal keratinocytes 
NHLF Lung fibroblast 
HeLaS3 Epithelial 
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This allows us to assess the area and our predicted enhancers for their function in other 
cells types and to determine if these enhancers have predicted functions in humans 
(Figure 19). The chromatin state by HMM indicated that in cells other than chondrocytes 
that our enhancers are on heterochromatins or inaccessible by the experiments. The 
+26kb appears to act as an insulator and interacts with the repressor CTCF in ChIA-PET. 
The -35kb is repressed in most cell types but in HMEC and HSMM where it is a weak 
enhancer and a poised promoter in HUVECS and h1-hESC (Figure 19). This requires further 
validation but builds on a picture of how enhancers drive their cell type specificity which 
will be discussed in detail later.  
We examined the +60, +55, +26, -35, -65 and -87kb by cloning 100bp either side of the 
histone peaks into the HSP68/LacZ/GW and creating transgenic mice, the names of each 
enhancers are based on an estimation from UCSC genome browser and does not 
represent the exact distance from the TSS. Enhancer sizes ranged from 2.5kb to 700bp 
initially before regions were shorten to a minimum of 400bps. The exact locations and size 
for mouse and humans are given in Table 6.   
Table 6: Location of possible aggrecan enhancers in the mouse and human accessions  
 
Enhancer 
Mouse (mm9) Human (hg19) 
Coordinates  Size 
(bp) 
Actual 
distance 
(kb) 
Coordinates  Size 
(bp) 
Actual 
distance 
(kb) 
+60kb chr7:86,258,
701-
86,259,111 
411 +60.3 chr15:89,417,
233-
894,17,661 
429 +70.6 
+55kb chr7:86,251,
764-
86,254,274 
2511 +53.3 chr15:89,410,
372-
89,412,708 
2337 +64.0 
+26kb chr7:86,224,
417-
86,226,396 
2015 +28.0 chr15:89,376,
262-
89,378,225 
1964 +31.6 
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+26kb Small chr7:86,224,8
23-
86,225,626 
804 +26.0 chr15:89,376,
621-
89,377,479 
859 +29.9 
+3kb chr7:86,201,
124-
86,202,499 
1376 +2.8 chr15:89,350,
322-
89,351,819 
1498 +3.6 
*-10kb chr7:86,188,
658-
86,189,016 
504 -9.7 chr15:89,335,
961-
89,336,323 
363 -10.7 
-27kb chr7:86,171,
136-
86,172,814 
1679 -27.2 chr15:89,314,
768-
89,316,511 
1744 -31.9 
-35kb chr7:86,165,
553-
86,167,458 
1906 -30.9 chr15:89,311,
396-
89,313,708 
2313 -33.0 
-35kb Small chr7:86,166,
240-
86,166,651 
412 -31.7 chr15:89,312,
808-
89,313,168 
361 -33.5 
-60kb chr7:86,138,
571-
86,139,868 
1298 -59.8 chr15:89,291,
111-
89,292,883 
1773 -55.6 
-65kb chr7:86,134,
232-
86,136,363 
2132 -62.0 chr15:89,283,
882-
89,286,567 
2686 -60.1 
-68kb chr7:86,130,8
51-
86,132,182 
1332 -67.5 chr15:89,282,
199-
89,283,340 
1142  
-87kb chr7:86,115,
696-
86,118,311 
2616 -80.1 chr15:89,259,
357-
89,262,271 
2915 -84.4 
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-87kb Small chr7:86,116,
387-
86,117,140 
754 -81.2 chr15:89,260,
172-
89,260,980 
809 -85.7 
-90kb chr7:86,108,
776-
86,111,305 
2530 -89.6 chr15:89,251,
996-
89,256,471 
4476 -94.7 
-100kb chr7:86,097,
840-
86,100,140 
2301 -100.5 chr15:89,238,
296-
89,240,649 
2354 -108.4 
-108kb chr7:86,090,0
87-
86,091,743 
1657 -108.3 chr15:89,233,
127-
89,234,795 
1669 -113.5 
-115kb chr7:86,083,7
18-
86,084,710 
993 -114.7 chr15:89,224,
742-
89,225,738 
997 -121.9 
-128kb chr7:86,070,0
48-
86,071,779 
1732 -128.3 chr15:89,202,
247-
89,205,439 
3193 -144.4 
Genomic co-ordinates for enhancer regions and their size in the mouse and human 
accessions mm9 and hg19 respectively. The actual distance from Acan transcriptional start 
site (TSS) is calculated by the 5’ co-ordinate of the enhancer to the 5’ of the TSS in 
kilobases. Bold are the enhancers tested in vivo, italics are the enhancers that reporter 
constructs were created but never examined. 
 
We chose to use Gateway® based cloning due to the high throughput and efficient 
generation of construct as well as the ease and availability of a destination vector with a 
silent promoter to allow assessment of enhancer activity (the HSP68 minimal promoter). 
One of the major pitfalls of using this system is that we did not establish a baseline of the 
HSP68 construct with no enhancers attached and we failed to examine the mouse or 
I.M.H.Li  PhD Thesis 
 
Page | 124  
 
human minimal promoter working alone or alongside the enhancers to establish the 
endogenous pattern of expression. But not withstanding we were able to compare each 
enhancer to each other. The LacZ used in the constructs is a bacterial reporter from 
Escherichia coli that encodes the enzyme β-galactosidase (β-gal). β-gal is able to catalyse 
the hydrolysis of β-galactosides into monosaccharides., When introduced to the β-
galactoside 5-bromo-4-chloro-3-indolyl-beta-ᴅ-galactopyranoside (X-gal)   it has its benefit 
of acting as a reporter for gene activity.  Β-gal is able to hydrolyse  the X-gal substrate into 
galactose and 5-bromo-4-chloro-3-hydroxyindole, then two of the second product is then 
oxidised into the insoluble 5.5’-dibromo-4,4’-dichloro-indigo precipitate.Which, as the 
name suggests, is a indigo substrate that is easy to visualise (Anson and Limberis, 2004). 
Both dimerization and oxidation steps can only occur in the presence of ferric and ferrous 
ions that acts as electron acceptors (Lojda, 1970).In transgenic mice the blue staining 
indicates the activity of the transgene and therefore the expression pattern of the 
enhancer.  
Initially, for screening we used founder embryos in “transient experiments” to assess the 
function of the cis- acting elements due to the higher throughput compared to generating 
lines. However, we would have to re-inject the constructs if we wanted to analyse the 
regions in more detail. We collected founders at E15.5 which falls within the age of the 
histone modifications peaks found on the ENCODE tracks (E14.5) due to developmental 
rates being variable. Collections of founders at E16.5 or greater was avoided due to the 
keratinisation of the skin that reduced the penetration of the substrate. We also could not 
account for the insertion sites and copy number introduced into the genome therefore 
the possibility of site of integration (SOI) was always present. This was eliminated or 
reduced by identification of common expression patterns within the same litter or 
creation of lines for some of the enhancers.  
β-gal activity is pH dependant and endogenous activity within certain tissues such as 
heart, skeletal muscle, brain, kidney and spleen can occur. Exogenous expression can be 
differentiated by using a stain solution of around pH 8.0 (Tenu et al., 1971, Weiss et al., 
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1999). Furthermore, endogenous E.coli and activity from metallic contamination is 
possible but can be differentiated by observing bilateral and symmetrical expression.  
Interestingly, all the enhancer regions examined expressed in transgenic mice at E15.5 and 
these were added as custom tracks for mouse and human on the UCSC browser for 
comparison (Figure 18 and Figure 19). The results of each enhancers will be discussed 
further and are grouped into: 
• +26kb and -35kb enhancers 
• -65kb and -87kb enhancers  
• -55kb and +60kb enhancers 
To discuss the properties and their roles in regulating Acan. 
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Figure 17: LOD analysis of Acan locus for possible enhancer compared to user determined regions 
Read out on UCSC genome browser compared to regions identified by user and regions identified using LOD scoring on the mouse mm9 accession. The 
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tracks from top to bottom. “Enhancer prediction” are the user predicted enhancers colour co-ordinated so region can be compared between accessions, 
in black with “lod=” are the LOD scores, the higher the number the stronger the prediction. The Limb histone and DNaseI hypersensitivity are in purple. 
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Figure 18: USCS limb specific histone modifications and identification of possible enhancers in Acan 
 
Read out on UCSC genome browser compared to regions identified by user and regions tested using transgenic mice on the mouse mm9 
accession. The tracks from top to bottom. “Enhancer prediction” are the user predicted enhancers colour co-ordinated so region can be 
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compared between accessions. “Enhancers” are the enhancers that express. The Limb histone and DNaseI hypersensitivity are in purple. The 
fibroblast DNaseI hypersensitivity is in black. 
 
 
Figure 19: Liftover into human accession for comparison of predicted enhancers 
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UCSC genome browser readout for the human hg19 accession. Mouse predicted enhancers were liftovered onto the accession and the 
enhancers which expressed are coloured. The histone modification tracks are layered from different cell types. Chromatin interactions with 
PolII and CTCF in the cells K562 and HeLa cells by ChIA-PET experiments are the tracks that follow. The coloured tracks “Chromatin state 
segmentations by HMM from ENCODE/Board” map the chromatin state for each region 
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4.1.2. The +26kb enhancer expresses in all chondrocytes at E15.5 
Intronic enhancers are not uncommon, they aid in the higher order of the 
chromatin and gene expression. The first intronic region of Acan, +26kb, was 
able to drive expression at E15.5 with consistent manifestations within three 
littermates, of which there were no other inserts, Table 7 gives an overview of 
the transgenic experiment and the percentage of expressing. This led us to 
believe that the expression was reproducible with little SOI or copy number 
effects. Whole mount images reveal strong activity in the growing limbs, digits, 
ribs and the tail following the characteristic expression of Acan in skeletal 
development but is not present in the craniofacial cartilage which appears 
absent when visually inspected. The enhancer is also able to drive expression in 
the vibrissae and hair follicles (Figure 20). 
Table 7: Number of transgenic and expressing in transient experiments of the +26kb 
Construct Expresser/ Transgenic 
(%) 
Total embryos 
analysed in 
transient 
transfection 
+26kb 3/3    (100) 16 
“Expresser” are the embryos which presented with β-gal expression. “Transgenic” were 
the embryos genotyped positive for LacZ and the percentage is the number of genotyped 
positive embryos compared to the expressers. The final column is the total embryos 
analysed in a litter 
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Figure 20: Whole mount images of the +26kb Acan enhancer at E15.5 
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Whole mount images of the +26kb at E15.5. (A-B) full image of founder embryos. (F) 
higher magnification shows expression in the developing limb, humorous, ulna and 
radius and in the ribs (C and E). The bones in the limbs have high β-gal activity (D) with 
expression in the hair follicles. (E) coronal view of E15.5 embryo showing the vibrissae, 
ribs and sternum stained blue. G and H show another founder expression after 1hour 
and then 16hours showing intense skin expression but early skeletal staining. 
 
Histologically with 6μM sections counter stained with eosin, which gives a good contrast 
between LacZ positive cells and unstained tissue, at E15.5 the +26kb element was able 
to drive tissue specific expression of the transgene in chondrocytes (Figure 21). The 
skeletal elements express the transgene seen in all chondrocytes including the 
hypertrophic cells in the forelimb, the occipital bones and ear, paw and ribs that follow 
normal expression of Acan expression (Figure 21) (Shibata et al., 2003). The expression 
of the +26kb is detected in the IVD, which arises from two different cell progenitors but 
do morphologically resemble chondrocytes (Kletsas et al., 2015, McCann et al., 2012). 
Staining is seen in both the outer fibrillary annulus fibrosis (AF) that surround the 
nucleus pulposus (NP).The detection of the transgene in the glomeruli of the kidney 
shares similar expression pattern to the Acan family member Versican (Rudnicki et al., 
2012, Naso et al., 1995). This initially was usual as the glomeruli arise from the 
metanephric mesenchyme from the mesoderm which are different progenitors from the 
Acan expressing chondrocytes. Although Acan antibody staining has been localised to 
the apical epithelial tubules and basement membrane in the developing kidney at E15.5 
(Lee et al., 2005). However, whenwe generated more founder lines, they showed similar 
chondrocyte staining but more intense skin staining and lacks kidney expression (Figure 
21 M-T). These differences in expression between different founders could be a result of 
the random insertion of the transgene. Alternatively the expression may be in the 
capabilities of the enhancer but the sequence we used is to long (therefore, containing 
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silencing elements) or too short (missing elements), these suggestions are speculative 
and requires further confirmation.  
Figure 21: Histological examination of the +26kb Acan enhancer at E15.5 shows 
chondrocyte expression 
 
Representative histological sections of E15.5 embryos of the +26kb enhancer after 
overnight incubation with the X-gal substrate and counter stained with eosin. (A) 
Vibrissae of the superficial area present with blue staining. Chondrocytes are the primary 
expresser of the +26kb enhancer seen in the chondrocytes of the Meckel’s cartilage [M], 
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jaw [J] and digits [HD] (B), skull and occipital bones (C), humerus [H], radius [R] and ulna 
[U] (D), humerus (E), ribs (F), vertebra (G), femur (H),  metatarsal and phalanges of the 
hindpaw (I), the intervertebral disks of the lumber spine (J) and the tail (K). Interestingly, 
there appears to be specific staining in the glomeruli of the kidneys (L). Sections of 
another +26kb founder embryo show strong, non-consistent developing dermal skin 
staining as well as hair follicles (M-S) but chondrocyte staining in the ear (O), limb (P), 
femur (Q), paw (R) but no kidney expression is seen (T). 
 
4.1.3. The -35kb enhancer expresses in chondrocytes during development 
After the known enhancer (-10kb) (Han and Lefebvre, 2008) the first region in the non-
coding DNA (intergenic) which we identify of significance is the -35kb. The development 
of the transient embryos generated high similarities between littermates. Therefore, to 
analyse further we generated lines from founder mice to determine any differences that 
could be as a result of copy number or SOI. We examined four lines initially lines 2, 8, 9 
and 10 (Figure 22) and then took lines 2,8 and 9 forward for interrogation at different 
stages of development. The aim was to see if the enhancer was always on or switched 
on or off at different stages of cartilage and bone development up until post-natal 
maintenance.  
At E15.5 whole mount show that the staining for the -35kb region was intense with a 
global localisation within skeletal elements, expressing in the axial and appendicular 
skeleton (Figure 22). The staining is complete with the entire cartilage structure being 
marked as opposed to the -10kb, which was confined to the core regions of the 
appendicular skeleton (Han and Lefebvre, 2008). When sectioned the embryos reveal 
chondrocyte specific deposition of the X-gal substrate (Figure 23). Expressing in the 
developing limb, ribs, Meckel’s, the costal IVD and in the lumber IVD in both 
proliferating and hypertrophic chondrocytes. The costal and lumbar IVD differ by the 
lack of expression in the NP in the costal seen both in sagittal and coronal (Figure 23F 
and N). There are no expression in other tissues that are known to express Acan such as 
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the lungs and heart. This suggests that the -35kb enhancer is only capable of driving 
expression in cartilage and hints at the existence of non-chondrogenic enhancers. 
 
Table 10 provides an overview of the expressing regions of the transgene at E15.5.  
To examine the temporal activity of the -35kb lines were examined at E13.5 and 8 
weeks. At E12.5 the limbs are forming and expanding by E12.5, at E13.5 and between 
E13.5 and E15.5 there is a significant activation of genes as chondrocytes undergo 
hypertrophy and commitment to articular cartilage, osteoblast or other fates (Taher et 
al., 2011). Therefore, we wanted to see if there were any temporal dampening of the -
35kb between these stages and into postnatal development examining at 8 weeks and 6 
months of age (Pitsillides and Ashhurst, 2008, Decker et al., 2014a, Decker et al., 2014b).  
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Figure 22: Whole mount of the different -35kb embryos at E15.5 
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Whole mount images of the different -35kb lines at E15.5. (A) Line 2, (B) Line 8, (C) Line 
9, (D) Line 10. (E) Coronal view of a representative of the spine showing activity of 
enhancer in the vertebra. (F) Sagittal view of the ribs and humerus. (G) ribs and vertebra 
sagittal. (H) coronal front view, showing tail, ribs and craniofacial staining. (I) complete 
skeletal elements staining in the forelimb and hindlimb (J). Clearing the embryos showed 
that in the -35kb there is strong skeletal staining in the spine and ribs seen in the whole 
mount (K-N) and staining covers the entirety of the long bones of the limbs (O-Q). 
Figure 23: Histological examination of the -35kb Acan enhancer at E15.5 
 
Histological analysis of the -35kb enhancer at E15.5. LacZ staining is present in the 
chondrocytes of the front paw’s phalanges and metacarpals (A); the ulna [U], radius [R] 
and humerus [H] (B and E); in the ribs (C); the femur (G); the growing annulus fibrosus 
and nucleus pulposus of the lumbar spine and tail (D and K) but not present in the 
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nucleus pulposus of the costal spine (F); staining is present in the chondrocytes of 
Meckel’s cartilage (H), the ear (L) and skull (O). Transverse sections show that the costal 
spine is only stained in cartilage tissue (M) and is present in the jaw (N). Staining is also 
noted in the vibrissae but absent from non- chondrocyte based tissues such as the eye 
(O), kidney (P), lungs (C) or tongue (H). 
 
At E12.5 the transgene was clearly active in the developing limb cartilage and 
metatarsal-phalanges strongly between lines (Figure 25A-C, G-I). There was variability in 
craniofacial, somatic and brain expression of the transgene (Figure 25). Histologically, X-
gal deposition is seen in the epaxial and hypaxial somites, the limbs and the developing 
jaw but not in the heart or lungs (Figure 25J-O). At 13.5 the limbs have progressed in 
development and closely resemble the expression observed at E15.5. Whole mount 
show manifestation of the transgene in the limbs, ribs and craniofacial (Figure 24A-F). 
Similar to the later stages of embryonic development we see chondrocyte specific 
expression but with no sign of decrease in any of the chondrocytes irrespective of their 
stage in maturation (Figure 24G-L).  
Postnatally, at 8 weeks and 6 months the expression does not falter, here we present 
only the 8 weeks as there were no observational differences between 8 weeks and 6 
months in terms of localisation and intensity of expression. The articular cartilage of the 
condyle and hip, the growth plates in the sternum and tail were clearly seen in whole 
mount after overnight incubation with X-gal (Figure 26). There was minor variability in 
the intensity in other cartilage types such as the xiphoid process and in the patella but 
no expression in non-cartilage tissues such as the ribs and kidney (Figure 26). The ureter 
in the kidney may have ectopic or endogenous expression at 8 weeks (Figure 26). The 
chondrocytes of the superficial region of articular cartilage (Figure 27C, F, G and K), the 
growth plates (Figure 27A, B and J) are the main expressers at 8 weeks of age as well as 
the superficial region of the costal cartilage. Other cells types in soft tissues such as in 
the lungs (Figure 27D) fail to express with the exception of the lumen of the aortic wall 
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(Figure 27H). The xiphoid showed little expression (Figure 27L) but the IVD showed 
strong expression in the end plates and in the AF but not in the NP (Figure 27B and I). 
This keeps the to the chondrocyte specificity of the -35kb seen at the earlier stages of 
development and marks out areas that overlap previously documented Acan expression 
although it does not mark all Acan expressing tissues (Fukada et al., 1999, Chambers et 
al., 2002, Melrose et al., 2008). The -35kb’s ability to express in early development and 
into late adulthood suggests that it plays a key role in the regulation of its target gene. 
What needs to be established is its function, and if the knock-out of this region will have 
a deleterious effects.  
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Figure 24: Whole mount and histological images of the -35kb Acan enhancer at E12.5 
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Figure 25: Histological examination of the -35kb enhancer at E12.5 
 
Examination of the -35kb lines at E12.5 shows minor differences between lines 2 (A), 8 
(B) and 9 (C) but all share similarities in the limb staining (G-I) in whole mount. 
Histologically there is expression in the early limbs (L and O), ribs (K) and Meckel’s 
cartilage (J) but no staining in the heart or lung (N) and little in the brain (M).  
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Figure 26: Whole mount images and histological examination of the -35kb at E13.5 
 
E13.5 embryos expression whole mount from lines 2 (A) and 8 of the -35kb enhancer (B) 
showing skeletal elements with β-gal activity. Coronal view shows craniofacial staining 
but not complete ribs (C) and in the spine (E). Higher magnification of the vertebra (F) 
and the limbs (D). Histologically all chondrocytes are stained blue in Meckel’s cartilage 
(A), ribs (B), skull (C and F), limb (D) and paw (E). 
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Figure 27: 8 week old mice lines of the -35kb enhancer whole mount and histology 
 
 
 
[TOP] Whole mount images of 8 week old tissue taken from the -35kb lines 2, 8 and 9 
shows similarities in staining for enhancer activity in the tail, hip, condyle and ribs with 
line 9 being the strongest at this age. There are weak staining in the xiphoid in lines 2 
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and 8 but stronger in line 9 which may be a copy number effect. There are other regions 
that the enhancer is able to express in the cartilage rings in the aorta and patella but not 
in the lungs or kidney.  
[BOTTOM] The -35kb expresses in 8 week old mouse in chondrocytes in the ribs 
expressing in the costal cartilage but stops at the ossified regions (A), growth plates [GP] 
from the sternum- costal cartilage (E) and knee (J); the superficial regions of the articular 
cartilage of the metatarsals (K), hip (F), condyle (C) and plateau of the knee (G) as well as 
the meniscus (C). In the tail and spine the enhancer is active in the end-plates and weakly 
in the annulus fibrosus [AF] but is absent from the nucleus pulposus [NP] (B and I). The 
enhancer does not express in the lungs (D) and very weakly in the xiphoid (L). The 
internal connective tissue of the aorta is marked by the -35kb (H). 
 
4.1.4. Identification of transcription factor binding in the +26kb and -35kb enhancer 
Enhancers can interact with multiple TFs at any one time, but key regulators have 
temporal importance and a loss results in loss of function on a transcription level. To 
identify and understand the TFs that modulate the activity of the +26kb and -35kb 
enhancers we used the program Biobase to screen for binding motifs and combined this 
with conservation by alignment using ClustalW to determine if each region was worth 
perusing (highly evolutionary conserved regions are more likely to be of significance). 
Sox9 has been previously been shown to activate the Col2a1 (Bridgewater et al., 1998, 
Bridgewater et al., 2003, Lefebvre et al., 1997, Zhou et al., 1998) and the Acan promoter 
and known enhancer (Sekiya et al., 2000, Han and Lefebvre, 2008, Doege et al., 2002) 
and it is classed as the master transcription factor that regulates the chondrocyte 
phenotype in development (Akiyama et al., 2002). We find that Sox9 is predicted to 
interact with both enhancers with strong degrees of conservation at 6 sites in the +26kb 
and 8 sites in the -35kb (Figure 29 and Figure 30 Red). Each region contain the single 
binding site of Sox9 or the double binding site in opposing direction with 3-4bp of 
separation seen in chondrocyte specific interactions (Bridgewater et al., 2003, Ohba et 
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al., 2015). Rbpj-k is an important Notch signalling mediator and is important in 
maintenance of post-natal articular cartilage with a chondrocyte specific knock out using 
the AcanCre(ERT2) postnatally resulted in OA like pathology (Liu et al., 2015, Mirando et 
al., 2013, Liu et al., 2016). Therefore we added Rbpj-k to the TF scree and found three 
conserved motifs in the +26kb and -35kb enhancer (Figure 29 and Figure 30 Green). 
NFAT1 was another TF taken into account due to the its age-dependant activity in 
chondrocytes, its regulation of Notch dependant differentiation and its role in regulating 
Sox9 in development (Lin et al., 2014, Zanotti and Canalis, 2013, Rodova et al., 2011, 
Wang et al., 2009). One binding site in each enhancer was identified for NFAT1 (Figure 
29 and Figure 30 Yellow). The consensus sequence for each TF is shown in Figure 28.  
 
Figure 28: Binding motifs of Sox9, Nfat and Rbpj-k 
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Binding sequences for (A-B) Sox9, the class 2 binding of a doublet Sox9 binding sequence 
reading in opposing directions separated by 304 nucleotides (A). (B) monomer sequence 
of Sox9 not generally associated with chondrocytes. (C-D) rbpj consensus binding 
sequence. (E) Nfat1 consensus binding sequence. 
Figure 29: ClustalW alignment for the +26kb enhancer and possible transcription 
factoring binding sites 
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ClustalW alignment of the +26kb sequence between mouse, human and opossum. Using 
biobase seven Sox9 binding sites were identified (in red), three rbpj-k (green) and NFAT 
(yellow) that were examined using eletromobility shift assays. 
Figure 30: ClustalW alignment of the -35kb enhancer and outline of possible 
transcription factor binding sites 
 
ClustalW aligned mouse -35kb sequence to chicken and human with eight Sox9 binding 
sites (red), rbpj-k (green) and NFAT (yellow) that were examined using electromobility 
shift assays.  
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EMSAs provide a relatively quick method for detecting in vitro if a DNA region binds to 
the TF, as DNA bound to proteins migrating through a gel matrix moves slower than 
DNA alone you can determine, by labelling, the DNA or protein if a binding occurs by 
visualising the gel. The use of in vitro translated proteins from vectors to generate the 
proteins used in EMSAs removes the anonymity of the binding protein from nuclear 
protein extract and the requirement of using an antibody that targets the suspected 
protein (super-shift) which gives cleaner and clear binding patterns on a EMSA gel and 
more confidence in the identity of protein which has bound to the sequence. There are 
two types of competitive EMSAs, direct and indirect, the direct method labels each 
binding region by end labelling with P32, fluorophores or biotin and examines for 
binding for an appearance of a band on the gel. Indirect is the method utilised in this 
study due to the cost-effective and rapid screen of large amounts of binding motifs, this 
method labels a control or known binding motif for the TF. If the sequence that is 
predicted to bind is incubated with the protein first it should bind reducing the free 
protein for the labelled control sequence to bind to, this mean the band is diminished if 
the sequence of interest is interacting. To ensure it is the binding site that was predicted 
is the site that is binding we introduce point mutations into the oligo (mt) and this 
should reduce the efficiency or completely abolish the binding interactions, this ensure 
that in designing the oligos there was no accidental introduction of binding sites.  
Sox9 interacted with the +26kb enhancer at sites 1 and 4, albeit weakly in both cases, 
where mutations in the binding sites resulted in the control oligo binding (Figure 31). 
Initially, the -35k sites were interrogated using increasing concentration of the oligos 
without mutations, which identified sites 2 and 3 with good competition and site 7 as 
another site (Figure 32). Site 4 on the 100% concentration lacks a band due to technical 
error. Each site was then examined alongside their mutated version showing that 
mutations into the Sox9 binding motif removed the binding affinity and reconfirmed the 
binding ability of the three sites (Figure 33). 
The EMSA for rbpj-k reveal that the protein has two interaction sites in the +26kb, site 1 
and 3 however the mutations in site 1 were unable to adequately block the binding 
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(Figure 34A). In the -35kb only one site was able to bind, Site C, but we were unable to 
produce a clean EMSA gel to demonstrate the ability of the mutations to diminish 
binding (Figure 34B). In terms of NFAT1 binding both enhancers were able to bind to the 
NFAT core binding domain protein (Figure 35). 
 
Figure 31: Sox9 indirect competitive EMSA for the +26kb enhancer 
 
Indirect competitive electomobility shift assay for the 6 regions of the +26kb possible 
Sox9 binding using a labelled Sox9 control probe. Lane 1 UP is the lysate from the in vitro 
translation reaction with no vector to determine any non-specific binding. The second 
lane is the probe with no competitor to show it is binding to the proteins. The third lane 
is the control competitor therefore the band should be removed if it is able to bind.  Sites 
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1 and 4 are able to bind the Sox9 protein and introduction of mutations into the binding 
sites (1mt and 4mt) diminishes the binding activity so the band reappears.  
Figure 32: Sox9 indirect competitive EMSA for the -35kb enhancer with increasing 
concentration of competitor 
 
Indirect competitive electromobility shift assay using a Sox9 control probe that is able to 
bind to Sox9 protein for the -35kb enhancer region. Lane 1 UP is the lysate from the in 
vitro translation reaction with no vector to determine any non-specific binding. The 
second lane is the probe with no competitor to show it is binding to the proteins. The 
third land is unlabelled control oligo (competitor) it is able to compete and bind to the 
protein so the signal is diminished when increasing the concentration of the control 
oligo. Each competitor is increased by 20%, 50% and 100%. Sites 2 and 3 are able to 
compete with the control probe to remove the band therefore binds to Sox9 in vitro. Site 
7 only with the highest concentration is able to compete with the control probe. Site 4 
appears to bind but this was done in error, the probe was not added into the reaction. 
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Figure 33: Sox9 indirect competitive EMSA for the -35kb enhancer with mutated 
sequence 
 
Indirect competitive shift assay. Lane 1 UP is the lysate from the in vitro translation 
reaction with no vector to determine any non-specific binding. The second lane is the 
probe with no competitor to show it is binding to the proteins. The third lane is the 
control competitor therefore the band should be removed if it is able to bind.  This 
confirms that sites 2, 3 and 7 of the -35kb is able to bind to Sox9 in vitro but not site 1. 
Introduction of mutations into each binding sites removes the binding to Sox9 (2mt, 3mt 
and 7mt). 
 
 
 
I.M.H.Li  PhD Thesis 
 
Page | 154  
 
Figure 34: Rbpj-k indirect EMSA for the +26kb and -35kb enhancer 
 
Indirect competitive shift assay for Rbpj-k for enhancers +26kb (A) and -35kb (B). Lane 1 
UP is the lysate from the in vitro translation reaction with no vector to determine any 
non-specific binding. The second lane is the probe with no competitor to show it is 
binding to the proteins. The third lane is the control competitor therefore the band 
should be removed if it is able to bind. Site 3 is able to bind to Rbpj-k in vitro and 
mutations introduced to the Rbpj-k binding site abolishes the binding. Site 1 was able to 
interact but mutations could not remove the binding as effectively. For the -35kb Rbpj-k 
there was an increase of competitor from 20%, 50% to 100%, only site 3 binds to Rbpj-k 
protein in vitro. 
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Figure 35: The -35kb and +26kb enhancer binds with NFAT core binding domain with 
different affinities  
 
Indirect competitive Electromobility shift assay using the NFAT core protein binding to 
detect interactions within the +26kb and -35kb enhancer. The NFAT control oligo was 
used as the probe and an unlabelled oligo of the same sequence is the control 
competitor. Lane 1 UP is the lysate from the in vitro translation reaction with no vector 
to determine any non-specific binding. The second lane is the probe with no competitor 
to show it is binding to the proteins. The third lane is the control competitor therefore 
the band should be removed if it is able to bind. Both NFAT sites in the +26 and -35kb are 
able to bind weakly to the NFAT protein and introduction of mutations into the 
sequences diminishes the binding. 
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4.1.5. In vivo analysis of transcription factor binding site mutations 
To assess the importance of the TF binding site we cloned the mutated sequences into 
the HSP68/GW cassette and generated transgenic mice, to assess the role of Sox9 in the 
-35kb we introduced mutations into Sox9 binding sites 2, 3 and 7 together and collected 
at E15.5, the same time point we observe staining in the WT. We expected for Sox9 
mutations to completely abolish the expression of the enhancers. Therefore, to our 
surprise the transgene was still active but no longer in the chondrocytes, the expression 
had shifted into the fibroblast of the skin and in some cases the perichondrium there 
were no longer expression in the chondrocytes, in the ribs, limb and IVD (Figure 36). To 
determine if a single site was important and responsible for the shift in expression we 
injected each site mutated individually. Sox9 sites 2 and 3 showed no chondrocyte 
specific expression in the limbs or other cartilage based tissue (Figure 37). Site 3 did 
present with superficial staining although this requires more transgenic animals to be 
generated to confirm. Site 7 looked as though there were no chondrocyte specific 
expression when observed whole mount (Figure 38A), with more staining in the 
vibrissae. However, there appears to be a population of chondrocytes that are active 
with the transgene seen in the forelimbs radius and ulna (Figure 38F and G), but no 
staining is observed in the metacarpals, metatarsals, phalanges (Figure 38H and J), ribs 
or ear. By eye there seems to be no defined characteristics for the chondrocytes that 
are expressing the transgene as the sagittal section of humerus (Figure 38E) show no 
chondrocyte staining in the proliferating, pre-hypertrophic or hypertrophic cells.   
Figure 36: The -35kb Sox mut 2_3_7 at E15.5 abolishes expression in the chondrocyte 
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Mutations in all three of the sox9 binding sites in the -35kb enhancer abolishes the 
expression in the chondrocytes. Two different expression is seen which may be as a result 
of SOI effects. The first (Top) still remains in skeletal elements but the perichondrium 
seen in the forelimb and ribs. No expression is seen in the vertebra and IVD but some in 
the meninges. The second expression patter resides in the epidermis or developing 
dermis of the skin (Bottom).  
Figure 37: The -35kb Sox mut_2 and Sox mut_3 at E15.5 are no able to express in the 
chondrocyte 
 
Individual mutations in the Sox9 binding sites of the -35kb enhancer removes the 
expression in the chondrocytes and other tissues. Binding sites 2 alone (top) only 
presented with notochord expression. Binding site 3 (Bottom) also abolishes the 
expression of the enhancer albeit there are some ectopic epidermal expression. In both 
cases the previously observed expression of all three sites mutated is not reproduced. 
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Figure 38: The -35kb Sox mut_7 expresses weakly in the chondrocyte  
 
The Sox9 binding site 7 of the -35kb enhancer when mutated removes the expression in 
almost every chondrocyte. However there is expression in the forelimb central 
chondrocytes in the radius [R] and ulna [U] but not in the humerus [H] (* F and higher 
magnifications G). There is expression in the vibrissae (B) and in the glomeruli of the 
kidney (I). (A) is the whole mount of a representative embryo; (C) ribs, (D) ear; (E) 
humerus; (H) front paws and rear paws (J).  
 
We generated -35kb rbpj-k mutated sequence transgenic mice to interrogate the effect. 
On visual inspection there appears to be no effects on the majority of the embryos at 
E15.5 but some did stain (Figure 39). At E15.5 it appears that the rbpj-k binding site has 
no effect on the chondrocyte specificity, although the staining is more scattered. There 
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is increased ectopic expression in the fibroblast in the skin (Figure 39) and it is noted 
that there is increased vasculature expression. Table 8 gives an overview of how many 
constructs were expressed and Table 9 summarises the expression of each of the TF 
mutations tested. 
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Figure 39: Rbpj-k binding site mutations at E15.5 does not affect chondrocyte expression  
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Mutations in the Rbpj-k binding site in the -35kb has little effect on the chondrocyte 
specific expression of the enhancer. However, the expression appears more scattered 
and more expression in the skin in 3 of the 4 embryos that expressed. [H] humerus; [R] 
radius; [U] ulna. There appears to be vasculature expression not seen in the wildtype 
enhancer [*].  
Table 8: Overview of expression verses number of expressing of transcription factor 
binding sites mutations at E15.5 
Construct Expresser/ 
Transgenic (%) 
Total embryos 
analysed in transient 
transfection 
-35kb WT 4/4 (100) 17 
-35kb Sox 
mut_2_3_7 
3/3    (100) 30 
-35kb Sox mut_2 1/2    (50) 15 
-35kb Sox mut_3 4/4    (100) 14 
-35kb Sox mut_7 2/4    (50) 9 
-35kb 
rbpj_mut_C 
4/5    (80) 20 
“Expresser” are the embryos which presented with β-gal expression. “Transgenic” were 
the embryos genotyped positive for LacZ and the percentage (in brackets) is the number 
of genotyped positive embryos compared to the expressers. The final column is the total 
embryos analysed in a litter. 
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Table 9: Summery of binding site mutation expression 
Tissue Intensity of staining 
-35kb 
Sox 
mut 
2_3_7 
-35kb 
Sox mut 
2 
-35kb 
Sox mut 
3 
-35kb 
Sox mut 
7 
-35kb 
Rbpj 
mut_ C 
Chondrocranium - - - - ++S 
Nasal cartilage/ olfactory  ± - - - - 
Meckle’s cartilage/ mandible - - - - ++S 
Costal cartilage of the ribs - - - + +++S 
Femur - - - - +++S 
Tibia - - - - +++S 
Fibula - - - - +++S 
Digits of hindlimb - - - + +++S 
Digits of forelimb - - - + +++S 
Scapula/ humerus - - - - +++S 
Ulna - - - + +++S 
Radius  - - + +++S 
Intervertebral discs - - - - +S 
Lumbar spine - - - - +S 
Cartilage of the ear/ 
occipital  
- - - - +S 
Tail - - - - ++S 
Brain - ++ ± - - 
Vibrissae - - - ++++ ++++ 
Heart - - - - - 
Lung - - - - - 
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Liver - - - - - 
Tongue - - - - - 
Skin ±±± - ±± - ±±±± 
Kidney - - - +++ - 
Blood vessels - - - - ±± 
Summary of the staining intensities and location for the +26kb and -35kb enhancer. – is 
not detected; + weakly detected; ++ not completely uniform staining throughout tissue; 
+++ majority of tissue stained; ++++ strong staining in entire tissue; ± staining present in 
some founder embryos but not all. “S” dictates that the expression was not uniform but 
scattered or “patchy” in some areas of the tissue. 
 
4.2. Two Acan cis-elements that have defined developmental roles 
Many genes can contain several DNA regulatory elements, the most characterised being 
the β-globin enhancer (Caterina et al., 1994). Each element may be responsible for 
temporal and spatial activation of a gene, guiding the precise activation for 
development and normal homeostasis and when it is no longer needed, it eventually 
become inactive. Inactive enhancers have also been shown to be essentially in long 
range activation of genes, for example in B cells the Igk enhancer MiEk is inactive but 
interactions with the active enhancer Tcrb enhancer Eβ changes the localisation of CBFβ 
controlling Tcrb recombination (Proudhon et al., 2016). Currently, it is rare to find 
cartilage proteins that have greater than two enhancer elements to varying degrees. For 
example, the Col10a1 is under influence of tissue specific enhancers located between -
2410 and -1875bp (Gebhard et al., 2004, Beier et al., 1997) and -4.4 to -3.8kb (Zheng et 
al., 2009) that together follow the complete expression of Col10a1 that are intergenic. 
The Col11a2 has two chondrocyte specific enhancers (Bridgewater et al., 1998), the 
Col27a1 contains at least three enhancers in the first intron (Jenkins et al., 2005). 
However, the Col2a1 is regulated by intronic sequences, an 18bp region in the first 
intron (Rossi and de Crombrugghe, 1987, Leung et al., 1998, Zhou et al., 1998, Lefebvre 
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et al., 1996), the 7th intron (Shinomura et al., 2012), in the 2nd intron that regulates 
splicing (McAlinden et al., 2005). Col1a2 on the intergenic enhancers regulates 
fibroblasts at -19.5kb (Bou-Gharios et al., 1996, Antoniv et al., 2001, De Val et al., 2002). 
So we wanted to determine if Acan is under a higher order level of transcription, seeing 
as there is a large region of non-coding similar to Sox9 which houses multiple enhancers 
that drives different expression in different tissues (Mead et al., 2013).  
4.2.1. The -65kb enhancer element of Acan is able to express in chondrocytes at E15.5 
After identifying the -65kb region upstream of the Acan TSS as a possible enhancer, the 
region was cloned into the HSP68 gateway vector and analysed transiently to determine 
if it was able to express. At E15.5 there were two expression patterns seen in whole 
mount (Figure 40A -C). Skeletal element staining were observed in the core regions of 
the forelimbs, hindlimbs and in the ribs (Figure 40D and F). However, staining was not 
distinguished in the paws or the tails in one embryo. In the second there was mass 
staining in the skin making it difficult to distinguish if there were skeletal staining (Figure 
40C, E and G). Histologically, the -65kb at E15.5 is expressed by the chondrocytes but 
unlike the +26kb and -35kb it is not in every chondrocyte. In the skull there is strong 
staining in the ventral bone but closer magnification of the dorsal regions shows only a 
scattered few cells are staining for B-gal activity (Figure 41C and D). The limbs present a 
staining pattern that is reserved for the core regions of the long bones of the radius, 
ulna and humerus (Figure 41F and G), and femur (Figure 41K), closer inspection of the 
histology sections shows that the cells appear to be mainly hypertrophic chondrocytes 
of the radius, ulna and humerus (Figure 41N) No staining is observed in any regions of 
the IVD (Figure 41 M), Meckel’s cartilage (Figure 41B), vibrissae (Figure 41A), in the paws 
(Figure 41 L), tail (Figure 41 O) or the kidneys (Figure 41 P). Scattered strong staining is 
seen in the vertebral body (Figure 41J) and ribs (Figure 41H and I). Staining in the 
superficial skin, near the epidermis is seen in the embryos that expressed in the skin 
(Figure 40C and Figure 41K and O). Lastly, the eye appears to express and stains with X-
gal in the vitreous humor (Figure 41 E). 
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Figure 40: Whole mount images of the -65kb enhancer 
 
Whole mount images of the two expression patterns seen in the -65kb enhancer at 
E15.5. (A) Sagittal image of a representative embryos with core element staining in the 
limbs and ribs. (B) rear view showing vertebrate staining. (C) other staining pattern seen 
in whole embryos of complete skin staining (D) a higher magnification of the forelimb 
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and ribs displaying staining and the hindlimb (F). (E) shows skin staining in the limbs and 
in the vibrissae, however craniofacial features are difficult to decipher (G).  
Figure 41: Histological examination of the -65kb enhancer 
 
Histological examination of two -65kb enhancer at E15.5. C, G, K, O and P come from the 
pan skin expressing embryo with t. Staining is seen in chondrocytes but of a select 
subset, in the forelimb (F) it localises in the hypertrophic chondrocytes. In the ribs, (H and 
I), vertebrae (J), tail (O) and scattered in the skull (*) (D) it appears scattered to specific 
chondrocytes and in the carpels of the fore paw there is some but not a significant 
amount (L). Staining is absent from the vibrissae (A), Meckel’s cartilage (B) and IVD 
(M).The eye stained with X-gal (E) as did the cutaneous layer of the skin in some of the 
embryos identified by the arrows (O and P). The -65kb does not express in lungs (H) or in 
the kidney (P).  
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4.2.2. Characterisation of the far up stream enhancer -87kb in aggrecan gene 
Transient transgenic mice at E15.5 harbouring the -87kb enhancer construct presented 
staining in skeletal elements (Figure 42), therefore a line was established for further 
analysis. Whole mount at E15.5 showed joint and ribs staining with X-gal but there was 
little or no staining in other areas (Figure 42H). On the limbs it appears confined to the 
central regions and in the paws it resides in the joints between the distal, proximal and 
metacarpals (Figure 42E and F). However, one line expressed differently to the others, in 
the craniofacial region, we cannot determine if this is real or if there were possible SOI 
or copy number effects where on some occasions there would be staining in areas 
where the transgene lands in an open chromatin (Figure 42B) and the limbs expressed 
more weakly in comparison (Figure 42A, D and G). 
Histologically, the -87kb does not express in the IVD (Figure 43O and R), tail (Figure 
43D), jaw (Figure 43S), kidney (Figure 43N) and in Meckel’s cartilage (Figure 43A). There 
is weak expression in the ear chondrocytes (Figure 43J) and in the femur (Figure 43L) 
and more scattered and superficial staining seen in the forelimb (Figure 43G) and ribs 
(Figure 43I and Q). Closer inspection of the radius (Figure 43F) and humerus (Figure 43E, 
K and P) show that the chondrocytes that stain appear to move in the direction of the 
growing cartilage towards the articular cartilage. Additionally, this pattern of favouring 
the joints is seen in the entire limb (Figure 43G). There is strong consistent staining in 
the eye (Figure 43M) and of the chondrocytes of the vertebra seen in transverse (Figure 
43T) coronal (Figure 43C) sections. In the paw the carpals are strongly stained whereas 
when the chondrocytes migrate towards the distal areas like the phalanges the staining 
is localised to the joints (Figure 43H). 
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Figure 42: Whole mount images of the -87kb enhancer 
 
I.M.H.Li  University of Liverpool 
 
Page | 169  
 
Whole mount images of expression patterns seen for the -87kb enhancer at E15.5. (A) 
Little expression seen mainly in the joint in the hips and shoulder, and patterns is noted 
in the paw and rear of the head. (D) Show higher magnification of the forelimb and (G) is 
a higher magnification of the hindlimb. (B and C) shows strong staining in the ribs (H) 
and in the bones of the fore and hind limb. There is intense staining between the bones 
of the paws (E and F). In the hindlimb (I) the staining is more localised into the core 
regions. Clearing the embryos with KOH shows greater detail in the skeletal elements 
showing that the -87kb expressing in the skeletal elements but not in the distal limbs 
where it resides in the joints (J-R). 
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Figure 43: Histology images of the -87kb enhancer 
 
Eosin counter stained sections of a representative of the -87kb at E15.5. The staining is 
scattered marking certain chondrocytes in the humerus (E), ribs (I and Q), femur (L), ear 
(J), radius and ulna (G and F). The chondrocytes are patterning towards to ends of the 
bones and primordial articular cartilage seen in higher magnification of the humerus (K 
and P), the vertebra and the carpels are stained uniformly but the metacarpals are 
stained more towards the forming articular cartilage (H). The IVD (O), tail (D), kidney (N) 
and Meckel’s (A) does not stain and only the proximal vibrissae express. Additionally, 
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there is staining is seen in the eye and transverse sections show that there is little 
staining in the lumbar region (R) and jaw (S) until the costal vertebra (T). 
 
4.2.3. Interrogation of the -87kb at different developmental ages 
The -87kb enhancer favours expression in the joints. Therefore, the next step was to 
determine if that expression changes with age. At 8 weeks of age the -87kb expression is 
strong in the articular cartilage seen whole mount tissues of the knee (Figure 46G and 
H), femoral head (Figure 46B). In the hind paw the joints are stained strongly (Figure 46 
C), as well as the growth plates of the ribs (Figure 46A) and cartilage end plates of the 
tail (Figure 46I). The patella (Figure 46E) and xiphoid (Figure 46D) but no staining is seen 
in the kidneys with the exception of some endogenous staining (Figure 46F). 
Histologically, the growth plate chondrocytes stain in both the sternum (Figure 46J) and 
the cartilage end plate, but in the IVD there is staining surrounding the nucleus pulposus 
in the annulus fibrosus, but not in the nucleus itself (Figure 46L). The articular cartilage 
chondrocytes are expressing in the superficial regions in the knee (Figure 46K and Q) 
and femoral head (R) cartilage. However it must be noted that the images presented as 
evidence the X-gal staining appears non-uniform, strong in some cases or non-
consistent between different mice, although they are from the same line. One 
explanation for this is due to penetration issues of the X-gal stain this may have arisen 
from failure to open up the joint at the time of staining or tissue processing, this means 
the substrate or processing solutions were unable to penetrate into the central parts of 
the knee joints. We are certain that the inconsistencies are not a result of the transgene 
position effect or copy number as these mice are different from the same litter from 
one founder. Furthermore sectioning errors that rose from poor processing or poor 
technique that resulted in loss of samples or folding of the sections made it difficult to 
select images to present in the data set. The images are chosen as the best 
representation and the clearest image of chondrocyte staining in the knee. In the paw 
the articular cartilage chondrocytes are the only cells to express B-gal (Figure 46N) this is 
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seen more clearly in a higher magnification (Figure 46O). In the ribs it is mainly the 
superficial cells that are expressing (M) and in the xiphoid there is continuous staining 
throughout (Figure 46P).  
Figure 44: E12.5 whole and histology images of the -87kb enhancer 
 
At E12.5 the -87kb is absent from the limbs seen in whole mount (A-C) and clearing the 
embryos with KOH yields similar observations (E and F) and by histological examination 
(I). Additionally, it is not expressed in the forming ribs or jaw (H and J). It is present in the 
brain (J) and although histological sections are absent it remains in the somites. 
 
To determine the earliest point of expression for the -87kb enhancer, embryos were 
analysed at E12.5 and E13.5. At E12.5 the embryos expresses but not in the limbs 
(Figure 44A-C) but expression is confirmed in the somites. Sectioning reveals there are 
no chondrocytes or precursors expressing the transgene in the jaw (Figure 44G), ribs 
(Figure 44E) or limbs (Figure 44F) but staining is observed in the rear of brain only 
(Figure 44F), unfortunately sections deeper into the embryos were not obtained. A day 
later, at E13.5, definitive expression is seen in the whole mount, most noticeable is the 
rostral to ventral staining in the skin (Figure 45A). The developing joints do not stain at 
this stage but minor expression is seen in the limbs more proximal and towards the 
humerus and hip (Figure 45B and C). Histologically, there are no chondrocytes 
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expressing the enhancer, but in the fore paw there are a subgroup of cells that are 
active (Figure 45D) and this is seen more weakly in the hind limb (Figure 45G). The 
somites are expressing but not the ribs (Figure 45E). Other regions such as the nasal 
area does not express (Figure 45H) whereas the brain (Figure 45I) and eye (Figure 45F) 
presents with X-gal activity. 
Figure 45: Whole mount and histological samples of the -87kb enhancer at E13.5 
 
At E13.5 the enhancer (-87kb) starts to express in the limbs, as whole mounts shows that 
there is strong staining in the entire embryos with the exception of the external limbs 
such as the paws (A-C). In the limbs the expression is localised to a subset of cells not in 
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the chondrocytes that are forming the skeletal limbs and joints (D and G). The brain (I), 
somite’s (E) and the eye (F) but the vibrissae do not (H).  
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Figure 46: 8 week old tissue samples and histology of the -87kb enhancer 
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8 week old tissue taken from the -87kb enhancer line and stained for B-gal activity. 
Whole mount of the ribs (A), femoral head (B), paw (C), Condyle (G), tibial plateau (H) 
and tail (I) shows specific staining in the joints and areas known to contain chondrocytes. 
Staining is also seen in the xiphoid (D) and the patella (E) but not in the kidneys (F). 
Histologically, the staining is seen in the superficial regions of the articular cartilage of 
the femoral head (P), knee and meniscus (O and K) (it must be noted that due to 
penetration and user error staining in these regions do not appear consistent and strong 
but these were the images chosen due to clarity) and tarsals (L and M). These is staining 
in the xiphoid (N), superficial region of the ribs (K), growth plates (J), the cartilage end 
plates of the IVD (J) but not in the nucleus pulpous (J). 
 
4.2.4. Exploration of the minimal sequence able to drive expression of the -87kb 
enhancer 
The original sequence of the -87kb is large for an enhancer, 2.6kb, naturally we wanted 
to establish the minimal sequence capable of driving expression. Using conservation we 
cloned the opossum sequence to determine evolutionarily, how active the -87kb was, 
and this fragment was 1100bp. A shorter sequence of 754bp was generated from the 
most evolutionary conserved region. The fragments were cloned into the HSP68 vector 
and transient expression of transgenic mice were analysed at E15.5. The opossum 
sequence failed to express in chondrocyte specific areas but appeared on the snout of 
the mouse (Figure 47A-C). The expression when analysed histologically, showed no 
expression in chondrocytes in the limbs (Figure 47H), IVD (Figure 47G), ribs (Figure 47F), 
ear (Figure 47I) or in the Meckel’s cartilage (Figure 47E) but expression was seen in the 
superficial region of the nose (Figure 47D). 
The smaller fragment was able to express and was more defined in the ribs and limbs 
(Figure 48A and B) but due to skin staining it was difficult to establish the skeletal 
element staining. Histologically, the staining was chondrocyte specific, although more 
cells were stained than with the larger fragment it was still scattered and looked to 
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favour the joints (Figure 48C).Unfortunately, due to technical errors there was a lack of 
quality histological images to further identify the expression pattern of the smaller 
fragment, therefore it remains to be further investigated. 
Figure 47: Opossum sequence of the -87kb enhancer is not able to express 
 
Analysis of the opossum sequence of the -87kb enhancer. Transgenic mice only 
presented in whole mount with staining on the nose with minor staining in the back of 
the head (A-C). Histologically, there are no chondrocyte staining in the ribs (F), tail (G), 
forelimb (H), ear (I) or in Meckel’s cartilage (E). The staining is apparently only in the 
superficial region of the mouth (D and E). 
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Figure 48: 700bp fragment of the -87kb enhancer is able to express 
 
A 700bp of a smaller region of the -87kb was tested in transgenic mice. Transient 
transgenic embryos at E15.5 showed strong staining in skeletal elements, (A) shows a 
representative embryos. Due to sectioning issues there were poor attainment of 
presentable histological images, (C) shows the humerus, radius and ulna with similar 
scattered pattern of expression of the whole sequence of the -87kb. 
4.2.5. Identification of transcription factor binding regions of the -65kb and -87kb 
 
To establish which TFs interact with the -65kb and -87kb enhancer to bring about their 
unique express, each sequence was aligned to other species using ClustalW to help 
identify conserved TF binding sites. The -65kb  was not as well conserved, as the 
sequence was only able to align to the human sequence. The -87kb sequence was better 
conserved as it aligned up to opossum seen in Figure 49 and Figure 50. Using Biobase 
multiple Sox9 binding sites were found in the -65kb and -87kb elements, there were 5 
sites in the -65kb and in the -87kb there was 10 sites, in both there only one site 
containing the paired adjacent Sox9 binding site (Bridgewater et al., 2003). There were 
other conserved TF binding sites that were of interest, such as the Mef2, Hif and Gli 
proteins in the -65kb which may regulate the hypertrophic chondrocyte specific 
expression. In the -87kb there were notch effectors such as rbpj-k, age related proteins 
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such as Nfat and other such as SP1, SP3, Hifs, AP1 and TWIST1. For EMSA experiments 
only Sox9, Nfat and rbpj-k was examined. 
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Figure 49: ClustalW alignment of the -65kb enhancer and possible transcription factor 
binding sites 
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ClustalW alignment of the -65kb enhancer between human and mouse. Transcription 
factors identified using Biobase transfec was annotated. Sox9 binding sites are shown in 
red numbered 1-5. Hypoxia -inducible factor (Hif) are shown in yellow. Myocyte 
enhancer factor 2 (Mef2) are shown in blue. The zinc finger protein Gl3 is shown in 
green. Only Sox9 binding sites were used in EMSA experiments.  
Indirect competitive EMSA experiments with Sox9 protein and Sox9 control probe 
revealed that in the -65kb one area (site 3) interacted in vitro with Sox9 and mutations 
introduced into the binding sequence resulted in a loss of binding (Figure 51A). Site 5 
also produced a weaker signal compared to control, although a band is still seen but 
mutations failed to diminish this binding. The mutated sequence did not produce a Sox9 
binding site and there were no remnants of a binding site. In the -87kb there are 3 
binding sites revealed by EMSA, sites 1-2, 5 and 9 and mutations in these sites removed 
the binding (Figure 51B).  
For the -87kb enhance Nfat binding was examined by EMSA due to its suggested role in 
adult cartilage and age related regulation (Rodova et al., 2011). Of the 3 predicted sites 
in indirect competitive assays all the sites bound and mutations abrogated the affinity of 
the sites (Figure 52). Although mutated fragments were generated by GeneArt™ string 
for the -87kb Sox9 and Nfat binding sites and cloned into the expression vector for in 
vivo analysis, due to time and financial constraints transgenic mice were not generated. 
Therefore, the importance of these TFs and their interactions with the -87kb remains to 
be explored. 
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Figure 50: ClustalW alignment of the -87kb enhancer and possible transcription factor 
binding sites 
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ClustalW alignment of the conserved regions of the -87kb, the mouse sequence is aligned 
to human and opossum. Sox9 binding sites are shown in red, Rbpj-k is shown in blue, 
green marks the Nfat binding sites, TWIST1 is highlighted in yellow, Hif in grey and 
Activator protein 1 (AP1) in pink. Rbpj-k, Sox9 and Nfat binding sites were used for EMSA 
experiments. 
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Figure 51: Indirect competitive EMSA for Sox9 in the -65kb and -87kb enhancer 
 
Indirect competitive Electromobility shift assay using the Sox9 to detect interactions 
within the -65kb and -87kb enhancer. The Sox9 control oligo was used as the probe and 
an unlabelled oligo of the same sequence is the control competitor. Lane 1 UP is the 
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lysate from the in vitro translation reaction with no vector to determine any non-specific 
binding. The second lane is the probe with no competitor to show it is binding to the 
proteins. The third lane is the control competitor therefore the band should be removed 
if it is able to bind. Sox9 interacts in the -65kb in vitro only at one site (site 3) where as in 
the -87kb there are 3 binding sites, (1-2, 5 and 9). Mutations in these sites removes the 
binding seen by the mutation copy (mt). 
Figure 52: Indirect competitive shift assay for Nfat binding in the -87kb enhancer 
 
Indirect competitive Electromobility shift assay using the NFAT core protein binding to 
detect interactions with the -87kb enhancer. The NFAT control oligo was used as the 
probe and an unlabelled oligo of the same sequence is the control competitor. Lane 1 UP 
is the lysate from the in vitro translation reaction with no vector to determine any non-
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specific binding. The second lane is the probe with no competitor to show it is binding to 
the proteins. The third lane is the control competitor therefore the band should be 
removed if it is able to bind. In vitro Nfat interacted with all 3 identified binding sites and 
mutations (mt) in those sites removed the binding.  
4.3. Analysis of the 3’ intronic enhancers of Acan  
4.3.1. Background  
Enhancers do not only reside within the intergenic regions, regulatory elements closer 
to the 3’ end of a gene are able to drive strong expression of target genes or drive 
splicing of gene isoforms (known as intronic splice enhancers) (Wang et al., 2012). 
Recent loss of DNA methylation studies have shown that in human colon carcinoma 
(HCT116) and DKO1 (HCT116 cells with DNMT3b knocked out) showed that the majority 
of enhancers reside in the introns of genes (Blattler et al., 2014). The importance of 
these intronic enhancers were interrogated in Gli3 where 6 enhancers located in the 
second, third, tenth and thirteenth introns drives limb specific and central nervous 
system expression (Anwar et al., 2015, Abbasi et al., 2010). Additionally, in the vascular 
endothelial growth factor receptor Flk1 an enhancer in the tenth intron is able to drive 
expression of reporter constructs in arterial endothelial cells, starting as a pan-vascular 
expresser and then becoming arterial restricted in mouse and zebrafish (Becker et al., 
2016). This enhancer is under the influence of Gata and Ets TFs and Rbpj-k restricts the 
expression to arterial cells. Therefore, we screened the 3’ intronic sequences of Acan 
but there were few limb specific histone marks for enhancers in these regions but areas 
of high conservation. Acan is not only expressed in the cartilage, there is detectable 
expression in the heart valves and brain which were rarely seen in the intergenic 
enhancers identified, so we reasoned that the areas of conservation may house other 
tissue specific enhancers. 
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4.3.2. The last intron  
Within the last intron of Acan the ENCODE analysis showed that it contained a small 
H3K4me1 but no other histone marks or DNase1 hypersensitivity to mark an enhancer. 
However, it was very well conserved in Fugu but not present in Zebrafish or chicken. 
Due to its conservation we believed that it may have a function, therefore it was cloned 
into the HSP68/LacZ vector and examined in E15.5 mice. When we examined the 
embryos  the staining presented with 3 different patterns (Figure 53A-C). This suggests 
that, although the DNA fragment that was cloned is able to act as an enhancer due to its 
ability to drive the report, it may be influenced by the environment it was inserted into. 
The first expression (ET217) was pan- skin up until the distal limbs where staining is 
observed in the joint area (Figure 53A, D, G and J). There were gradual reduction in the 
skin expression with more craniofacial expression (Figure 53E and K) and weaker joint 
expression (Figure 53E and H) in ET218. The final expression, ET219, was mainly at the 
tips of the paws (Figure 53F), nasal (Figure 53F and L) and rear of the skull (Figure 53I). 
All three expression patterns do not appear to localise to skeletal elements, which 
suggests the enhancer may not be chondrocyte specific or active in the developing 
skeleton. To validate this theory histological examination was carried out.  
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Figure 53: Whole images of the variable expression pattern of the +60kb region 
 
Whole mount images of the different expression patters of the +60kb regulatory 
element. ET217 showed pan- skin expression (A and J) with areas in the limbs (D) and tail 
(G) resembling the joint staining. ET218 showed less expression in the skin (B), the limbs 
(E) showed weak patterning particularly in the hindlimb (H), the craniofacial showed 
LacZ activity. ET219 showed minimal skin staining and no skeletal element activity (C). 
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On the limbs at the tips of the distal phalanges (F) and the nasal showed blue stain 
deposition (L). The rear of the skull stained along the cranial sutures. 
Histologically, the three patterns were widely different from each other sharing very few 
similarities, hinting that the region we cloned was too large, too short, missing an 
insulator region or other core regulatory elements. If the region was too large there is a 
chance that multiple elements were present that can produce multiple effects, if the 
sequence was too small, key sequences for TFs may be missing resulting in different 
proteins regulating the same sequence. One other factor is the position effects, the 
sequence may have insulator regions that causes it to disrupt the local environment that 
the transgene inserted into (Franke et al., 2016). There was only one expression pattern 
that expressed in chondrocytes, in ET218, there were weak expression in the core 
chondrocytes of the long bones such as the clavicle (Figure 55A and C), ribs (Figure 55H) 
radius and ulna (Figure 55F) but the pattern is weak and scattered (Figure 55E). There 
was noted expression in the kidneys similar to the +26kb (Figure 55I) but no expression 
in the paws (Figure 55B), Meckel’s cartilage (Figure 55D) or vibrissae (Figure 55G). The 
pan-skin expression staining, ET217, resided in the fibroblasts and surrounded the 
forming bones of the paw (Figure 54D), radius, ulna (Figure 54C) and femur (Figure 54I), 
but no chondrocytes appear to be staining in the limbs (Figure 54E), IVD (Figure 54B) or 
the femur itself. However, there was a patch of staining in the chondrocytes seen in the 
femur when sectioned adjacently (Figure 54H). There were no staining in the vibrissae 
(Figure 54F), Meckel’s cartilage (Figure 54A) and again staining was seen in the kidney 
(Figure 54G). The weaker expression in ET219 showed spinal cord staining (Figure 56A), 
nasal (Figure 56C), regions in the ear (Figure 56H) and in the nucleus pulposus of the tail 
(Figure 56E) but no chondrocyte expression in the femur (Figure 56I), bones of the ear 
(Figure 56H), paw (Figure 56D), vertebra (Figure 56A), fore limb (Figure 56G) or in 
Meckel’s cartilage (Figure 56B). This embryo did not present with staining in the kidney 
(Figure 56F) unlike the other. 
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Figure 54: Histology sample of ET217 of the +60kb enhancer 
 
Sections of the ET217 embryos with no chondrocyte specific staining in the metacarpals, 
phalanges (D), radius, ulna or humerus (C and E). In the femur the staining surrounds the 
forming bone (I) but in a subset of chondrocyte of the femur there was localised 
expression (H). The staining was seen in the fibroblasts of the nose (F) and jaw (A), and 
around bones (D and C) but not in the Meckel’s cartilage (A). There was also noticeable 
staining in the kidney residing in the Bowman’s capsule (G) but no staining in the 
vertebra. 
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Figure 55: Histological examination of the ET218 embryo of the +60kb enhancer 
 
Sections of the ET218 of the +60kb element embryos showed chondrocyte staining in the 
pre- hypertrophic cells in the clavicle (A and C) and radius and ulna (F and E) and in a 
scattered pattern in the ribs (H), but low magnification of the fore limb shows very weak 
expression of the LacZ (E), there was no staining in the paw (B), Meckel’s cartilage (D) or 
vibrissae (G).There was noticeable staining in the kidney residing in the Bowman’s 
capsule (G). 
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Figure 56: Histological examination of ET219 of the +60kb enhancer 
 
Sections of the ET219 embryos of the +60kb with no chondrocyte specific staining in the 
metacarpals, phalanges (D), the vertebra (A), Meckel’s cartilage (B), femur (I), skull (C) 
radius, ulna or humerus (D).There is no staining in the kidney or the chondrocytes in the 
tail (E) but staining is seen centrally in the nucleus pulposus. Staining in the ear is not 
localised to the chondrocytes but rather the membrane (H) similar to the nasal cavity (C). 
The spinal cord is seen to express the transgene (A). 
4.3.3. Enhancer in the 12th intron of Acan  
Due to evolutionary conservation a 2.5kb region of the 12th intron that had minor 
histone marks for H3K4me1 in the limb indicating a poised enhancer was cloned into the 
HSP68/LacZ vector to be examined at E15.5, this was named +55kb. Whole mount 
revealed that there was enhancer activity although it did not look cartilage specific 
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(Figure 57A-C). Staining seemed to line the edges of joints (Figure 57E), the spinal cord 
(Figure 57C) but not the vertebra (Figure 57D) and areas of the skull (Figure 57B). There 
was staining the tail seen clearly (Figure 57E and F) that resembles the pattern of the 
annulus fibrosis. Histologically, there were no chondrocyte staining seen in the paw 
(Figure 57G) and vertebra (Figure 57H). In the tailit appeared to mark the chondrocytes 
(Figure 57J) but in the IVD of the lumbar spine activity of the enhancer was on the edge 
of the nucleus pulposus (Figure 57K), there was noted staining in the peritubular 
interstitial cells of the kidney (Figure 57I and L).  
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Figure 57: Whole mount and histological images of the +55kb enhancer 
 
Whole mount images of the +55kb regulatory activity at E15.5 shows staining in the 
limbs, tail, skull and in the spinal column (A-C). Higher magnification shows no 
observable vertebra staining (D) but in the limbs staining is localised to the joints and the 
central regions of the tail (E and F). Histologically, there is no chondrocyte staining in the 
paw (I), spine (J) but some in the tail (M and Q). Staining is seen on the edge of the 
nucleus pulposus of the lumbar spine (N) and in the kidney (G and H). Transverse sections 
show weak staining in the lungs (T) but no staining in the limb (L and P) or ribs (O).There 
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is staining in the vibrissae (K) and in the epidermis of the skin (R) and possibly in the eye 
but not in the brain (S). 
To determine if the expression changed at earlier time point in development or 
postnatally, embryos were collected at E12.5 and tissue was collected from 8 week old 
mice. Whole mount images of E12.5 embryos showed staining in the spinal cord (Figure 
58E and F), a central area of the skull (Figure 58D) and regions under the forelimb 
(Figure 58A and B) but not in the hindlimb (Figure 58C) following developmental process 
of expanding rostral –caudally and dorsal – ventrally. In 8 week old tissue cartilage 
tissue did not stain for X-gal such as the condyle (Figure 59D) and plateau (Figure 59F) of 
the knee, hip (Figure 59C) and ribs (Figure 59G). However, in tissues, such as the lungs 
(Figure 59B), there was strong staining and in the kidneys it was reserved for the 
Bowman’s capsule (Figure 59E). Additionally, in the xiphoid there was some staining 
observed (Figure 59A) a cartilaginous tissue which leaves the question of what connects 
these different tissue types that allows this enhancer to function. . In the tail staining did 
not localise to the cartilage end plates but rather in the central zones where the annulus 
fibrosis and nucleus pulposus reside (Figure 59H and I). Upon examining histologically 
the chondrocytes did not stain in the ribs (Figure 60A), growth plate of the sternum 
(Figure 60D), articular cartilage of the femoral head (Figure 60D), or knee (Figure 60E 
and F). On some occasions ectopic staining was seen in single cells in the ribs (Figure 
60C). When examining the IVD and the tail we see that there is no staining in the 
cartilage end plate, growth plate, or annulus fibrosis, but centralised in the nucleus 
pulposus (Figure 60G, H and I). Other non-cartilage based tissue staining was localised in 
the lungs (Figure 60K) and in the inner lumen of blood vessels (Figure 60L) as well as in 
the peritubular interstitial cells in the kidneys (Figure 60J). The staining in the kidneys 
remain even at 6 months of age whereas the lungs intensity of staining was reduced but 
still present, but no staining was in the articular cartilage (Figure 61).  
I.M.H.Li  PhD Thesis 
 
Page | 196  
 
Figure 58: E12.5 whole mount and histological examination of the +55kb enhancer 
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Whole mount images of the +55kb element at E12.5 presents with no limb staining (A) 
but staining in the spine (G, F, I and J) and localised staining at the proximal region of the 
fore limb (E and F) but not in the hind limb (F), there is also a localised spot on the head 
(H and G) that presents the stain deposition. Clearing the embryos with KOH show no 
skeletal element staining and more localised staining in the spinal cord (B-D). 
Histological examination show that the staining is in the epidermis (K and L) but no 
staining in the ribs (M), kidney (N and O) or IVD (P).  
Figure 59: 8 week old tissue whole mount images of the +55kb enhancer  
 
At 8 weeks of age the +55kb whole mount tissue images show none of the cartilage of 
the femoral head (C), condyle and plateau of the knee (D and F) or ribs (G) have any 
transgene activity. But in the lungs (B) and kidneys (E) there is B-gal activity. The xiphoid 
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(A) has ectopic staining*. In the rain there is blue staining seen in the central region of 
where the annulus fibrosis and nucleus pulposus reside (H and I)  
Figure 60: Histological examination of the -55kb enhancer in 8 week old tissue 
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Histological examination of tissue at 8 weeks of age show that there is no chondrocyte 
staining in the ribs but one cell [*] (A and C), growth plate of the sternum (B) or in 
articular cartilage of the femoral head (E) or knee (F and G).In the IVD there is no 
staining in the growth plates or annulus fibrosis but in the central area of the nucleus 
pulposus there is X-gal activity (I, J and K) but not in the bones (L). In tissue that do not 
contain cartilage there is staining in the peritubular interstitial cells of the kidney (W, X, Y 
and Z), in the lungs (N), the basal lumen of the skin (P and Q), renal (S and T), in the 
lumen of the aorta (O and R) and other blood vessels (H and M).  
Figure 61: 6 month old tissue images of the +55kb enhancer 
 
Whole mount of tissue at 6 months of age show that there is no chondrocyte staining in 
the hip (A), or knee (B) but blue is seen in the kidney (C) and lung (D). Histological 
examination of the knee show there is no staining in the growth plates or articular 
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cartilage (E-H) or in the femoral head (I). In tissue that do not contain cartilage there is 
staining in the peritubular interstitial cells of the kidney (M-P) and in the lungs (J-K).  
 
4.3.4. Antibody staining to determine Acan expression and HAPLN3 expression 
To determine if Acan expression co-localises with the +55kb enhancer staining sections 
were stained for the Acan G1 domain using the BR1 antibody.  
To test the antibody sections from the -87kb enhancer embryos at E15.5 was stained. 
The antibody localises to Acan expression in cartilage elements such as the ribs, skull 
and Meckel’s but not in the kidney at this stage (Figure 62).  
 
In wildtype and +55kb enhancer kidneys examined at 8 weeks of age shows Acan 
localises to the tubules rather than the glomeruli (Figure 63). Antibody staining in the 
kidney was masked by the x-gal staining rendering co-localisation difficult (Figure 65). In 
the lungs Acan is found mainly in the vessels (Figure 64). Similar to the kidney the x-gal 
staining prevented the antibody binding in the +55kb lung (Figure 66). In the IVD of the 
+55kb enhancer analysed by BR1 staining the binding localises to the growth plate and 
the annulus fibrosis that surround the nucleus pulposus, which also expresses Acan but 
areas are masked by the x-gal staining (Figure 67). It is interesting to note that although 
the kidney and lung sections were from mice at the same age and processed the same, 
the antibody staining in the wildtype kidney tubules was not observed in the x-gal 
positive +55kb kidney. The reason for this is unclear, but repetition of this experiment 
would allow us to Reveal the extent of this staining. 
 
The BR1 antibody rarely co-localises with the +55kb enhancer x-gal staining in the IVD 
and does not overlap in the kidney or lung suggesting that the enhancer may not drive 
expression of Acan in these tissues. The nearest gene to the +55kb other than Acan is 
HAPLN3 therefore we examined the protein expression of HAPLN3, however, antibody 
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staining doesn’t not localise HAPLN3 to the glomeruli but rather the medulla of the 
kidney and the bronchioles of the lungs (Figure 68 Figure 69).  
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Figure 62: BR1 antibody staining in E15.5 embryos 
 
BR1 antibody staining on E15.5 embryo sections from the -87kb enhancer as this was the 
sections available at the time. A-F is no antibody control. G-L are the primary BR1 
antibody. Staining is localised to the cartilage elements only in the skull (G and H), 
Meckel’s (I) and ribs (J and K) but not in the kidney (L). 
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Figure 63: BR1 antibody in wildtype 8 week old kidney 
 
BR1 antibody staining on wildtype kidney. A-C are the no primary antibody control, D-I 
are the no antigen retrieval controls and J-P are the BR1 stained. Staining is localised to 
the tubules but not present in the glomeruli [G]. 
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Figure 64: BR1 antibody staining in wildtype 8 week old lungs 
 
BR1 antibody staining on wildtype lung. A-C represent no primary antibody control, D-I 
are the no antigen retrieval controls and J-P are the BR1 stained. Staining is localised to 
the vessels [V] and weakly in the alveoli.  
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Figure 65: BR1 staining on the +55kb enhancer 8 week old kidney 
 
BR1 antibody staining on +55kb X-gal stained kidneys of 8 weeks of age. The X-gal 
staining appears to block the antibody binding.  
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Figure 66: BR1 staining on +55kb 8 week old lungs 
 
BR1 antibody staining on +55kb X-gal stained lung of 8 weeks of age. The X-gal staining 
appears to block the antibody binding. Staining is present in the vessels. 
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Figure 67: BR1 antibody staining on +55kb enhancer 8 week old IVD 
 
BR1 antibody staining on +55kb X-gal stained IVD of 8 weeks of age. The X-gal staining 
appears to block the antibody binding in the nucleus pulposus. Staining is observed in the 
chondrocytes of the growth plate, in the annulus fibrosis and in the nucleus pulposus but 
not where the X-gal staining is present.  
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Figure 68: HAPLN3 antibody staining in 8 week old mice kidney 
 
8 week old wildtype kidney stained with primary antibody raised against HAPLN3 with 
antigen retrieval (A-C) and no primary antibody (D-F). Staining resides mainly in the 
medulla (A) and does not stain the glomeruli (B).  
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Figure 69: HAPLN3 antibody staining in 8 week old mice lungs 
 
8 week old wildtype lungs stained with primary antibody raised against HAPLN3 with 
antigen retrieval (A and B), no antigen retrieval (C and D) and no primary antibody (E 
and F). Staining is localised to just the bronchioles and no other structures (B). 
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Table 10: Overview of expression pattern of the six Acan enhancers 
Tissue Intensity of staining 
+60kb +55kb +26kb -35kb -65kb -87kb 
Chondrocranium ± - +++++ +++++ ++ ± 
Nasal cartilage/ 
olfactory  
± - ++++ +++++ - + 
Meckle’s cartilage/ 
mandible 
- - +++++ +++++ - - 
Costal cartilage of the 
ribs 
±±± - ++++ +++++ +++ + 
Femur ±± - ++++ +++++ +++ ++ 
Tibia ± - ++++ +++++ +++ ++ 
Fibula ±± - ++++ +++++ +++ ++ 
Digits of hindlimb - - ++++ +++++ + +++ 
Digits of forelimb - - ++++ +++++ + +++ 
Scapula/ humerus ± - +++++ +++++ +++ ++ 
Ulna ± - +++++ +++++ +++ ++ 
Radius ± - +++++ +++++ +++ ++ 
Intervertebral discs - ++++ +++++ +++++ - - 
Lumbar spine - ++ +++++ +++++ ++ ++++ 
Cartilage of the ear/ 
occipital  
- - +++++ +++++ +++ ++ 
Tail ± ++++ +++++ +++++ + - 
Brain - - ++ ± - - 
Vibrissae - - +++ +++ - ± 
Heart - - - - - - 
Lung - + - - - - 
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Liver - - - - - - 
Tongue ± - - - - - 
Skin ± + - - ±±± - 
Kidney ± +++ ±±± - - - 
Blood vessels ± +++ - - - - 
Summary of the staining intensities and location for the Acan enhancer. – is not 
detected; + weakly detected; ++ not completely uniform staining throughout tissue; +++ 
majority of tissue stained, ++++ strong staining in entire tissue; +++++ entire tissue is 
stained and has intense signal; ± present in some founder embryos but not all. 
 
4.4. Analysis of the Acan enhancers in vitro  
4.4.1. Characterisation of ATDC5 expression of cartilage genes 
The ATDC5s had been differentiated for 20 days and to determine the gene expression 
qPCR was undertaken. The ATDC5 expressed high levels of Col2a1 with little Col1a1 
suggesting a chondrocyte phenotype. However, the Sox9 content was low, which was 
concerning for chondrocytes, whereas the Runx2 expression was relatively higher in 
comparison to the Col2a1 and Sox9. In terms of aggrecan expression there is detectable 
levels of Acan and lower levels of TIMP3, this allows us to perform further assays using 
the ATDC5 cells. 
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Figure 70: Relative gene expression of ATDC5 differentiated for 20 days. 
 
 
qPCR results from ATDC5 cells when RNA is extracted after 20 days differentiated. The 
ATDC5 resemble chondrocytes by expressing more Col2a1 than Col1a1 but there are 
lower levels of Sox9 with more Runx2. Additionally, Acan is expressed in the ATDC5 
detected by Taqman probes. Error bars are expressed as SEM. 
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4.4.2.  Expression of Acan enhancers in vitro 
pGl3 promoter vectors with the Acan enhancers cloned upstream were examined for 
activity in T/C28-I2 and NIH3T3 cells initially. The -35kb, unlike in vivo, expresses weakly 
in the chondrocyte cell line as well as the -65kb enhancer. The +26kb, -10kb and -87kb 
expresses highly. In the fibroblast cells the +26kb and -10kb enhancers retain high 
expression when compared to vector alone whereas the -87kb is reduced suggesting a 
chondrocyte affinity of the -87kb. Additionally, the -65kb and -35kb retain a low level of 
activity in the fibroblast. 
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Figure 71: Normalised response of enhancers in chondrocytes and fibroblasts in vitro 
 
In T/C28-I2 cells the enhancers +26kb, -10kb and -87kb have high level of activity 
whereas the -35kb and -65kb expresses weakly compared to vector control. In 
comparison in the NIH3T3 the -87kb has reduced expression but the +26kb and -10kb 
have relatively higher expression compared to vector alone but still low levels of -35kb 
and -65kb activity. *p=<0.05, Error bars are SEM. 
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4.4.3. Response of Acan enhancers in vitro to catabolic agents in ATDC5 cells 
The ATDC5 cells were used to examine the effects of hOSM and IL-1β on the activity of 
the Acan enhancers. Upon transfection and then treatment with the cytokines the cells 
were assayed for luciferase activity. There is no significant effects of these agents on the 
+26kb and -10kb enhancer. There is a slightly non-significant increase in the -35kb 
enhancer to IL-1β treatment. The -65kb increases in activity significantly in the presence 
of IL-1β and the -87kb enhancer’s activity is dampened with hOSM treatment. 
Figure 72: Effects of catabolic agents on enhancers’ response in ATDC5 
 
ATDC5 cells are transfected with luciferase reporter vectors for the chondrocyte specific 
Acan enhancers and then treated with either human oncostatin M (hOSM) or IL-1β and 
then assayed for luciferase activity after 24hours. The effects of the two agents have no 
significant effects on the +26kb, -10kb and -35kb enhancers. The -65kb responds to IL-1β 
treatment by increasing expression whereas hOSM treatment reduces the activity of the 
-87kb enhancer. *p=<0.05 and error bars are presented as SEM. 
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4.5. Analysis of -35kb Acan Cre  
4.5.1. Background  
As previously mentioned, enhancers are capable of driving tissue specific expression of a 
target gene. This quality allows the enhancer sequence to be used to analyse temporal 
and spatial effects of knockouts and knock-ins by driving Causes recombination (Cre) 
enzyme in a tissue specific way while avoiding some of the lethality of embryonic stem 
cells (ES cells) knock-outs (Heffner et al., 2012, Sharma and Zhu, 2014). The Cre 
recombinase is a Bacteriophage P1 38 kDa protein that catalyses intra and inter 
molecular recombination of DNA in a site specific way. The recombination occurs 
between a 34bp sequence known as loxP with a minimum of 82bp between each site to 
be efficient and is direction dependant (Sauer and Henderson, 1988).The loxP sites can 
be in the same direction on the chromosome, different chromosome or in opposite 
directs to result in deletions, duplications, translocation and inversions. The Cre can be 
engineered to only act or activated in inducible manner by using tetracycline or by using 
drugs. A fusion of a triple mutated human ligand binding domain 
(G400V/M543A/L544A) of the oestrogen reception allows the enzyme to be attached to 
HSP90 in the cytoplasm therefore not active. Upon injection of 17-β-estradiol analogous 
such as tamoxifen acts as an antagonist of the receptor, allows the translocation of the 
Cre into the nucleus and allows time dependant activation. The first oestrogen 
responsive Cre is known as CreER and a highly sensitive version has been engineered to 
be 10 times more reactive once tamoxifen is injected (CreERT2) (Indra et al., 1999, 
Brocard et al., 1997).  
There has been many Cre’s designed to target chondrocyte progenitor cells, Prx1-Cre 
(Logan et al., 2002),GDF5- cre (Rountree et al., 2004) , Sox9 (Akiyama et al., 2005) and 
others targeting differentiated chondrocytes such as Col10, Col11 and Col2-cre 
(Ovchinnikov et al., 2000, Hilton et al., 2007, Koyama et al., 2008, Fujimaki et al., 
2005).Unlike Col2a1, Acan is expressed continuously in chondrocytes and the -35kb 
enhancer does not have other non-chondrogenic expression seen in the Col2a1-cre such 
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as in the kidney (Kolpakova-Hart et al., 2008, Long et al., 2001, Fosang et al., 2013). 
Additionally, there is a current dual luciferase and Cre that uses the -10kb enhancer in 
tandem repeat that is able to drive expression in chondrocytes following the expression 
of Acan and allows real time tracking of the transgene (Cascio et al., 2014). Another 
Acan –cre was generated by knocking in the IRES-Cre-ERT2 downstream of the 
endogenous Acan stop codon that drives expression even at 6 months (Henry et al., 
2009). This cre allows the analysis of developing and adult cartilage which is beneficial 
to studying age related diseases such as OA. Therefore, we generated an Acan-Cre using 
the -35kb and the human Acan minimal promoter to drive the CreERT2 named pChu9 
and generated 4 lines for interrogation.  
To examine the response and activity of the Cre we crossed the pChu9 mice with R26R 
reporter mice that contains a floxed LacZ  visualise cells that the Cre is active in during 
development (E15.5) and adult mice (Soriano, 1999). 
4.5.2. Determination of the expression of the pChu9 lines 
To establish the expression pattern of the pChu9 lines and to ensure the -35kb enhancer 
is reproduced under the influence of the human promoter. Female pChu91, pChu92, 
pChu93 and pChu94 mice were time mated with male R26R overnight, after checking for 
successful copulation plugs this day was classed as E0.5. On day E13.5 tamoxifen was 
injected and embryos were collected at E15.5 and stained for β-gal activity. Whole 
mount showed variability in the strength of expression in the craniofacial, mainly the 
skull. pChu91 showed little or no expression in these areas but still expressed in the 
skeletal elements seen in the -35kb enhancer, but was the weakest of the 4 lines (Figure 
73A, E and I). pChu92 (Figure 73B, F and J), pChu93 (Figure 73C, G and K) and pChu94 
(Figure 73D, H and L) showed similar expression in the limbs and ribs. However, there 
were differences seen in the tail of the lines with pChu94 expressing the strongest 
(Figure 73H). Clearing the embryos with 1% KOH and glycerol reveals the skeletal 
element staining more clearly, pChu91 (Figure 73 M, N, Q and R), pChu92 (Figure 73W, 
X, AA and AB), pChu93 (Figure 73O, P, S and T) and pChu94 (Figure 73Y, Z, AC and AD) all 
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show good staining in the limbs, spine, jaw, ribs, metacarpals and tarsals but pChu94 
shows more intense spinal and tail expression (Figure 73Z and AC).  
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Figure 73: Whole mount images of E15.5 pChu9 lines 
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E15.5 whole mount images of pChu9 lines and cleared embryos shows skeletal element 
staining in the spine, ribs, fore and hind limb. Each line expresses pChu91 (A, E and I), 
pChu92 (B, F and J), pChu93 (C, G and K) and pChu94 (D, H and L) to varying degrees, 
cleared embryos show the expression pattern clearer, pChu91 sagittal (M), back (N), 
hindlimb and tail (Q) and the forelimb (R). pChu92 sagittal (W), back (X), hindlimb and 
tail (AA) and the forelimb (AB). pChu93 sagittal (O), back (P), hindlimb and tail (T) and 
the forelimb (S). pChu94 sagittal (Y), back (Z), hindlimb and tail (AC) and the forelimb 
and hindlimb (AD). 
Histological examination of the pChu91, pChu93 and pChu94 show that they express in 
skeletal elements. The pChu91 shows scattered expression in Meckel’s (Figure 74A), ribs 
(B), femur (Figure 74C), metacarpals and carpels (Figure 74D and E) but little Figure 
74expression in the ear (Figure 74F), the expression is chondrocyte specific. pChu93 
shows more intense staining than pChu91, but still scattered in the ribs (Figure 74G), 
radius, ulna (Figure 74H) and metacarpals (Figure 74K) Staining is stronger in Meckel’s 
cartilage (Figure 74I) but little is detected in the ear (Figure 74L) and absent from the 
vibrissae (Figure 74J) unlike the -35kb enhancer driving the HSP68 minimum promoter. 
The pChu94 mimics the pChu93 in expressing strongly in the paw (Figure 74P) and 
Meckel’s (Figure 74R), however, more staining is observed in the ear (Figure 74Q). All 
the chondrocytes in the pChu94 have had the cre active with staining seen in the 
humerus, radius and ulna (Figure 74M, N and O).   
4.5.3. Activation of the pChu9 lines at 8 weeks shows expression in cartilage elements 
To determine if the pChu9 lines were active in adult mice, injections of tamoxifen was 
carried out at 8 weeks of age and the mice culled and tissue collected after 8 weeks. In 
whole mount tissue the no tamoxifen pChu94 showed no expression in any of the tissue 
(pChu94-Tx), whereas there is strong activity in the pChu94 (pChu94 +Tx) with lower 
intensity in pChu93 (pChu93 +Tx) and the transgene is poorly activated in the pChu92 
(pChu92 +Tx). There is strong staining in the tail, knee, superficial region of the scapula, 
femoral head and in the ribs of the pChu94 when the Cre is activated compared to the 
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other lines. There is also spinal cord staining not seen in the other lines. Unfortunately 
due to time constraints histological examination of the tissue was not performed. With 
the lack of histological examination of the adult tissue we cannot say for certain if the 
cre recombinase is efficient in removing the floxed gene in adult tissue, this may be a 
hindrance to any future use of this transgenic mouse line.  
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Figure 74: Histological examination of the pChu9 lines at E15.5 
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Sections of pChu91, 3 and 4 counter stained with eosin. pChu91 expresses in 
chondrocytes but the activation of the Cre is scattered and weak in terms of intensity in 
the Meckel’s cartilage (A), ribs (B), femoral head (F), metacarpals and fore paw (D and E) 
and ear (F). The pChu93 activation is greater than the pChu91 but still scattered in the 
ribs (G) and metacarpals (N). However, in Meckel’s (I) and in the radius and ulna there is 
consistent activation but it is not uniform (H). There is little expression in the ear (L) and 
no expression in the vibrissae. The pChu94 expresses the strongest compared to the 
other two lines in the limb (M) seen in higher magnification of the radius and ulna (N) 
and humerus (O) as well as Meckel’s (R)and the forepaw (P). The ear is weaker and non-
uniform in expression (Q), which is different to the -35kb enhancer. 
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Figure 75: Whole mount images of adult tissue of the pChu9 lines 
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Adult tissue from the pChu92, 3 and 4 lines injected with tamoxifen at 8 weeks of age 
and collected 8 weeks after shows that the pChu94 Cre is activated more successfully 
than the other two when compared to no tamoxifen although the spinal cord is also 
staining for β-gal activity. TmX: tamoxifen. 
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5. DISCUSSION 
5.1. The use of in vivo mouse models versus in vitro cell assays for assessing cis-
acting elements 
In this study transient and stable mouse lines were analysed to characterise cis-acting 
elements of Acan this was done prior to analysis within immortalised cells lines. The 
reasoning to complement in vivo with in vitro was due to the nature of studying 
enhancers. In vitro studies do not show appreciation of interactions between different 
cells or understanding how the enhancer is working temporally or spatially in deed there 
is no appreciation of how enhancers express in the whole organism. Additionally, the 
use of cells is a more targeted towards the available cell lines and primary chondrocytes 
are difficult to obtain from adults and perform poorly in tissue culture conditions due to 
the loss of ability to divide. Furthermore, they may not recapitulate the expression that 
is seen in vivo as popular immortalised human rib chondrocytes T/C-28- I2, T/C28-A2 
and T/C 28-A4 express lower matrix genes, show reduced synthesis and turnover of 
matrix protein therefore variability in cell culture may not recapitulate the expression of 
ACAN seen in vivo (Finger et al., 2003). Furthermore, there are limited similarities 
between SW1353 (human chondrosarcoma cells) and primary human chondrocytes with 
limited response to cytokine treatment (Gebauer et al., 2005). In contrast, the 
chondrocyte within tissue is in a high load and hypoxic conditions, normal tissue culture 
conditions are atmospheric oxygen (around 21%) in a static condition therefore not 
physiological. On the other hand, the use of cell lines cannot be completely discredited, 
the mouse cells ATDC5, that was also used in this study are embryonic carcinoma 
chondroprogenitors clones that can be induced through an insulin-dependent pathway 
to follow growth plate cartilage development in vitro, they undergo cellular 
condensation after 5 days of treatment and cartilaginous nodules form at 11 days up to 
31 days can be used at different stages to recapitulate in vivo development (Suwanwela 
et al., 2011, Shukunami et al., 1997, Atsumi et al., 1990). As ATDC5s undergo induction 
they express collagen type 2 and 5 during early phases and collagen 9 and 11 at the later 
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stages with collagen 10 being the last collagen to start expressing as cells undergo 
hypertrophy Other ECM genes such as link protein and Acan are expressed very well by 
these cells once differentiation occurs, however, hypoxia delayed early chondrogenesis 
and suppressed hypertrophy which underlines differences between normal physiology 
and cultured conditions but the relative effects of an enhancer, especially for Acan 
expression can be examined in vitro with degrees of confidence (Chen et al., 2005, 
Shinomura et al., 2006, Chen et al., 2006). Furthermore, in a collaboration with the 
University of Newcastle, EMSAs were performed using nuclear protein extracts (with the 
same extraction protocol) from the human chondrosarcoma cell line SW1353 from cells 
cultured at Newcastle University and at the University of Liverpool, UK, were examined 
for Sox9 binding and compared to the IVT protein. The same cell line cultured in 
different labs contained different binding patterns for Sox9 but neither cell line 
contained the correct band size for Sox9 and super-shifts only showed shifts in the IVT 
proteins (Figure 85). Cells can, depending on the lab that has prepared and cultured, 
have phenotypic, genotypic and karyotypic drifts. This can result from prolonged culture 
times, high passage number, cell senescence and sub-population selection (Herrmann et 
al., 2007). Population selection can arise from faster growing cells, sheer forces from 
pipetting or even trypsinisation times, which means with time the population of cells 
will diverge slowly from the original culture.  This shows the variability within cultured 
cells and a minor disadvantage of using certain cell lines for enhancer examination. 
In vivo models are not without problems, difficulties in generating founders of lines 
plagued this project, with no detectable founders verified by genotyping after oocyte 
injections, mice were weaned and reach sexual maturity but time mating’s with 
wildtype F1 females yielded no expression at E15.5 and genotyping of the embryos by 
tail snip showed no transgene, or transgene, but no expression. From females and 
confirmed males founders (F0) that expressed through time mating experiments then 
fostered other problems such as no germline transmission, as Mendelian ratio the 
offspring (F1) should in theory carry 50% of the transgene. This was not the case as in 
some cases there were no transmission, although F0’s were positive, or the females 
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were genotype positive when the line was culled and the founder was taken for 
examination. This may mean that the F0’s were mosaic that may have arisen from late 
integration of the transgene. Two other possibilities are that the transgene were 
silenced or the transgene was mutated. Due to the nature of transgenic mice 
experiments the transgene is inserted randomly and copy number can vary, in terms of 
gene silencing it is not unlikely that the cassette inserted into a transcriptionally 
repressed region and was unable to change the chromatin landscape to activate its own 
transcription regions such as repressors, DNA methylation sites, X-linked inactivation or 
genome imprinting, although rare can occur.  
One other consideration for this project that must be highlighted, that are often over 
looked, are the environmental conditions the mice are subjected too. As mentioned 
previously, the animal unit at the University of Liverpool is SPF, this means that the mice 
are free from a wide range of potentially pathogenic bacteria, virus and parasites that 
are found in non-SPF condition. This has been shown to have effects on drug response 
and immune response. For example SPF housed mice have immune systems resembling 
that of new-born humans and changing the condition to housing shared with wild and 
store brought mice changed the immune system to one resembling that of adult 
humans (Beura et al., 2016). This has profound effects on the immune system response, 
mice when injected with cyclophosphamide, a drug that dampens the immune system 
and fragmented dsDNA, results in multiple organ failure from systemic inflammation 
and sepsis and eventually death in non-SPF housed animals, however, SPF mice do not 
display this phenotype (Dolgova et al., 2015). Another example is that in the AD10- anti-
NGF mice have progressive neurodegeneration and cognitive decline but in a SPF-unit 
the behaviour of the mice are milder (Tzanoulinou et al., 2014). Although, he effects on 
transgenic visualisation cassettes and other transgenic mice have not been study 
extensively and may not have a major effect on the genetics of the mice. The remaining 
factor from the housing unit that credits a mention is the effects on human interactions 
on the mice, as noise is one factor that is not controlled and results is increased 
physiological distress in mice, although the genetic bases may be minimal the effects on 
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breeding could have had profound effects on the speed in which lines were analysed in 
this study (Lauer et al., 2009). During the time of study the animal unit has had two 
construction sites within close proximity that has caused noticeable vibrations and 
sound pressures into the unit detected by users and would have been identified by mice 
who have hearing that extends to the ultrasonic frequencies not heard by humans. It 
has been shown that excessive noise by construction equipment leads to an increase in 
still births, reduced litter sizes and reduced weight (Rasmussen et al., 2009, Reynolds et 
al., 2010). 
In regards to the SOI and position effects of using transgene and the effects of inserting 
cassettes into the genome are considerations for the physiological relevance of these 
enhancer regions. However, enhancer can act irrespective of their location, the p53 
responsive element controls stress response by contacting with the centromere when 
the wild type location is abolished and the sequence is placed in an ectopic locations in 
the genome the element is able to reconnect with the target gene (Link et al., 2013). 
This suggests that in this study the enhancers identified, should be able to regulate 
expression irrespective of their location but the effects on the chromatin landscape and 
the looping of the DNA may have differential expression that has not been accounted 
for.  
Lastly, identification of biologically significant regions using only transgene analysis 
requires complementary research using knock-out studies as transgenic studies. This is 
because the enhancer screens using transgenic mice that we have used in this study do 
not tell us if these regions are functionally relevant or if they play an important role in 
the regulation of the gene we believe they are targeting.  One major consideration with 
the use of mice is they may not mimic human physiology exactly but does give us a good 
indication of what is happening.  
5.2. In silico annotation of genes for enhancers requires functional validation 
With advancement in technology and computing power there has been a plethora of 
data generated for gene regulation in terms of ChIP-seq targeting TFs and histone 
I.M.H.Li  PhD Thesis 
 
Page | 230  
 
modifications, DNase1 hypersensitivity, micrococcal nuclease digestion followed by 
sequencing (MNase-seq), Formaldehyde-assisted isolation of regulatory elements 
followed by sequencing (FAIRE-seq), Assay for transposase-accessible chromatin using 
sequencing (ATAC-seq), 3C, 4C, 5C, Hi-C, ChIA-PET and (Meyer and Liu, 2014, Belton et 
al., 2012). These techniques provide information on the chromatin state, the occupancy 
and the conformation of the DNA. With ENCODE the data for each of these techniques 
are publically available to researchers to analyse and identify region of interest to 
examine functionally. Histone marks have been regarded an indicator for enhancers and 
other regulatory elements in the genome, with active enhancers highly enriched in 
H3K27ac. Histone modifications H3K27ac, H3K4me1 and H3K4me3 along with 
evolutionary conservation was used in this study and found that these were good 
criteria for candidate enhancers within the Acan locus. However, not all enhancers were 
highly conserved, the -65kb region could not be found in the opossum or fugu sequence 
whereas the other (+60, +55, +26, -10kb, -35kb and -87kb) are conserved to a minimum 
of opossum. There were further sequences within the locus that were not examined but 
held good indicators for enhancer activity that cannot be ruled out to having a function. 
High conservation of DNA and RNA have shown tissue specific similarities between close 
and distantly related vertebrate species and tissue specific expression patterns can be 
seen despite sequence divergence to larger sequences (Pennacchio et al., 2006). 
However, conservation in non-coding regions of intergenic and intronic regions of genes 
do not always correlate with gene specific regulatory elements, although a good 
indicator to functionally relevant regions, as ChIP-seq experiments are able to detect 
functionally active cis acting elements that are not evolutionary conserved and do not 
confer biological advantages (Birney et al., 2007).  
The use of LOD scoring and the table browser utility of the UCSC genome browser only 
gave highly significant regions that were conserved and held histone modifications 
resembling that of enhancers. This may be problematic technique to use, as the 
enhancer definition evolves with new and more advanced techniques, for example 
H3K4me3 generally mark promoters, but the -65kb held this enrichment with no 
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mapped gene TSS within its vicinity. It has been shown, at least in cancer cells, that the 
H3K4me3 modification can mark enhancer activity, therefore this mark should not be 
excluded from enhancer screens (Proudhon et al., 2016). LOD scoring is based on the 
prediction that is user defined and could potentially exclude regions of genuine interest. 
It is interesting to note that when we performed liftover from the mouse to human and 
mapped the enhancers that in the 9 cell lines used in the chromatin state studies that 
only two Acan enhancers gives signals of enhancer activity, the +26kb is marked as a 
weak enhancer in HMEC cells but an insulator in the other cell types. Additionally, the -
10kb in H1-hESC, HSMM and NHEK is marked as weak enhancers but has repressive 
marks in the other cells types. The -35kb is marked as a promoter, the -65kb is weakly 
transcribed and the +60kb, +55kb and -87kb are repressed (Figure 19). These 
predications give an indication of what the chromatin state is like in other cells and 
allows a picture to develop of the function of these enhancers in non-chondrogenic 
cells, they do not however, provide any indication of the function of these regions. 
For simplicity the approximate positions of the +60, +55, +26, -10, -35, -65 and -87kb 
were taken as the start of the region examined to the TSS, even in shorter constructs 
the name was kept to avoid confusion.  
5.3. The multiple chondrocyte expressing enhancers of Acan 
Cis-acting elements such as enhancers have the ability to control temporal and spatial 
expression of gene in a tissue specific manner irrespective of their position and 
orientation, the mammalian genome appears to have an abundance of regulatory 
elements compared to coding sequences (Bulger and Groudine, 2010, Shen et al., 2012). 
It is becoming more apparent that there are more genes under the influence of multiple 
enhancers that dictate robust expression and responsiveness to cellular and 
physiological stress, particularity the imprinted genes and the Hox gene cluster that 
allow co-ordinated limb patterning (Verfaillie et al., 2016, Riso et al., 2016, Gonzalez et 
al., 2007, Tschopp et al., 2011, Spitz et al., 2003). 
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ACAN is an important molecule for the normal physiology of the developing and adult 
cartilage. Understanding the transcriptional inputs that direct Acan expression in the 
chondrocyte will provide critical information that brings about its expression under 
normal condition and provides avenues to explore its dysregulation and loss in diseases 
such as OA and genetic linked chondrodysplasias. Previous studies have demonstrated 
the role of Sox9 along with Sox6 and L-Sox5 that directs the expression of the -10kb 
enhancer (Han and Lefebvre, 2008). However, this enhancer appeared incomplete 
hinting of the existence of other regulatory elements. Zebrafish studies have offered a 
more comprehensive insight into the Acan enhancers with other studies suggesting a 
high level regulator upstream of the known enhancer (Hu et al., 2012, Ikeda et al., 
2014). We find two enhancers capable of driving tissue-specific expression of the 
chondrocytes found upstream of the TSS. One within the first intron of Acan and  one at 
-35kb. These enhancers drive a more global chondrocyte phenotype compared to the 
known, -10kb, which is confined to the core regions. It is curious to note that we used 
limb specific criteria for selection of enhancer elements that were not chondrogenic but 
rarely did we see expression outside of the chondrocyte. The reason for the specificity 
of the enhancers may be detailed by the TFs that dictate the cell-type expression or the 
chromatin environment in the chondrocytes compared to other cells types.  
The intronic sequence (+26kb) and the -35kb up stream element are able to recapitulate 
Acan expression at E15.5 occurring in all chondrocytes irrespective of their maturation 
stage suggesting they might direct Acan transcription on a basal level, a summery is 
described in Figure 76. It is known that enhancers rarely act alone; they can have a 
shadow or other enhancer that co-operate to bring about expression (Werner et al., 
2007, Wenger et al., 2013). The onset of Acan expression is around E10.5 in the mouse, 
a time point that was not examined in this study, it may be of interest to examine these 
two enhancers at earlier time points to determine if they are supporting each other, 
having additive effects, or responsible for timely activation of Acan. The -35kb, +26kb 
and the -10kb human sequences were identified to express in the zebrafish enhancer 
detection experiment showing that their conserved sequences can drive similar 
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expression in other animal models (Hu et al., 2012). The consistent overlap in expression 
between the +26kb and -35kb suggests that there is redundancy or that each enhancer 
allows the activation of Acan at distinct stages of development with a knockout of one 
enhancer delaying the onset of expression, this hypothesis would need to be examined 
and can be done so using CRISPR/Cas9 technology (Huang et al., 2016). Other enhancers 
identified in the screen such as the -108 and -115kb may contribute to chromatin 
landscape and have additives effects on the other enhancers, but in our screen inactive 
enhancers and enhancers from other cell types were not considered. Other cell type 
specific enhancers may add to the reservoir of regulatory elements that are clustered in 
close proximity of Acan, as we have not found regions that drives expression in the brain 
and heart valve. It may be that the enhancers they are found to regulate the 
chondrocyte expression are transiently active in busts or short periods of time in other 
regions that are missed by our reporter method.  
Furthermore, inactive enhancers in one cell type may be active in another, these serve 
to allow the effects of the other enhancers in a lineage, stage specific manner as well as 
allowing the local and distal effects to be corresponded into transcriptional output. For 
example, in B lymphocytes the IgK enhancers and the proximal enhancers 3’Ek, MiEk, 
Edk and Ck and Jk are active but in T lymphocytes they are inactive, using 4C-seq baits, 
show that each enhancer contributes to creating an transcription hub and 
rearrangement of the chromatin, but a removal off one leads to dissolution and 
reduction of transcription, not a complete loss (Proudhon et al., 2016). This study 
identified the inactive MiEk enhancer cluster significantly influence T cell receptor beta 
locus recombination (Proudhon et al., 2016). Therefore, the repertoire of enhancer 
function is ever growing and the Acan enhancers identified in this study may have 
unpredicted functionality.  
ACAN is stably expressed and turned over in adult cartilage and enhancers are generally 
explored in diseases such as cancers and in development with adult normal physiology 
being neglected (Chambers et al., 2002). We wanted to examine if any of the Acan 
enhancers are expressing in adult mice, however, we never interrogated its function in 
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the adult tissue. The -35kb enhancer replicate ACAN expression in articular cartilage in 8 
week and 6 month old mice. The relevance of an enhancer at this stage may allow 
binding of regulatory TFs to allow turn over, however, without further experimentation 
the role of the enhancer in adult cartilage cannot be certain (Kohn et al., 2012, Mirando 
et al., 2013). 
Figure 76: Schematic of the role of the -35kb and +26 Acan enhancers 
 
A hypothesis that arises from this body of work is that the -35kb +26kb are redundant, 
together along with the promoter and the -10kb there is normal expression of Acan. 
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When a mutation occurs in either the -35kb or +26kb there is reduced expression but the 
system is able to recover therefore not detrimental to transcription, but the loss of Sox9 
removes the chondrocyte expression of Acan driven by the enhancers. In the absence of 
the -10kb the other two enhancers drive normal expression of Acan but the -10kb is there 
to protect against stress or for timely expression of Acan during certain times of 
development. In the absence of the promoter there is a loss of expression of Acan in 
certain cells types but as long as the +26kb and -35kb are intact chondrocyte specific 
expression is not hindered but if both of these enhancers are lost there is defective 
chondrocyte expression. Finally, in adulthood Sox9 is replaced by other transcription 
factors such as NFAT, Rbpj-k or other TFs to maintain Acan turn over. 
5.4. The role of the -65kb and -87kb enhancers  
As mentioned before, it is known that enhancers rarely act alone; they can have a 
shadow or other enhancer that co-operate to bring about expression (Werner et al., 
2007, Wenger et al., 2013).  Of the two far up-stream enhancers, the -87kb appears to 
be temporally expressed, with our earliest detection in the chondrocytes was at E15.5. 
At this age the signal is weak, but appears to be following the interzonal regions of the 
joint, as the mouse ages the staining remains primarily in the articular cartilage but not 
the IVD, analysis of this enhancer during joint formation may shed a light on its 
functional role. It is known that at E14 mRNA of Acan is detected in the mouse’s tibial 
cartilage in the metaphysis and the epiphysis but weakly in the hypertrophic 
chondrocytes of the diaphysis (Shibata et al., 2003). Therefore, to find a regulatory 
element that appears solely in the hypertrophic chondrocyte such as the -65kb was 
unusual but not unexpected, as the Acan knock-in mouse also showed hypertrophic 
chondrocyte expression when the cre was activated (Henry et al., 2009). The precise-
timing of the morphological event in long bone formation and growth is important with 
the loss of Acan results in a smaller and disorganised hypertrophic zone in the growth 
plate of NMs, which suggest that an enhancer in the hypertrophic chondrocytes may 
have some importance and serves a different role as opposed to regulating 
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transcription, but rather the organisation of the chromatin. What we must also consider 
is the half-life of the β-gal which can range from minutes to greater than 20 hours in vivo 
depending the pH and temperature (Bachmair et al., 1986, Rojas et al., 2005). It maybe 
that the -65kb was active at an earlier stage of development but is inactive at E15.5 but 
the enzyme remained in the tissue, therefore the staining is an indicator of the cells 
progressing through the cartilage (Domowicz et al., 2009).  
In the zebrafish study the -65kb falls outside of the examined enhancers and the -87kb 
failed to express (Hu et al., 2012). The -65kb in fact when examined closely on the 
predication is not highly conserved so may not have the relevant machinery or available 
TFs in the zebrafish to bring about its expression. The -65kb is of interest to us mainly 
because of its different histone profile and DNase1 hypersensitivity compared to the 
other enhances identified in this study, the presence of the H3K4me3 and the fibroblast 
DNase1 peak indicates that the enhancer is highly active, the explanation of which may 
be more complicated than TF interactions but due to bending of the DNA and the 
promoter-enhancer interactions that have not been explored. 
The -87kb expression in 8 week old mice is impressive, staining in the growth plate and 
the superficial lay of the articular cartilage are a lot stronger when compared to the 
expression at E12.5 and weak expression at E15.5. This shows that this enhancer is (at 
least in part) responsible for adult expression of ACAN and may have a key role in the 
adult transcriptome of this gene. With this idea that the -87kb is adult cartilage specific 
it may mean that cells that are marked by the -87kb enhancer in early development are 
a different chondrocyte to other chondrocytes marked by the other Acan enhancers and 
have already committed to a lineage fate. Therefore, the -87kb may drive the lineage 
specificity towards the growth plate chondrocyte and into the superficial zone. 
Compared to the -35kb enhancer, the expression is almost identical, albeit the -87kb 
being strong at this stage. This may be due to the copy number and insertion site. The 
expression of both the -35kb and -87kb were in only the superficial zone and rarely in 
the deeper regions although ACAN is found in the deeper zones. This raises questions, is 
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the penetration of the X-gal poor or alternatively, is there a TF that drives expression in 
chondrocytes and restricts the enhancers to the superficial layers. Research that 
supports this idea of a TF is the work in lubricin (Prg4) which is expressed primary in the 
superficial zone chondrocytes of the articular cartilage (Reesink et al., 2016). The Prg4-
CreERT2 is an inducible cre knocked into exon 2 of Prg4. With immunofluorescence 
detection of the cre and X-gal staining of Prg4CreETT2 crossed with Rosa26floxLacZ mice 
show that Prg4 is expressed in the superficial a region at E17.7 and during development 
it remains in this region. However, in adult mice when lineage tracing was conducted for 
30 days, 6 months or 18 months show that these chondrocytes give rise to 
approximately 70% of the superficial chondrocytes but there are cells migrating into the 
deeper zones of the cartilage as opposed to remaining in the superficial region. The 
study suggests that these chondrocytes are progenitors to deep zone chondrocytes 
contrary to the dogma of chondrocytes expanding towards the superficial region of the 
cartilage (Kozhemyakina et al., 2015a, Kozhemyakina et al., 2015b). This hints that there 
is a restriction to the superficial zone placed on these chondrocytes and there is a 
trigger that allows them to migrate down. One of these triggers could be TFs that help 
retain the expression of the gene to the superficial region. Therefore, one can infer from 
this study that the two Acan enhancers (-35 and -87kb) may be under the same 
influence of this unknown TF. What is needed is to establish what is the regulation that 
retains the -35kb and -87kb to the articular cartilage and to the growth plate and if it is 
the same in the different regions. To do this one suggestion, albeit costly, is to fragment 
the enhancers and determine the minimal region that regulates expression and perform 
a TF platform assay. Alternatively, ChIP-seq or DNase1 hypersensitive can reveal 
sequences of TF binding that can be aligned to the TF databases to identify possible 
factors to be examined. 
5.5. 3’ intronic sequences found within the Acan locus  
When the intronic regions of Acan were examined it was noted that closer to the 3’ 
region of the gene there were less limb specific histone modifications. This may be 
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because the screen for histone modifications in the intergenic regions were over looked. 
The +60kb only had H3K4me1 suggesting it was poised whereas only weak/ poor peaks 
for the histones were seen at this stage of development where the histone ChIP-seq 
were performed. However, its expression at E15.5 was tissue specific in individual 
embryos but different when compared to each other. These regions rarely share 
similarities, although two do share some chondrocyte expression, this region was highly 
conserved down to fugu suggesting that evolutionary this region has withstood genetic 
stresses, hinting that this region has a beneficial purpose to the host, what this is 
remains to be examined.  . Looking at the sequence, it is small at 411bp, but could well 
house multiple TFs binding sites for different tissue types or the sequence is missing 
essential regions that may lie in the exons 16 and 17. However, its role in regulating 
Acan will require further investigation.  
The +55kb is a non-chondrogenic enhancer with lung, kidney and tissue specificity with 
expression at E15.5, 8 week and 6 month old mice showing nucleus pulposus staining. 
The specificity of the kidney staining in the glomeruli makes it unlikely to be due to 
endogenous LacZ staining, however Acan has not (as yet) been shown to express in the 
glomeruli and the function in this area is unknown (Sebinger et al., 2013, Weiss et al., 
1999). Only other members of the Lectican family such as VCAN and BCAN, appear to be 
critical in the kidney (Rudnicki et al., 2012, Naso et al., 1995). In terms of the lung ACAN 
was not found to express, rather its family member VCAN has been localised to this 
area. Areas where ACAN had been detected outside of the cartilage include the aorta, 
brain and skin and it is interesting to note that none of the enhancers identified in this 
study had been found in the aorta which may have been over looked (David et al., 
1989).  
The tissues containing +55kb expression all derive from different lineages, the lungs 
from E9 arise from the ventral foregut endoderm, glomeruli from the mesoderm 
(Abrahamson, 2009) and the nucleus pulposus is derived from the cartilage end plate 
into fibrocartilage (Kim et al., 2003, Jeong and Epstein, 2003). The different tissues leads 
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to the question of what links these three tissues if one enhancer can express in these 
regions and what drives its expression?  This may be due to the size of the +55kb 
(around 2.5kb) which could be split into three regions that can drive expression only in 
the kidney, lung and nucleus pulposus? 
To examine the last question, ENCODE data for histone modification in these regions 
can be obtained and examined. There are no signal for this area for any histone 
modifications in the lungs, but in the kidney there is a small peak of around 512bp, this 
is most promising, although it supports the idea that this enhancer may regulate these 
areas simultaneously (Figure 77). This leaves this gene specificity and minimal sequence 
of activity of the enhancer open for debate and requires further dissection to 
understand its true role in transcriptional regulation. 
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Figure 77: Analysis of the +55kb in other tissues 
 
The large +55kb region examined for histone modifications H3K4me1, H3K4me3 and 
H4K27ac in the lung and kidney with the limb and fibroblast overlaid. The +55kb is 
generally void of histone modifications but in the kidney highlighted in red.  
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5.6. Regulation of Acan enhancer activity by Transcription factors 
Enhancers serve as TF binding sites for co-ordinated transcription activation and 
regulation, Sox9 is known as the master regulator of chondrocyte fate so it was 
unsurprising that binding motifs were found within these Acan enhancers. We find that 
Sox9 binds to all the chondrocyte expressing enhancers although not always a class II 
binding. During the analysis of these regions publications of Sox9 ChIP-seq data became 
available (Ohba et al., 2015, Liu and Lefebvre, 2015, Garside et al., 2015). We used these 
to validate our EMSAs, by lifting over and converting the data into the mouse we 
layered each dataset to visualise where Sox9 binds. The Acan locus appears to interact 
with Sox9 frequently in both rat and mouse studies. This is true for our enhancers, the 
+26kb, -35kb, -65kb and -87kb all show Sox9 binding from the rat and class I and class II, 
this is different to the -10kb for which only the rat data supports Sox9 binding. The +60 
and +55kb enhancers do not have regions of Sox9 binding which strengthen the non-
chondrogenic potential, but raises doubts for the chondrocyte expression of the +60kb 
and if it is under the influence of another TF. Furthermore, the enhancers identified in 
our study are the only regions to interact with Sox9 in mouse limbs at E12, this may 
suggests differences in the threshold set by the ChIP-seq studies or that the interactions 
in cell culture are different from in whole limbs (Garside et al., 2015).  
Similar to the known enhancer these regulatory elements interact with Sox9 although 
not all of the enhancers engage in the suggested Class II binding of the Sox-dimeric 
motif. It may be that for -65kb and -87kb they interact through the less preferential Sox 
monomer and require an integrated input of other transcription factors (Ohba et al., 
2015). This leaves the question of why there are differences in the expression of the 
Acan enhancers when Sox9 appears to regulate them all, at least in vitro. To find Sox9 
binding interactions with the -65kb enhancer is intriguing, as over expression of Sox9 
leads to a reduction in chondrocyte maturation into hyper-trophy and a loss of Sox9  
accelerates this process, suggesting Sox9 has a repressive role in hyper-trophic 
chondrocytes (Akiyama, 2008, Akiyama et al., 2002, Akiyama et al., 2004, Bi et al., 2001). 
This leads to the idea that Sox9 binding to the -65kb may confer the enhancers 
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specificity to the chondrocyte but requires the action of other TFs, that may act 
synergistically or competitively with Sox9 to drive the hypertrophic part of its repertoire. 
Other studies support this notion with Sox9 being shown to have a dual role in 
repressing and activating transcription, it represses Col10a1 by direct interaction in 
growth plate chondrocyte to limit Col10a1 to hypertrophic cells only (Leung et al., 
2011). In a different case, Sox9 directly binds to vegfa in cultured primary chondrocytes 
to subdue the expression and inhibit vasculature formation and suppression of terminal 
differentiation (Hattori et al., 2010). Additionally, work screening 15kb up stream and 
10kb downstream of the CTGF gene (CCN2) in the RCS cell line using ChIP-on-chip for 
Sox9 found that the binding site was not the consensus binding site, but five CATTcAg 
and not as the dimeric motif at the proximal promoter (Oh et al., 2016). This could 
underline differences in regulation of the enhancers and the role of Sox9 and its 
differences in binding preferences. What this may mean is the binding preferences of 
Sox9 to the different enhancers may confer different activities, the stronger class II 
binding may be strong enhancers and the weak or more dynamically controlled 
enhancers require other TFs to function. This of course requires further examination to 
determine if the hypothesis is true. 
We wanted to examine the importance of Sox9 in regulating the Acan enhancers. To do 
so we took the -35kb element and subjected it to mutagenesis studies. Sox9 binding site 
mutations did not attenuate the transgene expression in vivo rather the expression was 
abolished from the chondrocyte and expression was generated in the periosteum or 
fibroblastic cells. This result supports the motion that Sox9 is required for the 
chondrocyte specificity and represses the expression in non-chondrogenic cell lineages. 
The shift indicates that other transcription factors are able to regulate the expression of 
the -35kb. The perichondrium expression has previously been noted in the Acan 
mutated chick(NM). In this model  a loss of aggrecan core protein resulted in a shift in 
regulatory gene products such as growth factors and signalling molecules particularly in 
the hedgehog effector Patched (PTCH) from the developing periosteum suggesting that 
a fault in Acan was able to reproduce a perichondrium effect (Domowicz et al., 2009). 
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The mechanism that is involved remains unexplored but an evaluation of the knock-out 
of the Sox9 binding sites in vivo, by the use of genome editing techniques, may help 
uncover  what is happening to the expression of the -35kb enhancer Sox9 mutated 
sequence and in the NM chick. When mutations are introduced in the three dimeric 
Sox9 binding sites independently there is a loss of chondrocyte specificity with each one. 
This questions if these three sites are interacting or stabilising the Sox9 binding to the 
enhancer. Additionally, none of the mutations individually reveal periosteum expression 
and site 7 retained some chondrocyte expression, which may suggests its redundant 
role in comparison to the other two binding sites, or that another transcription factor 
has activated that subset of cells. The single site mutations suggests that the removal of 
Sox9 binding allows or prevents a different protein from binding, as mutations in each 
site still allows a minimum of two other Sox9 binding sites, this may mean that there is 
occupancy around the regions blockading other TFs but not significant enough to drive 
the expression in the chondrocytes or that the DNA is looping in a direction to reduce 
binding of other TFs this idea requires further verification. Site 3 presented with some 
fibroblast expression in one transgenic embryo, which we cannot rule out a SOI effect. 
What is certain all 3 binding sites intact are required for the normal function of the -
35kb enhancer? What sox9 is doing at each site is to allow the remodelling of the 
chromatin to initiate transcription with the loss of all three sites the remodelling cannot 
occur so the chondrocyte specific expression is loss (Coustry et al., 2010). 
One possible TF that could be interacting is the Notch transcriptional effector Rbpj-κ, to 
determine if rbpj-κ is able to regulate the +26kb and -35kb as it does with Sox9 (Kohn et 
al., 2015, Mead and Yutzey, 2009), three possible rbpj-κ binding sites was identified in 
the -35kb sequence, with one binding in vitro and three binding sites in the +26kb, with 
sites 1 and 3 binding. Mutations in vitro we are able to abolish the binding in both 
enhancers binding sites apart from site 1 for the +26kb, which appeared to still bind 
albeit to a lesser extent. This may be due to the binding motif for Rbpj-k although not as 
strongly predicted is still partially intact in the mutant oligo at the site: CTTCCCAGGG 
when compared to the consensus (Figure 28 C). When the mutation to site C of the -
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35kb was introduced in vivo we saw very little change in chondrocyte specific expression 
of the transgene. In some cases the expression in the chondrocyte was scattered but 
still remained strong, in many of the transgenic embryos there was an increase in the 
expression in the dermal fibroblasts and there were expression in the blood vessels. It 
may be that the mutation in the Rbpj-κ site has changed the binding dynamic of other 
TFs at the -35kb enhancer but the change isn’t significant to result in a complete change 
in expression of the transgene. Rbpj-κ is required for terminal differentiation and 
regulates endochondral ossification and is necessary for the maintenance of joint and 
articular cartilage with a knockout of Rbpj-κ resulted in a reduction of Acan mRNA. 
Therefore we may not see an effect of our mutation until later stages of development 
and in adult mice. Alternatively it may only occur with both Rbpj-κ and Sox9 binding site 
mutations (Kohn et al., 2012, Chen et al., 2013, Kohn et al., 2015, Mirando et al., 2013). 
The similarities between the Sox9 and the Rbpj-κ mutants are the dermal fibroblast 
expression. Rbpj-κ mutations may expose a binding site for dermal fibroblast expression 
of the enhancer, or it could be an inhibitor of the expression of the transgene in other 
cell types. A diagram of the role of Sox9 and other TFs in different cell types generated 
from our observations and the literature is detailed in Figure 78 and Figure 79 to try and 
understand the role of the TFs in development and in the adult. With transgenics the 
transgene integration is random, the copy number is variable in each case and with the 
transgene theoretically being present in every cell type, there can be expression of 
transgene in regions that is not predicted. In the WT sequence of the -35kb there is 
always robust chondrocyte expression with little or no expression in any other cell type. 
The regulation by the transcription factors and various signalling pathways such as sonic 
hedgehog (ssh) allows for Sox9 and another transcription factor Nkx3.2, which represses 
the Gata proteins (Daoud et al., 2014), to establish the chondrocyte phenotype from the 
sclerotome, mesoderm and neural crest (Zeng et al., 2002, Liao et al., 2014, Akiyama et 
al., 2005, Akiyama et al., 2004). In other cell lineages there are transcriptional activators 
and repressors that dampen or intensify expression and activity of Sox9 to allow or 
prevent the differentiation into other cell types such as tenocytes (Sugimoto et al., 
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2013a), osteoblasts (Zhou et al., 2006, Dy et al., 2012, Goodnough et al., 2012) and 
vascular smooth muscle cells (vSMC)(Briot et al., 2014). During cranial development 
while differentiation of the dermal fibroblast occurs, Wnt/ β-catenin influences dermal 
cell differentiation by regulating the TF TWIST2 via Lef1 and TCF4 (Goodnough et al., 
2014). TWIST2 is a transcriptional repressor that has been shown to suppress Sox9 
mRNA (Tran et al., 2010). This may support the idea that the enhancers serve as one of 
the platforms for the signalling and TFs that down regulate the expression of Acan 
facilitating the differentiation of the stromal cells into dermal fibroblasts rather than 
chondrocytes. An approach to identify other biological important TFs that would 
eliminate the requirement fors identifying the sequence of the TF before functionally 
testing, is to carry out panel screen of enhancers relevant to the cell of interest. This will 
identify some of the TFs that bind and the possible combinations of TFs that bind in 
close proximity for further analysis, and the sequence can be pulled out using native 
ChIP. This, however, does not allow the identification of novel binding factors (Huang et 
al., 2016).  
We have yet to establish other TFs that are interacting with these Acan enhancers and if 
initiators or more core PIC complexes form at these enhancers, but the literature does 
suggest TFs AP-1, RUNX2 (Zhou et al., 2006), Mef2 (Gu et al., 2014, Arnold et al., 2007) 
family and Hox, which may aid Sox9 in enhancer activation and we have not explored 
the role of L-Sox5, Sox6 (Dy et al., 2010) or even the SoxC proteins (Dy et al., 2008) that 
have been shown to regulate different time points in chondrocyte maturation. NFAT1 
was predicted to bind to the +26, -35 and -87kb enhancers and we have shown that the 
protein binds in vitro to these constructs. For in vivo analysis were generated, but due to 
time constraints the experiment was not conducted. It is interesting to note that the 
enhancers share the same TF binding, although the function of each one has not been 
explored. A question which arises from this is that if all these TFs bind to the same 
enhancers and drive the same specificity what differentiates the chondrocytes from 
other cell types? There is a need to explain on a basic level, why TFs tissue specific 
knockout are so detrimental to the entire transcription and translation machineries 
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which leads to poor expression in only that cell type, not just in every cell that both the 
enhancer and TF are found. A question to ask is if Sox9 is present at all enhancers what 
are the factors that are interacting with Sox9 to create the differences seen in these 
Acan enhancer? And if these form stable transcription hubs to allow transcription only 
in the chondrocyte? 
A working model of the role of TFs competition at enhancers in different cell types in 
both development and in adult maintenance is depicted in Figure 78 and Figure 79. 
. 
Figure 78: Predicted diagram of the role of Sox9 in regulating enhancer expression  
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Assumptive diagram of lineage expression of the enhancers control by sox9. Signalling 
pathways regulate Sox9 such as Shh and BMP, other transcription factors such as nkx3.2 
and Twist two compete may away Sox9 binding in the area around enhancers to drive 
the precursors to other cell types such as the fibroblast, adipose, vascular smooth muscle 
or tenocytes. One hypothesis is when Sox9 is expressed in more abundance it binds to 
the enhancers that are chondrocyte specific and allows the chondrocyte expression of 
the gene regulated by the enhancers that serves as platforms for further engagement of 
extracellular matrix and chondrocyte specific genes. 
Figure 79: Predicted role of Sox9 in adulthood 
 
It may be in the adult system Sox9 acts as a regulatory to keep enhancers expressing in 
the chondrocytes but other transcription acts regulate their role and the effects they 
have on turn over or activation of certain Acan enhancers. It is possible that the 
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introductions of other transcription factors or the removal of sox9 leads the expression 
to divert into other cells.  
5.7. Evolutionary co-regulation of link proteins and Lectican protein family 
The proteoglycan family lecticans and the link proteins appear to have evolved 
evolutionary together, splitting from a core transcript early in evolution like the HoxA-D 
genes (Figure 80) (Spicer et al., 2003). It has been proposed that due to the close 
proximity on a genomic scale to the proteoglycan transcript to the link proteins that 
they are co-expressed and act on each other during the formation of the proteoglycan 
aggregates. It is known that HAPLN1 interacts with both VCAN and ACAN although 
through different domains, this may mean that the other HAPLNs may aid in the 
formation of these aggregates in other tissues (Matsumoto et al., 2003, Shi et al., 2004). 
Currently, there are very few experiments that link enhancers to the target gene 
generally they are linked to the nearest gene, HAPLN3 is genomically linked to Acan and 
is the most widely expressed link protein, although it is not expressed in chondrocytes. 
The knockout mouse have not been generated, from our data an interesting proposition 
and observation can be put forward. Due to the proximity of the genes and that they 
have emerged together in evolution, transcriptional regulation of the smaller gene, 
HAPLN, may arise from the larger proteoglycan. When the division of the major gene 
the transcriptions may have come from the same promoter and evolutiongave rise to 
the 4 different links and proteoglycans to allocate their tissue specificity, with Bcan and 
Ncan being neuronal specific but at different times at evolution (Figure 81). Genetic 
events results in a greater distance between the genes to allow for robust regulatory 
elements in different tissue types. Therefore, it may not be so farfetched that enhancers 
that lie within one gene regulates another gene to direct the tissue specific expression 
or that like bi-directional promoters that drive activity of neighbouring genes to allow 
coordinated expression of both genes, this may also  occur in enhancers (Ong et al., 
2002, Trinklein et al., 2004). This idea can be examined using bi-directional luciferase 
vectors and using 3C, 4C, 5C, Hi-C and in situ Hi-C technology to identify the gene in 
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which the enhancer identifies with (Jin et al., 2013). The reason for suggesting this 
possibility is that the intronic enhancers identified in this study, the +55kb, expresses in 
an area of the kidney not previously shown to be linked with ACAN but a where HAPLN3 
is detected by northern blot analysis (Spicer et al., 2003). It must be noted that 
enhancers can act on different genes in different cell types, for example the HS40 
enhancers of the β-globin gene also acts on the epsilon-globin gene (Bender et al., 2006, 
Bender et al., 2012, Chen et al., 1997, Nickol and Felsenfeld, 1988). Additionally, the 
+60kb region drives expression differently in different transient expression at E15.5, 
which may be down to SOI effects and the sequence requires shorting or protecting, but 
these areas are where HAPNL3 is expressed and the enhancer acts as a signalling/ TF 
binding platform along with other enhancers to drive both Acan and HAPLN3 
expression. These are all assumptions but are interesting discussion points. The intronic 
enhancer is unlikely to regular Acan as IHC does not localise ACAN to areas where the 
+55kb enhancer is expressing giving an indication that it is more likely to regulate solely 
HAPLN3, indeed HAPLN3 expresses both in the kidney (both tubules and glomeruli) and 
in the lungs when the tissues is examined in the human protein atlas 
(http://www.proteinatlas.org/ENSG00000140511-HAPLN3/tissue ). If the intronic 
enhancers regulates HAPLN3 rather than Acan then the regulation of the chondrocyte 
specificity of Acan is determine by the intergenic enhancers and the 5’ intronic regions 
such as the -35kb enhancer, (Figure 82), this can be examined using knock-outs of the 
enhancers. This could mean that the +55kb allows HAPLN3 to be activated at the same 
time as Acan transcription but in different tissue or the enhancer may not need Acan 
transcription to occur to be active. The hypothesis is greatly weakened when, data from 
unpublished gene array provided by Professor David Young and Kat Cheung from the 
University of Newcastle, show when MSCs undergo differentiation into chondrocytes 
Acan is transcribed but HAPNL3 is not, looking at the other lectican protein family Vcan 
is switched off when the cells become chondrocytes whereas the accompanying link 
protein HAPLN1 increases its expression putting doubts at least in chondrocytes the co-
regulation of the links and lecticans (Figure 92). However, in the whole mount the 
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tissues are different in expression, Acan is mainly found in the chondrocytes and rarely 
in the kidneys, our BR1 staining even shows that it is the tubules that express Acan. 
Does this mean that the +55kb regulates the HAPLN3 in the glomeruli irrespective of the 
enhancers host gene? Additionally, our antibody staining using HALPN3 antibody 
presents weaker expression in the mouse compared to the human data, it only 
expresses in the medulla and in the lungs only in the bronchioles, and this may be due 
to the antibody being raised for the human antigen. Our antigen retrieval using 
hyaluronidase rather than citric acid as they do in the human protein atlas may account 
for the differences, this leaves a very big questions of what the +55kb enhancer is 
regulating, we cannot rule out the possibility that the enhancer of regulates either Acan 
or HAPLN3 since we only utilised two antibodies, the transcript may be an isoform or 
short lived. Proteomics or knock-out experiments are required to explore this element 
in detail. The Bcan and HAPLN2 promoter direction may have occurred due to genomic 
rearrangement but overall the HAPLN and lectican co-regulation offers an interesting 
avenue for how enhancers and other regulatory evolved and if co-regulation occurs. 
Additionally, examining the role of the Acan enhancers on expression of the HAPLN3 
may yield a functional role for each regulatory element, it may not be inconceivable that 
there may be cross-talk between the regulatory elements of two genes that share 
similar genomic space..  
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Figure 80: The distance between link proteins and the lectican family 
 
Size and distance apart of the Lectican family members; Bcan, brevican; Acan, aggrecan; 
Ncan, neurocan; Vcan, versican, HAPLN1-4 are the link proteins 1-4.  
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Figure 81: Evolution of the link and lectican proteins 
 
Schematic of e lectican family and link protein evolution. It may be that in evolutionary 
time that these members evolved at different times, with Vcan being the oldest due to its 
widespread expression, Acan being next and Bcan being the youngest. This may hint that 
their regulation evolved together through both evolutionary and genetic stresses. 
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Figure 82: Possible interactions between enhancers found in the introns of Acan 
 
Schematic of the 3’ Acan enhancers and possible reason for their interaction that lead to 
their expression. The +55kb could be bi-directional and regulate the HAPLN3 gene as well 
as Acan due to the proximity of the enhancer to both genes (A) or the +55kb could have 
formed to regulate HAPLN3 so the expression of both genes are switched on at the same 
time, not necessarily in the same tissue . +55kb may not be the only enhancer to act on 
HAPLN3 as the two other intronic enhancer of Acan (+60kb and +26kb) are within the 
TAD of HAPLN3 and could play a role in its regulation. 
5.8. What are the functions of multiple Acan enhancers? 
The upstream elements,-35kb, -65kb, -87kb and the known -10kb, could co-operate to 
form an enhancersome for Acan, a functional hub that act in an additive fashion with 
the removal of one not impacting the others like the 5 α-goblin enhancers (Hay et al., 
2016). Proximal enhancers are more active in gene regulation compared to distal 
regions during development and lineage determinations, Acan contains multiple 
enhancers which is not surprising as it is similar to other genes (Huang et al., 2016). 
What is unusual is the identification of these four new enhancers which could cause 
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aggrecan to be primarily expressed in chondrocytes, thus enforcing the importance 
ofACAN to the chondrocytes and the lethality of its loss. Their roles overlap suggesting 
redundancy but the -65kb and -87kb are interesting, as this stage specificity highlights 
questions of how important ACAN is to the hypertrophic chondrocyte? And secondly is 
the regulation of ACAN expression in adult chondrocytes different to that of 
development? Are there enhancers within the Acan TAD that are polycombed and 
repressed in development, but switched on at later stages? 
To address this one of our collaborators at the Musculoskeletal biology group at the 
University of Newcastle, Professor David young and his student Kat Cheung have some 
exciting data. They are identifying human enhancers’ key to the chondrocyte. In one of 
their studies they are assessing histone marks in human MSC and then following 
differentiation of the cells into chondrocytes and reassessed the histones and 
investigated the transcripts by RNA microarray. With their permission I was able to 
assess their data in regards to the Acan locus in terms of the chondrocyte. This data fills 
the gap that is missing from the ENCODE analysis. The level of Acan transcription by RNA 
array is almost absent in MSCs and but increases after 14 days differentiating into 
chondrocytes. The results show there is a dramatic change in the enhancer activity, 
there are 8 regions that are tagged with the histone marks for enhancers, 3 poised 
enhancers, 4 promoters and 2 strong promoters with only one region repressed in the 
MSC stage. In the chondrocytes there are 15 enhancers, 13 strong enhancers, 14 poised 
regions, 7 strong promoters and 3 promoters in the same region we examined for 
enhancers using ENCODE. Corresponding this to our enhancers the -87kb and +55kb is 
not active in MSCs, but is tagged as an enhancer in the chondrocytes, the -10kb and 
+26kb are enhancers that become strong, and the -65kb remains an enhancer in both 
stages. The -35kb was a promoter in the MSCs, but a strong promoter in chondrocytes. 
The most interesting result is for the +60kb that the data suggest is not active in MSC 
but becomes a strong enhancer in chondrocytes. This informs us that these enhancers 
are playing a role in the chondrocyte and they may have lineage specific roles.  
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Enhancers can have effects up to 1MB away such as shh enhancer that is responsible for 
limb, digit development (Amano et al., 2009, Sagai et al., 2005). In this study there was 
no scope for long range identification of enhancers that may interact with Acan which is 
an area that can be explored. We also neglected to associate these enhancers with 
functions of Acan, rather we associated them with the expression pattern similar to 
Acan and that they are in the TAD of the gene, this is emphasised by the +55kb 
enhancer that could be regulating HAPLN3.  
Two interesting prospects can be put forward. Acan expression and turnover is critical 
for the normal function of joints, therefore the precise activation of Acan expression at 
decisive time points during chondrocyte maturation is important. The Examination of 
these enhancers under normal physiology may present minor changes but observing 
their roles by inactivation or in stressed situation may allow us to understand if they 
play a pivotal role in how skeletal and joint diseases arise. The second possibility that we 
put forward is that Acan relies on multiple enhancers to dictate the robustness of 
transcription. It cannot be ruled out that in the whole organism there are interactions in 
3D between the regulatory elements with each other or even with the promoter to 
stabilise the transcriptional machinery to bring about robust expression of Acan (Levine 
et al., 2014, Vernimmen et al., 2007). This may be because Acan does not contain a 
classical TATA box or core promoter and studies have shown its reliance on SP1 and AP1 
binding sites (Watanabe et al., 1995, Valhmu, 1998). One experiment that could be 
interesting is to determine if these enhancers can act as promoters in the absence of the 
core promoter to keep the production of transcripts for Acan in a tissue specific manner, 
thus providing a backup in case of mutations or loss of function in the promoter 
(Kowalczyk et al., 2012).  
Exploration of other histone marks can detail the activity surrounding the histones such 
as H3K122ac and H3K64ac have been recently been identified to mark promoters and 
with the absence of H3K27ac marking a class of functional enhancers (Pradeepa et al., 
2016). Utilising these data sets the visualisation of the Acan can be done and a 
regulatory story can be composed. For this the NCBI GEO databased contains data sets 
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from various experiments from across the world that can be visualised on the UCSC 
genome browser, each of the data sets can be annotated and layered onto the 
accession of interest, for this end the mm9 accession was generally used as it contained 
the histone modifications in the limb. The main drawback from this is that most of the 
data sets are created from cancer, haematopoietic or embryonic stem cells. In the 
Pradeepa et al study mentioned above they used mouse embryonic stem cells and 
leukaemia cell line (K562) to performed ChIP-seq and native ChIP using antibodies 
directed at H3K27ac, H3K4me3, H3K64ac, H3K122ac, H3K27me3 and H3K4me1 to 
screen for promoters and enhancers. To this end we took the data of the histone peaks 
for H3K64ac, H3K27ac and H3K122ac were placed into the mm9 to see if we were 
missing other enhancers (Figure 86). The results showed that although three regions 
within the Acan TAD has histone peaks for H3K64ac and H3K122ac, one of which is in 
exon, one is the -65kb and the other is the -100kb that was not analysed, suggesting 
they these enhancers may not fall into the active functional enhancer identified in the 
study (Pradeepa et al., 2016). 
Likewise, ATAC-seq data in haematopoietic cells can give us an idea of the topological 
and 3C organisation of the chromatin around the ACAN gene using data from the 
ENCODE matrix from Ross Hardison lab. In multipotent, oligopotent, immortalised and 
lineage restricted haematopoietic cells we find that out of the 6 enhancers found in this 
study and the known enhancer, only the +26kb remains as open chromatin. Whereas in 
these cells the other intronic, -10kb,-35kb, -65kb,and -87kb remain inaccessible. This 
may indicate how the lineage specificity is derived in the chondrocytes and kidney/lungs 
for the +55kb, by changing the organisation of the chromatin. It is interesting to note 
that there are two other regions in these cells that are open chromatin, one is the 
predicted -155kb the other lies between the -35kb and -60kb that was not flagged by 
our ENCODE analysis. I believe that other studies can be conducted to establish changes 
and if these change with disease.  
Not all enhancers are functionally important and a growing mass of data has generated 
that contradict and support the idea of enhancers having a dynamic function and are 
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responsive to the environment they are subjected too. One key pointis that almost all 
genes have more than one regulatory element and that no single cis or trans element is 
important without the others. A global view of haematopoietic lineage development in 
foetal and adult haematopoietic stem cells progenitors there are important enhancers 
defining each stage and a loss of any one of these enhancers delays the process. When 
certain enhancers are up-regulated during different differentiation stages of the cells 
they drive expression of the genes associated with that time point (Huang et al., 2016). 
The same is seen in self-renewing macrophages and embryonic stem cells but the 
commitment to macrophage lineages renewal is controlled by a different set of 
enhancers to that in the stem cells, suggesting that although certain cells in the human 
body share similar pathways, the control of each lineage is protected from the cross-talk 
of other nearby cells, this by the use of different regulatory processes found in each cell 
but dictated by the availability of the TFs (Soucie et al., 2016). In the well-established α-
globin set of enhancers, five enhancers were identified as super-enhancers, suggesting a 
higher order of importance compared to other enhancers that were functionally 
assessed. Evaluation of each one of enhancers individually show that not one enhancer 
is more important, rather each enhancer acts independently and has additive function 
but not the synergistic effects conferred by the term super-enhancer (Hay et al., 2016). 
This study not only discourages the use of the term of super-enhancers, but also 
highlights the requirement of functionally assessment an enhancer’s role. Therefore, 
one key aspect missing from my study is the assessment of functionality of the 
enhancers, do they co-operate, act independently, respond to developmental cues and 
are they essential to the chondrocyte? 
One other factor that may contribute to an enhancer activity is if it loops the chromatin 
and allows the binding of activators and pioneer factors or allows interaction with the 
promoter directly (Chopra et al., 2012, Eun et al., 2013, Goloborodko et al., 2016b, 
Kagey et al., 2010, Kim et al., 2015, Krivega and Dean, 2012, Larson et al., 2012). With 
recent studies in super enhancers they have focused on Med1 as a marker for SEs, Med1 
is a subunit of the mediator complex that interacts with the promoter and acts as an 
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interface for enhancers and promoters and its interactions often confer high level gene 
transcription.  ChIP-seq data from these studies can be annotated for Acan to determine 
if any of the enhancers interact directly or via intermediates with the mediator complex 
(Chen and Roeder, 2011, Voss and Hager, 2014, Plaschka et al., 2015). Data from the 
first group to coin the name super enhancer show that there are in fact two regions that 
have high affinity for Med1, one is located in the 11th intron not predicted in our studies 
as an enhancer and may not be chondrocyte specific (Whyte et al., 2013). The other is 
the -65kb enhancer. This suggests that the Acan promoter is interacted upon at two 
points through enhancers and that the -65kb holds greater importance in the 
transcriptional regulation of the gene compared to the other enhancers (Figure 
90)(Whyte et al., 2013). To determine how these interact, new Capture-C and DNA/RNA 
FISH would allow visualisation in fixed cells (Brackley et al., 2016, Brown et al., 2008, 
Brown et al., 2006). Other more advanced techniques such as modified Cas9’s from 
different species of bacteria such as Neisseria meningitides and Streptococcus 
thermophiles for genome editing, can be tagged by different coloured proteins to label 
regions of the genome to allow multi-colour labelling of DNA and can be visualised in 
real time and is only limited by the power and resolution of the microscope (Ma et al., 
2015a, Ma et al., 2015b, Zhang et al., 2015). 
In terms of assessing these enhancers, knock out using CRISPR/cas9 or even CRISPR/cas9 
panels that allow systematic identification of functional noncoding regulatory elements 
by targeting TFs in cells will allow an appreciation of the importance of each enhancer 
(Korkmaz et al., 2016). Additionally modified Cas9 and smaller cas’ can allow multiple 
activation and deactivation of the enhancer regions without effecting the strand length 
or deleting and adding regions to the genome, which are previously uncontrolled 
variable in transgenic experiments, this is because they recognise different DNA seed 
sequences and do not cross-talk with each other, therefore they can be used on the 
same sample in one experiment (Gao et al., 2016, Konermann et al., 2015, Ran et al., 
2013, Esvelt et al., 2013, Sander and Joung, 2014, Yang et al., 2013, Yang et al., 2016, Yin 
et al., 2014). The effects of enhancers on other regions of the genome can also be 
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determined if coupled with techniques such as ATAC-seq which allows the accessibility 
of the region to be assessed to determine if the knock-out upregulates other proximal 
and distal enhancers.  
To understand the functional aspect of the enhancers, epigenetics and experiments with 
OA models such as the DMM and loading model should be carried out to determine if 
enhancers play a role in disease progression (Poulet, 2016, Poulet et al., 2011). 
Methylation is an epigenetic modification on the histones as a result of environmental 
stress, which can results in activation or deactivation of the region by changes the 
binding of trans factors (den Hollander et al., 2015, Reynard, 2016, Reynard et al., 2014). 
Differential methylation is seen in OA patients and differences are seen in hip and knee 
OA, the arcOGEN GWAS and other methylation studies have found susceptibility loci for 
OA in GNL3, ASTN2 and CHST11 (arcOGEN, 2012, Nakajima et al., 2010, Kerkhof et al., 
2010, Gee et al., 2014). With help from Dr Louise Reynard in the osteoarthritis genetics 
group at the University of Newcastle, we were able to analyse the methylation data for 
knee and hip OA to determine if the Acan enhancers are differentially methylated. The 
analysed can data found within the appendix was reproduced with permission. Data was 
not available for the -87kb enhancer due to no probe coverage and the only region to be 
methylated is the -65kb which differentially methylated when compared healthy hip to 
OA hip in patients (Rushton et al., 2014). The exact role of this methylation, requires 
validation as methylation is not the only mechanism by which enhancers can be 
changed or modulatd in disease. To examine the role of the enhancers in a condition 
like OA, we used an in vitro analysis, using the ATDC5 cells. I transfected the cells with 
luciferase reporter constructs with the enhancers upstream of a minimal promoter, we 
opted against using the HSP68/LacZ vector in vitro and using a Dual-light assay that 
detects luciferase and β-gal activity, due to the fact the HSP68, although silent in mice is 
not silent in vitro. After verifying that the enhancers were able to express in vitro using 
the T/C28-I2 and NIH3T3 cells, we transfected the ATDC5, after differentiation, with the 
enhancer constructs and then added hOSM or IL-1β. Here the -35kb element was poorly 
expressed despite its activity in vivo, the -65kb was also unable to express as strongly as 
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the other enhancers. The -87kb appears to be chondrocyte specific, as in fibroblast the 
activity is greatly reduced. In the ATDC5 cells there were no significant effects of hOSM 
or IL-1β on the expression of the +26kb and -10kb. The -35kb increased in expression 
with IL-1β treatment, but this was not significant. The effects on -65kb by IL-1β hints 
that the -65kb is a responsive element and may be critical to increasing anabolic activity, 
the -87kb on the other hand responds to hOSM that down regulates its expression. OSM 
and IL-1β signal through different pathways, IL-1β works by signalling through the TRAF-
6/TAK-1/MKK-4/JNK-2 to promote aggrecanolysis by increasing the expression of 
ADAMTS-5, MMP1 and MMP13 in OA as well as reducing ACAN expression and 
downregulating Acan mRNA (Ismail et al., 2015a, Ismail et al., 2015b, Radons et al., 
2006). OSM signals through a JNK-2 independent pathway via the JAK/STAT and down 
regulates aggrecanase activity, OSM can also act synergistically with IL-1β (Rogerson et 
al., 2010, Barksby et al., 2006). The -65kb may be the developmentally important 
enhancer and as it is methylated in hip OA, it may point to a switch in OA cartilage to 
attempt to synthesise more matrix but due to methylation this is hindered. The -87kb 
appears to be important for the chondrocytes expression of Acan and the down 
regulation by OSM and Il-1β may be indication at its role in turnover or a lack of 
turnover. This may suggests that there are defined roles for these enhancers in adult 
tissue. This may be the turnover of ACAN but this may be limited as the half-life of ACAN 
in adult cartilage is around 3.4 years (Maroudas et al., 1998). Therefore, an area for 
further work would be to define the role of these enhancers in adult cartilage.  These 
enhancers may play a role in disease progress such as OA, although the data is very 
preliminary and it is not unusual for SNPs in noncoding elements predisposing a person 
to a disease Enhancers may be the regions of DNA that are blocked or up-regulated in 
diseases such as OA, that adds to the severity of the disease or prevents a response for 
the cell to rebuild its ECM. One enhancer may not be able to change a disease state, it 
may require other enhancers or other factors, such as targeting not just the Acan 
enhancer but the enhancers in collagen 2 and down-regulating the enhancers in 
enzymes such as MMP13. .  
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With the available data from ChIP-seq, ATAC-seq, ChIA-PET and combined with our 
analysis using EMSA and transgenic mice, these together build a picture of the 
developmental regulation of Acan, although  a view of what may happen in the adult  
remains to be examined. From this a picture can be painted of the chromatin landscape 
of the Acan TAD, the 3D structure of this “hub” can be determined with new technology 
and analytic tools being developed such as the PETModule and the 4D genome (Zhao et 
al., 2016, Teng et al., 2015). From the 4D genome approach looking at Hi-C of the IMR-
90 human lung cells there is no interactions between the +26kb enhancer with any of 
the enhancers of Acan, there is however interactions with other upstream regions of 
Acan and within  the HAPLN3 gene. The promoter (taken as chr15:89,346,048-
89,347,590) interacts with 34 regions, but of the enhancers the -10kb, -35kb and -87kb, 
the -35kb interacts with the -87kb and -65kb and the -87kb only interacts with the 
promoter and -35kb (Figure 91). This data may be biased to the lungs and in 
chondrocytes this may be completely different, but it gives us invaluable insight and the 
interactions with -65kb and -35kb may strengthen the idea of the -35kb playing the role 
of a promoter. 
 
5.9. Using Acan Cre as a tool for further research 
ACAN is express more steadily in adult cartilage than Col2a1 and is found both in the 
growth plate, articular cartilage and IVD but Col2a1 gradually decreases with age 
(Chambers et al., 2002, Neidlinger-Wilke et al., 2006, Chen et al., 2007). Therefore, there 
are advantage to using an Acan cre over a Col2a1 and allows control other tissue of 
activation and temporal control over the Cre’s activity (Ovchinnikov et al., 2000, 
Nakamura et al., 2006). There is an established Acan Cre that was a knock in into the 
3’UTR of Acan which allows analysis of floxed genes in vivo during development and 
adulthood (Henry et al., 2009). However, there are some draw backs as chondrocytes 
below the tide mark and in the deeper layers of the meniscus were not activated. Our 
group has also created a AcanCreERT2 using the known A1 enhancer sequence in four 
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time tandem repeat, cloned upstream of the Col2a1 proximal promoter that was 
different from the knock-in cre as it  the lacked tendon expression, therefore, we now 
have multiple transgenic mice models that can help us understand cartilage disease by 
using them in over-expressing or knock down of a gene specifically in the chondrocyte 
(Cascio et al., 2014).  
The drawback of other cre models are the non-chondrogenic expression in development 
which warrants a specific Acan cre. However, the reason to add the -35kb enhancer 
upstream of the human Acan minimal promote to the arsenal of Acan cres was the 
strength of the enhancer and and its activity in both development and adulthood.  
Additionally, when compared to the known A1 enhancer and the knock in cre, the -35kb 
driving the human promoter may be of a different lineage, or subset of chondrocytes, so 
the use of a different Acan cre can determine cell fate by mapping the expression after 
pulse chasing (Carlone, 2016, Wuidart et al., 2016, Vorhagen et al., 2015). This will shine 
a light on the identity of the chondrocytes and the different fate in which they may take 
and allow us to differentiate chondrocytes from for example the superficial articular 
chondrocyte from the rib chondrocytes. 
5.10. Conclusions 
Multiple enhancers were identified in the Acan locus that expressin chondrocytes as 
well as other intronic cis-acting elements that express elsewhere. The role of each 
enhancer remains to be assessed and their gene targets will need to be verified. Sox9 
regulates the -35kb enhancer in vivo and in vitro experiments show that the TF binds to 
all the chondrocyte expressed enhancers. The role of Sox9 may be structural and an 
activator in development, but its role outside of development in regards to these 
enhancers remains to be explored as well as the 3D chromatin landscape. These 
enhancers may act collectively or as an additive manner. Developmental interactions 
may be only required to allow robust expression of ACAN, but in adult tissues the 
enhancers act in a different capacity or to react to stress this is depicted in Figure 83. 
The developmental and adult landscape are different and it may be that the -87kb is the 
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most important in preserving Acan transcription in adulthood but the -65kb is essential 
for gene activation in development, images depicting the working models for the 
enhancers are outlined in Figure 83. The role of these enhancer in disease is unclear and 
their response may play critical roles in disease progression, although our preliminary 
data suggest they may be involved in the response cytokines that have a role in OA 
disease progression, their actual function in disease state may be minimal but requires 
further investigation. The pChu94 mouse is an inducible chondrocyte specific model that 
can be used to interrogate the loss of genes in chondrocytes or to assess the role of 
certain pathways in both development and adult cartilage. 
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Figure 83: Schematic of possible enhancer interactions based on known data 
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There are many possibilities for how these enhancers interact. They may not help each 
other but rather they may act as independent entities. A collation of the data we know it 
seems more plausible the -65kb is the key enhancer in keeping Acan transcription along 
with a region up stream that has not been identified in this study. The -65kb interacts 
with the mediator to drive the expression of Acan in a timely manner during 
development (A). The -10kb may loop the DNA to stabilise the transcriptional loops at 
the proximal promoter. The -35kb may acts as a promoter for the chondrocyte with the 
+26kb bringing downstream elements closer to the hub, again in development the -87kb 
is looped out. These 5 enhancers are key to the lineage determination of the 
chondrocyte, as they are the only regions to interact with Sox9 at E12, they act in an 
additive manner to stabilise the entire complex with fail safes to ensure the chondrocyte 
expresses Acan to keep the integrity of the cartilage. As the MSC commit to the 
chondrocyte each of the enhancer become active and the -87kb is switched on or even 
looped in to interact with the promoter, as the chondrocyte undergoes it lineage towards 
the articular cartilage the -87kb plays a more important role. These roles are yet to be 
defined.  
5.11. Future direction  
Functionally assessing enhancers and determining their functional relevance is pinnacle 
as it may reveal the role each enhancer works (Kvon, 2015, Hay et al., 2016). 
Determining the role of enhancers in adulthood and maintenance of the genomic 
landscape, appears to be important and differences in development and adult 
transcriptional regulation can be examined with the advancing field of molecular biology 
and the embracing genome editing tools. Establishing the role enhancers’ play on a 
global genomic scale can establish the role regulatory elements found in cartilage give 
rise to the entire join and the tissues that are found there, there may be regulatory 
elements that we are missing altogether and need to be considered as dynamic 
elements are forever changing. Targeting the -65kb and-87kb may be a possible area for 
OA treatment but requires further research into their function in disease and how 
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impactful they are if targeted. A major aim of future research is to understand the role 
of the enhancers and how they communicate to bring about co-ordinated development 
and maintaince of a whole organism, if this is dysregulated in diseases or can be 
targeted.  
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7. APPENDICES 
Figure 84: Direct EMSA comparing nuclear protein extracts from SW1353 cells and qPCR 
for Sox9 in SW1353 
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EMSA using nuclear protein extracted from SW1353 from Liverpool and Newcastle are 
ran alongside the in vitro transcribed Sox9 protein. Super shifts were performed with 
Sox9 anti-body and reveals that the size of Sox9 is different in cells from different areas, 
in fact there is no supershifts in any of the SW1353 lysates. The shift was generated by 
Dr L. Reynard at Newcastle University using probes and lysates generated at University 
of Liverpool. On an mRNA level there is actually Sox9 present in SW1353 compared to 
the Runx2. 
Figure 85: UCSC genome browser output with custom tracks from Sox9 ChIP-Seq 
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Sox9 ChIP-seq from different groups show that Acan interacts with Sox9 frequently. The 
identified Acan enhancers that express in the chondrocyte are the only sites to interact 
with Sox9 in embryonic mouse limbs at E12. In mouse chondrocytes the Acan enhancers 
interact in class I and II interactions and bind in rat chondrocytes.  
Figure 86: Analysis of histone modifications in the Acan locus that mark different types 
of enhancer 
 
New enhancer markers are being identified to aid in the identification of enhancer 
elements. Active enhancers different to those marked by H3K27ac have been 
characterised. The new class of active enhancers are marked by H3K64ac of which the 
Acan enhancers identified in this study do not overlap with the exception from the -65kb 
region which has a minor peak.  
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Figure 87: ATAC-seq of the Acan locus in haematopoietic cells 
 
ATAC-seq from haematopoietic cells allows an assessment of the chromatin landscape of 
Acan. Areas of open chromatin are marked by peaks. Only the +26kb appears to be open 
in these cell types. 
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Figure 88: Methylation data in hip and knee OA for the Acan locus 
 
DNA methylation differentially expressed regions. The -65kbis differentially methylated 
in OA hips compared to normal hips. Other regions do not appear to be affected by 
methylation in human OA. Data provided by Dr. L. Reynard.  
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Figure 89: Histone changes when MSC differentiate to chondrocytes in the Acan locus 
 
Gene expression and collated ChIP-data for genome state from MSC and 14 days of 
differentiation. Acan is only transcribed in chondrocytes. Each one of the Acan enhancers 
identified in this study shows enhancer activity in MSC with the exception of the -87kb 
which is inactive and the -35kb which are marked as a promoter. In chondrocytes the 
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+26kb and -10kb become strong enhancers, the -65kb remains an enhancer, the -35kb 
becomes a strong promoter and the -87kb is only active in chondrocytes as a strong 
enhancers suggesting that they play a role in the chondrocyte lineage determination or 
the tissue specificity of the Acan. Data provided by K. Cheung and Prof. D. Young.  
Figure 90: Med1 interaction sites in the Acan locus 
 
Data from Med1 ChIP-seq. Med1 is a subunit of the mediator that provides a bridge 
between DNA elements and the promoter to activate transcription. The Med1 localises 
strongly with the -65kb enhancer element and the 9th exon of Acan (red). Suggesting that 
the -65kb plays an important role in the activation of Acan transcription. 
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Figure 91: Interactions of the Acan enhancers in IMR-90 human lung cells from 4D 
genomes  
 
4D genomes output for the Acan region based on Hi-C. Interactions with other enhancers 
by the +26kb do not occur in the IMR-90 but the regions does interact with HAPLN3. The 
promoter (chr15:89,346,048-89,347,590) interacts with the -10kb, -35kb and -87kb. The 
-10kb only interacts with the promoter, the -35kb interacts with the promoter, -65kb and 
-87kb. The -65kb interacts with Exon 6 of Acan and the -35kb. The -87kb interacts with 
the promoter and the -35kb. We cannot discount other ling range interaction, data 
generated from: http://4dgenome.research.chop.edu/ . 
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Figure 92: RNA expression of MSC differentiated into chondrocytes for different Lectican 
proteins 
 
 
Gene profiles for transcription in the lectican and link protein families in the 
chondrocytes and MSCs. Acan is active in the chondrocyte but HAPLN3 does not, Vcan is 
active in the chondrocyte but HAPLN1 expression is reduced in the chondrocyte. Bcan 
and Ncan are neuronal specific and displays an erratic expression in the chondrocytes 
and this is reflected win HAPLN2 and HAPLN4. 
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“Not until they set aside their differences did I see the true power they all share deep 
inside. I see now that the circumstances of one’s birth are irrelevant; it is what you do 
with the gift of life that determines who you are.” – M. 1998. 
